CD117 antibody, nanoparticle conjugated to antibody, and use thereof

By developing highly binding CD117 monoclonal antibodies and conjugated nanoparticles, the problem of the lack of targeted delivery systems in existing technologies has been solved, enabling efficient delivery and gene editing of CD117+ cells, which has therapeutic potential.

WO2026238117A1PCT designated stage Publication Date: 2026-11-19YOLTECH THERAPEUTICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/097350
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-15
Filing Date
2026-05-15
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Existing technologies lack efficient targeted delivery systems for the specific delivery of bioactive substances to CD117+ cells, especially without inhibiting ligand-induced c-Kit phosphorylation.

Method used

Highly binding CD117 monoclonal antibodies and their conjugated nanoparticles have been developed for the delivery of bioactive substances such as mRNA to CD117+ cells, including the preparation of lipid nanoparticle conjugates containing antibodies and the use of expression vectors to edit genes in CD117+ cells.

Benefits of technology

It achieves highly efficient CD117+ cell-targeted delivery, reduces the impact on cell viability, and provides the possibility of gene editing and therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2026097350-FTAPPB-I100001
    Figure PCTCN2026097350-FTAPPB-I100001
  • Figure PCTCN2026097350-FTAPPB-I100002
    Figure PCTCN2026097350-FTAPPB-I100002
  • Figure PCTCN2026097350-FTAPPB-I100003
    Figure PCTCN2026097350-FTAPPB-I100003
Patent Text Reader

Abstract

Provided are a CD117 antibody, a nanoparticle conjugated to the antibody, and the use thereof. Specifically provided are an antibody or antigen-binding fragment thereof that binds to CD117 and a lipid nanoparticle conjugate in which the anti-CD117 antibody is conjugated. Also provided are a method for delivering a cargo (for example, a gene editing system) to CD117+ cells by using the lipid nanoparticle conjugate, and a method for preparing the lipid nanoparticle conjugate.
Need to check novelty before this filing date? Find Prior Art

Description

CD117 antibody and nanoparticles conjugated to it and their applications Technical Field

[0001] This disclosure relates to CD117 antibodies and nanoparticles conjugated to the antibodies, wherein the nanoparticles contain therapeutic or preventative agents (including, for example, nucleic acids, such as mRNA). Background Technology

[0002] Editing hematopoietic stem cells (HSCs) (e.g., targeted cutting or targeted base modification) can improve symptoms of related diseases such as sickle cell disease (SCD) and thalassemia.

[0003] There is still a need for target-specific delivery systems such as HSC.

[0004] CD117, also known as tyrosine protein kinase (c-Kit), is a cytokine receptor expressed on hematopoietic stem cells and some other cell types. Upon binding to stem cell factor (SCF), the tyrosine kinase activity of CD117 is activated, leading to phosphorylation and activation of downstream molecules, making it a potential target for therapy, diagnosis, and targeting of hematopoietic stem cells (HSCs).

[0005] Any reference or designation of any document in this disclosure is not an admission that such document is available as prior art. Every reference mentioned or cited in this disclosure is incorporated herein by way of its entirety. Summary of the Invention

[0006] This disclosure relates to monoclonal antibodies with high binding activity to CD117 in humans or non-human primates and their applications.

[0007] Some of the anti-CD117 antibodies disclosed herein exhibit high binding activity to CD117+ cells without inhibiting ligand-induced c-Kit phosphorylation. These characteristics suggest that the anti-CD117 antibodies disclosed herein are suitable for guiding cargo (e.g., gene editing systems) to CD117+ cells with minimal impact on cell viability.

[0008] Therefore, this article provides monoclonal antibodies capable of binding to CD117 (e.g., human or non-human primate CD117) and carriers (e.g., lipid nanoparticles) conjugated with the above antibodies for the delivery of bioactive substances to CD117+ cells (i.e., cells expressing CD117).

[0009] This article also provides nucleic acids containing nucleotide sequences encoding anti-CD117 antibodies, vectors and host cells including these nucleic acid sequences, and methods for preparing lipid nanoparticle (LNP) conjugates containing anti-CD117 antibodies.

[0010] In one aspect, this disclosure provides an antibody or antigen-binding fragment thereof that binds to CD117, comprising:

[0011] (a) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:2; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0012] (b) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:3; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0013] (c) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:4; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0014] (d) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:5; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0015] (e) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:6; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0016] (f) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:7; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0017] (g) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:8; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0018] (h) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:9; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0019] (i) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:10; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0020] (j) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:11; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0021] (k) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:12; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0022] (l) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:13; or CDR variants having one or more amino acid substitutions, deletions or additions (e.g., substitutions, deletions or additions of 1, 2 or 3 amino acids) with any of the three CDRs.

[0023] (m) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:14; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0024] (n) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:15; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0025] (o) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:16; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0026] (p) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:17; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0027] (q) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:18; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0028] (r) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:19; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0029] (s) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:20; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0030] (t) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:81; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0031] (u) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:82; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0032] (v) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:83; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0033] (w) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:84; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0034] (x) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:85; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0035] (y) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:86; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0036] (z) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:87; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0037] (aa) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:88; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0038] (ab) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:89; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs; or

[0039] (ac) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:90; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0040] In some implementations, the CDR is defined according to the Kabat, IMGT, Chothia, or AbM numbering system.

[0041] In another aspect, this disclosure provides a nucleic acid molecule that encodes the disclosed antibody or antigen-binding fragment that binds to CD117.

[0042] In another aspect, this disclosure provides an expression vector containing the nucleic acid molecules of this disclosure.

[0043] In another aspect, this disclosure provides a host cell containing the expression vector of this disclosure.

[0044] In another aspect, this disclosure provides a lipid nanoparticle conjugate comprising:

[0045] (1) Lipid nanoparticles (LNPs), and

[0046] (2) An antibody or antigen-binding fragment thereof that binds to CD117, wherein the antibody or antigen fragment thereof is conjugated to the surface of an LNP.

[0047] In another aspect, this disclosure provides a method for delivering a bioactive substance to cells, comprising:

[0048] The lipid nanoparticle conjugates of this disclosure are contacted with cells expressing CD117 to deliver the bioactive substances contained in the lipid nanoparticle conjugates to the cells. In some embodiments, the contact occurs in vivo, in vitro, or outside the body.

[0049] In another aspect, this disclosure provides a method for editing intracellular genes expressing CD117, comprising: contacting the cells with a lipid nanoparticle conjugate of this disclosure to allow delivery of bioactive factors contained in the lipid nanoparticle conjugate to the cells, said bioactive factors being a gene editing composition / system that edits a target gene in the cells. In some embodiments, the method is an in vivo, in vitro, or ex vivo editing method.

[0050] In another aspect, this disclosure provides a method for preparing lipid nanoparticle conjugates, the method comprising: contacting an antibody or antigen-binding fragment thereof of the present disclosure with an LNP to allow the antibody or antigen-binding fragment thereof to conjugate to the surface of the LNP, thereby generating the lipid nanoparticle conjugate.

[0051] In another aspect, this disclosure provides a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof that binds to CD117 and / or a conjugate thereof.

[0052] In another aspect, this disclosure provides a method for treating or improving a disease or condition, the method comprising administering to the subject an effective amount of the disclosed antibody binding to CD117 or an antigen-binding fragment thereof, a conjugate thereof, or a pharmaceutical composition thereof; or administering to the subject's cells the disclosed antibody binding to CD117 or an antigen-binding fragment thereof, a conjugate thereof, or a pharmaceutical composition thereof.

[0053] It should be understood that, within the scope of this disclosure, the above-described technical features and the technical features specifically described below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be described in detail here. Attached Figure Description

[0054] Figures 1A and 1B illustrate the binding activity of different antibodies to human CD117 antigen. The results show that the nanobodies disclosed herein all bind to human CD117 antigen efficiently.

[0055] Figures 2A, 2B, and 2C show the statistical results of in vitro cell transfection with luciferase assays using nanobodies conjugated with different antibodies-LNPs / unconjugated antibody-LNPs. The results demonstrate that the multiple nanobodies-LNPs disclosed in this invention exhibit highly efficient CD117+ cell-targeted delivery.

[0056] Figure 3 shows the binding activity of the antibodies obtained from the second immunization with the human CD117 antigen. The results show that the nanobodies obtained from this immunization all bind to the human CD117 antigen efficiently.

[0057] Figure 4 shows the statistical analysis of in vitro cell transfection luciferase assay for antibody-LNP constructed from conjugated and re-immunized antibodies / unconjugated antibody-LNP. The results show that the multiple nanobodies-LNPs disclosed in this paper exhibit highly efficient CD117+ cell-targeted delivery. Detailed Implementation

[0058] This article provides a novel anti-CD117 antibody suitable for therapeutic use. It also provides nanoparticles conjugated with the antibody, methods for using the antibody-conjugated nanoparticles, and preferred therapeutic uses of the antibody-conjugated nanoparticles.

[0059] the term

[0060] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. For the purposes of interpreting this specification, the following terminology will be applied, and where appropriate, terms used in the singular will also include the plural form, and vice versa. All patents, applications, published applications, and other publications are incorporated herein by reference in their entirety. If any description of terminology set forth herein conflicts with any document incorporated herein by reference, the terminology set forth herein shall prevail.

[0061] Unless otherwise defined elsewhere in this document, all other technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art.

[0062] As used herein (including the appended claims), unless the context clearly indicates otherwise, singular terms such as “a”, “an” and “the” include their corresponding plural indicators.

[0063] Unless the context clearly indicates otherwise, the term “or” is used to mean the term “and / or” and is used interchangeably with the term “and / or”.

[0064] The term “lipid” refers to a group of organic compounds, including but not limited to fatty acid esters, and is generally characterized by poor solubility in water but soluble in many nonpolar organic solvents. Although lipids are generally weakly water-soluble, certain classes of lipids (e.g., lipids modified with polar groups, such as DMG-PEG2000) have limited water solubility and are soluble in water under certain conditions. Known types of lipids include biomolecules such as fatty acids, waxes, sterols, fat-soluble vitamins, monoglycerides, diglycerides, triglycerides, and phospholipids. Lipids can be classified into at least three categories: (1) “simple lipids,” including fats and oils, as well as waxes; (2) “compound lipids,” including phospholipids and glycolipids (e.g., DMPE-PEG2000); and (3) “derived lipids,” such as steroids. In addition, as used herein, lipids also include lipid-like compounds. The term “lipid-like compounds,” also simply “lipids,” refers to lipid-like compounds (e.g., amphiphilic compounds with lipid-like physical properties).

[0065] The term "ionizable lipid" has its common meaning in the art and can refer to lipids comprising one or more charged portions. In some embodiments, ionizable lipids can be positively or negatively charged. For example, ionizable lipids can be positively charged at lower pH levels, in which case they can be referred to as "cationic lipids." In some embodiments, the positive charge in cationic lipids originates from the presence of quaternary nitrogen atoms. In some embodiments, cationic lipids comprise zwitterionic lipids that are positively charged in the environment in which they are intended for use (e.g., at physiological pH).

[0066] The term "polyethylene glycol (PEG) lipid molecule" refers to a molecule that contains both a lipid portion and a polymer portion (PEG).

[0067] The term "neutral lipid" encompasses any lipid molecule that exists in a neutral or zwitterionic form at or within a selected pH value or range. In some embodiments, the selected useful pH value or range corresponds to the pH conditions of the environment in which the lipid is intended to be used, such as physiological pH.

[0068] The term “genome editing vector” refers to nucleic acid molecules that encode components of a genome editing system, such as, but not limited to, CRISPR / Cas proteins (e.g., Cas9, Cas12, Cas13, IscB, etc.), base editors or lead editors, and any associated necessary components, such as appropriate guide RNA (gRNA).

[0069] The term "composition" is intended to cover products containing optionally specified amounts of a specified ingredient (such as a bioactive molecule, such as mRNA, as described herein).

[0070] The term "nucleic acid" refers to a polymer of nucleotides of any length and includes, for example, DNA and RNA. Nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases and / or their analogues, or any substrate that can be incorporated into the polymer by DNA or RNA polymerase or by a synthetic reaction. Polynucleotides may contain modified nucleotides, such as methylated nucleotides and their analogues. Nucleic acids can be single-stranded or double-stranded. As used herein and unless otherwise stated, "nucleic acid" also includes nucleic acid mimics such as locked nucleic acids (LNA), peptide nucleic acids (PNA), and morpholino nucleic acids. As used herein, "oligonucleotide" refers to a short synthetic polynucleotide whose length is generally, but not necessarily, less than about 200 nucleotides. The terms "oligonucleotide" and "polynucleotide" are not mutually exclusive. The above description of polynucleotides applies equally and fully to oligonucleotides. Unless otherwise stated, the left-hand end of any single-stranded polynucleotide sequence disclosed herein is the 5' end; the left-hand direction of a double-stranded polynucleotide sequence is referred to as the 5' direction. The direction of addition from 5' to 3' of the newly formed RNA transcript is called the transcription direction; the sequence region on the DNA strand that has the same sequence as the RNA transcript and is located at the 5' end relative to the 5' end of the RNA transcript is called the "upstream sequence"; the sequence region on the DNA strand that has the same sequence as the RNA transcript and is located at the 3' end relative to the 3' end of the RNA transcript is called the "downstream sequence".

[0071] The terms “peptide” and “protein” are used interchangeably herein to refer to a polymer having multiple amino acid residues linked by covalent peptide bonds. That is, the description of a peptide is equally applicable to the description of a protein, and vice versa. The terminology applies to naturally occurring amino acid polymers as well as amino acid polymers in which one or more amino acid residues are non-naturally occurring amino acids (e.g., amino acid analogs). As used herein, the terminology covers amino acid chains of any length, including full-length proteins (e.g., antigens).

[0072] The term "antigen" refers to a substance that can be recognized by a subject's immune system (including the adaptive immune system) and can trigger an immune response (including an antigen-specific immune response) upon the subject's exposure to the antigen. In some implementations, the antigen is a protein associated with diseased cells, such as cells infected with pathogens, or neoplastic cells (e.g., tumor-associated antigens (TAAs)).

[0073] The term "epitope" is a site on the surface of an antigen molecule that binds to a single antibody molecule, such as a localized region on the surface of an antigen capable of binding to one or more antigen-binding regions of an antibody, and which, in an animal, such as a mammal (e.g., a human), possesses antigenic or immunogenic activity and can elicit an immune response. An immunogenic epitope is the portion of a polypeptide that elicits an antibody response in an animal. An antigenic epitope is the portion of a polypeptide that binds to an antibody by any method known in this art, including, for example, by immunoassay. An antigenic epitope is not necessarily immunogenic. Epitopes typically consist of chemically active surface groups of a molecule, such as amino acids or sugar side chains, and possess specific three-dimensional structural features and specific charge characteristics. Antibody epitopes can be linear or conformational. Linear epitopes are formed from a continuous amino acid sequence in a protein. Conformational epitopes are formed from amino acids that are discontinuous in the protein sequence but are bound together when the protein folds into its three-dimensional structure. Inducible epitopes are formed when the three-dimensional structure of a protein undergoes a conformational change, such as after activation or binding of another protein or ligand. In some embodiments, an epitope is a three-dimensional surface feature of a polypeptide. In other embodiments, an epitope is a linear feature of a polypeptide. Generally, an antigen has several or many different epitopes and can react with many different antibodies.

[0074] The term "antibody" is intended to include B-cell polypeptide products within the immunoglobulin class of polypeptides, capable of binding to a specific molecular antigen, and consisting of two pairs of identical polypeptide chains, each pair having a heavy chain (approximately 50-70 kDa) and a light chain (approximately 25 kDa), each amino-terminal portion of each chain including a variable region containing approximately 100 to approximately 130 or more amino acids, and each carboxyl-terminal portion of each chain including a constant region. See, for example, Antibody Engineering (Borrebaeck, ed., 2nd edition, 1995); and Kuby, Immunology (3rd edition, 1997). In certain embodiments, the specific molecular antigen may be bound by the antibody provided herein, including polypeptides, fragments thereof, or epitopes. Antibodies also include, but are not limited to, synthetic antibodies, recombinant antibodies, camelified antibodies, internal antibodies, anti-idiotype (anti-Id) antibodies, and functional fragments of any of the above, where a functional fragment refers to the retention of the antibody heavy or light chain polypeptide as part of the binding activity of the antibody from which said fragment is derived. Non-limiting examples of functional fragments include single-chain Fv (scFv) (e.g., including monospecific, bispecific, etc.), Fab fragments, F(ab') fragments, F(ab)2 fragments, F(ab')2 fragments, disulfide-linked Fv (dsFv), Fd fragments, Fv fragments, bifunctional antibodies, trifunctional antibodies, tetrafunctional antibodies, and microantibodies. Specifically, the antibodies described herein include immunoglobulin molecules and immunoactive portions of immunoglobulin molecules, such as antigen-binding domains or molecules containing antigen-binding sites (e.g., one or more CDRs of an antibody). Such antibody fragments can be found in, for example, Harlow and Lane, Antibodies: A Laboratory Manual (1989); Mol. Biology and Biotechnology: A Comprehensive Desk Reference (Myers, ed., 1995); Huston et al., 1993, Cell Biophysics 22: 189-224; Plückthun and Skerra, 1989, Meth. Enzymol. 178: 497-515; and Day, Advanced Immunochemistry (2nd edition, 1990). The antibodies presented herein can be any class of immunoglobulin molecules (e.g., IgG, IgE, IgM, IgD, and IgA) or any subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2).

[0075] Generally, the basic antibody structural unit comprises a tetramer, each tetramer consisting of two pairs of identical polypeptide chains, each pair having one light chain and one heavy chain. The amino-terminal portion of each chain includes a variable region of approximately 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxyl-terminal portion of the heavy chain may define a constant region primarily responsible for effector function. Human light chains are typically classified as κ and λ light chains. Furthermore, human heavy chains are generally classified as α, δ, ε, γ, or μ, and antibody isotypes are defined as IgA, IgD, IgE, IgG, and IgM, respectively. Within both the light and heavy chains, the variable and constant regions are linked by a “J” region of approximately 12 or more amino acids, with the heavy chain also including a “D” region of approximately 10 or more amino acids.

[0076] Each light chain / heavy chain (VL / VH) pair has a variable region that forms an antibody binding site. Therefore, in general, a complete antibody has two binding sites. Except for bifunctional or bispecific antibodies, the two binding sites are generally identical. Typically, the variable domains of both the heavy and light chains contain three hypervariable regions, also known as "complementarity-determining regions (CDRs)," located between relatively conserved frame regions (FRs). The CDRs are usually aligned with the frame regions to enable binding to specific epitopes. Generally, from the N-terminus to the C-terminus, the variable domains of both the light and heavy chains contain FR-1 (or FR1), CDR-1 (or CDR1), FR-2 (FR2), CDR-2 (CDR2), FR-3 (or FR3), CDR-3 (CDR3), and FR-4 (or FR4). The location of the CDR and the frame region can be determined using various definitions well known in the art, such as those by Kabat, Chothia, and AbM (see, for example, Johnson et al., Nucleic Acids Res., 29:205-206 (2001); Chothia and Lesk, J. Mol. Biol., 196:901-917 (1987); Chothia et al., Nature, 342:877-883 (1989); Chothia et al., J. Mol. Biol., 227:799-817 (1992); Al-Lazikani et al., J. Mol. Biol., 273:927-748 (1997)). The definition of antigen binding sites is also described in the following literature: Ruiz et al., Nucleic Acids Res., 28:219-221 (2000); and Lefranc, MP, Nucleic Acids Res., 29:207-209 (2001); MacCallum et al., J.Mol.Biol., 262:732-745 (1996); and Martin et al., Proc.Natl.Acad.Sci.USA, 86:9268-9272 (1989); Martin et al., Methods Enzymol., 203:121-153 (1991); and Rees et al., in Sternberg MJE (ed.), Protein Structure Prediction, Oxford University Press, Oxford, 141-172 (1996). In the combined Kabat and Chothia numbering schemes, in some embodiments, the CDR corresponds to an amino acid residue that is part of the Kabat CDR, the Chothia CDR, or both.The hypervariable region contains amino acid residues from the “CDR” (i.e., VL-CDR1, VL-CDR2, and VL-CDR3 in the light chain variable domain and VH-CDR1, VH-CDR2, and VH-CDR3 in the heavy chain variable domain). See Kabat et al. (1991), Sequences of Proteins of Immunological Interest, 5th ed., U.S. Public Health Service, National Institutes of Health, Bethesda, Maryland (Defining the CDR region of an antibody based on sequence); see also Chothia and Lesk (1987) J. Mol. Biol. 196:901-917 (Defining the CDR region of an antibody based on structure).

[0077] As used herein, the term “scFv” refers to a single polypeptide chain containing VL and VH domains linked by a linker (see, for example, Bird et al., Science 242:423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, edited by Roseburg and Moore, Springer-Verlag, New York, pp. 269-315 (1994)). Such scFv molecules may have a general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH. Suitable prior art linkers consist of repeating GGGGS amino acid sequences or variants thereof. For example, a linker with the amino acid sequence (GGGGS)4 can be used, but variants thereof can also be used (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448). Other available linkers are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31:94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56, and Roovers et al. (2001), Cancer Immunol. In some cases, a disulfide bond may also exist between the VH and VL of the scFv. In some embodiments, scFvs can form di-scFvs, which refers to two or more individual scFvs tandem to form an antibody. In some implementations, scFv can form (scFv)2, which refers to two or more individual scFvs linked together to form an antibody.

[0078] As used herein, the term "single-domain antibody (sdAb)" has the meaning commonly understood by those skilled in the art as an antibody fragment consisting of a single monomeric variable antibody domain (e.g., a single heavy chain variable region) that maintains the ability to specifically bind the same antigen bound by a full-length antibody. Single-domain antibodies, also known as nanobodies or VHHs (Variable domain of heavy chain of heavy chain antibody), are the smallest functional antigen-binding fragments. For further descriptions of single-domain antibodies, nanobodies, and VHHs, refer to Muyldermans' review article (2001, Reviews in Molecular Biotechnology 74: 277-302). The terms "frame" or "FR" residues refer to those variable domain residues other than the hypervariable region residues defined herein as CDR residues.

[0079] The term "conserved sequence modification" refers to amino acid modifications that do not significantly affect or alter the binding characteristics of an antibody or antibody fragment containing an amino acid sequence. Such conserved modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into the antibodies or antibody fragments of this disclosure using standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. A conserved substitution is a substitution in which an amino acid residue is replaced by an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids having basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Therefore, one or more amino acid residues of the CD117-binding antibody or its antigen-binding moiety disclosed herein may be replaced by other amino acid residues from the same side chain family.

[0080] The term "administer / administration" refers to the act of injecting or otherwise physically delivering a substance present outside the body (such as the lipid nanoparticle composition described herein) into a patient's body, such as via mucosal, intradermal, intravenous, intramuscular delivery, and / or any other physical delivery method described herein or known in this art. When treating a disease, condition, disorder, or symptom thereof, the substance is typically administered after the onset of said disease, condition, disorder, or symptom. When preventing a disease, condition, disorder, or symptom thereof, the substance is typically administered before the onset of said disease, condition, disorder, or symptom.

[0081] The term “targeted delivery” or the verb form “targeting” refers to a process that promotes the delivery of an agent (such as the therapeutic payload molecule in the lipid nanoparticle composition described herein) to a specific organ, tissue, cell, and / or intracellular compartment (referred to as the target site) compared to delivery to any other organ, tissue, cell, or intracellular compartment (referred to as the non-target site). Targeted delivery can be detected using methods known in the art, for example by comparing the concentration of the delivered agent in the target cell population with the concentration of the delivered agent in the non-target cell population after systemic administration.

[0082] The term "bioactive substance" refers to a preventive agent or a therapeutic agent. A "preventive agent" is any agent that can completely or partially inhibit the development, recurrence, onset, or spread of a disease and / or its related symptoms in a subject. A "therapeutic agent" is any agent that can be used to treat, prevent, or alleviate a disease, condition, or disorder, including any agent used to treat, prevent, or alleviate one or more symptoms of a disease, condition, or disorder and / or its related symptoms.

[0083] The term "therapy" refers to any regimen, method, and / or agent that can be used to prevent, manage, treat, and / or improve a disease, condition, or disorder. In some implementations, the term "therapies" refers to biological, supportive, and / or other therapies known to those skilled in the art, such as medical personnel, for the prevention, management, treatment, and / or improvement of a disease, condition, or disorder.

[0084] The term "coding" refers to the inherent property of a specific nucleotide sequence in a polynucleotide (such as a gene, cDNA, or mRNA) that serves as a template for the synthesis of other polymers and macromolecules that have a defined nucleotide sequence (i.e., rRNA, tRNA, and mRNA) or a defined amino acid sequence and the resulting biological characteristics in biological processes. Therefore, if the transcription and translation of the mRNA corresponding to a gene produces a protein in a cell or other biological system, then that gene encodes that protein. Both the coding strand (whose nucleotide sequence is identical to the mRNA sequence and is usually provided in the sequence listing) and the non-coding strand (which serves as a template for gene or cDNA transcription) can be referred to as encoding the protein or other product of that gene or cDNA.

[0085] The term "expression vector" refers to a vector containing a recombinant polynucleotide that includes an expression control sequence operatively linked to a nucleotide sequence to be expressed. The expression vector contains sufficient cis-acting elements for expression; other elements for expression may be provided by a host cell or in an in vitro expression system. Expression vectors include all those known in the art, such as clomids incorporated into the recombinant polynucleotide, plasmids (e.g., naked or contained in liposomes), RNA, and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses).

[0086] The term "operably linked" refers to a functional connection between a regulatory sequence and a heterologous nucleic acid sequence, resulting in the expression of the latter. For example, the first nucleic acid sequence is operably linked to the second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. Similarly, if a promoter affects the transcription or expression of a coding sequence, the promoter is operably linked to the coding sequence. Typically, operably linked DNA or RNA sequences are contiguous and, when the binding of two protein-coding regions is required, they are located within the same reading frame.

[0087] The terms “patient,” “subject,” “individual,” etc., are used interchangeably herein and refer to any animal or its cells, whether in vitro or in situ, and are applicable to the methods described herein. In some non-limiting embodiments, the patient, subject, or individual is a human.

[0088] As used herein, a nuclease is a protein or polypeptide capable of catalyzing (e.g., cleaving) internal regions of nucleic acids (e.g., DNA or RNA), wherein the DNA-binding activity is sequence-specific and dependent on the sequence of the guiding RNA. Exemplary nucleases include Cas cleaving enzymes / nicking enzymes and their inactivated forms (“dCas DNA binders”). As used herein, “Cas nuclease” encompasses Cas cleaving enzymes, Cas nicking enzymes, and dCas enzymes. Cas cleaving enzymes / nicking enzymes and dCas enzymes.

[0089] In some embodiments, the endonuclease comprises one or more mutations that eliminate nuclease activity. In various embodiments, the endonuclease is the Cas9 protein or a variant thereof. In some embodiments, the endonuclease is a Cas9 nickase, a Cas12a nickase, or a Cas12i nickase. In some embodiments, the endonuclease is selected from Cas9, Cas12e, Cas12d, Cas12a, Cas12b1, Cas12b2, Cas13a, Cas12c, Cas12d, Cas12e, Cas12h, Cas12i, Cas12g, Cas12f (Cas14), Cas12f1, Cas12j (CasΦ), Cas13a, Cas13b, Cas13d, and Argonaute, and optionally has nickase activity such that only one strand is cleaved.

[0090] As used herein, the terms "guide RNA," "guide RNA," or "gRNA" generally refer to a short ribonucleic acid capable of interacting (e.g., binding) with endonucleases and binding or hybridizing with a target genomic site or region. In some embodiments, the gRNA is a single-molecule guide RNA (sgRNA). In some embodiments, the gRNA may contain a spacer extension region. In some embodiments, the gRNA may contain a tracrRNA extension region. In some embodiments, the gRNA is single-stranded. In some embodiments, the gRNA contains naturally occurring nucleotides. In some embodiments, the gRNA is chemically modified gRNA. In some embodiments, the chemically modified gRNA is a gRNA containing at least one nucleotide with a chemical modification (e.g., 2'-O-methyl sugar modification). In some embodiments, the chemically modified gRNA contains a modified nucleic acid backbone. In some embodiments, the chemically modified gRNA contains 2'-O-methyl-phosphothioester residues. In some embodiments, the gRNA may be pre-complexed with endonucleases.

[0091] As used herein, functionalized PEG lipids (polyethylene glycol lipids) refer to PEG lipids in which the polyethylene glycol portion has been derivatized into chemically reactive groups that can be used to conjugate a targeting moiety (e.g., an antibody) to the PEG lipid. Functionalized PEG lipids can react with a targeting moiety (e.g., an antibody) after LNP formation, thereby conjugating the targeting moiety to the PEG portion of the lipid. The conjugated targeting moiety can then serve as the targeting moiety of the LNP.

[0092] Anti-CD117 antibody (antibody that binds to CD117)

[0093] According to one aspect of this disclosure, an antibody or antigen-binding portion thereof that binds to CD117 is provided, said antibody being capable of binding to cell surface receptor CD117 (also known as c-kit).

[0094] In some implementations, the CDRs sequence of the anti-CD117 antibody is obtained according to numbering methods known in the art, including but not limited to Kabat, Chothia, IMGT, AbM, and Contact.

[0095] In some implementations, the CDRs are defined according to the Kabat scheme, and the CDRs are selected from:

[0096] (a) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:2; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0097] (b) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:3; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0098] (c) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:4; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0099] (d) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:5; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0100] (e) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:6; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0101] (f) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:7; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0102] (g) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:8; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0103] (h) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:9; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0104] (i) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:10; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0105] (j) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:11; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0106] (k) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:12; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0107] (l) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:13; or CDR variants having one or more amino acid substitutions, deletions or additions (e.g., substitutions, deletions or additions of 1, 2 or 3 amino acids) with any of the three CDRs.

[0108] (m) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:14; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0109] (n) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:15; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0110] (o) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:16; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0111] (p) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:17; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0112] (q) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:18; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0113] (r) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:19; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0114] (s) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:20; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0115] (t) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:81; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0116] (u) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:82; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0117] (v) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:83; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0118] (w) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:84; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0119] (x) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:85; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0120] (y) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:86; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0121] (z) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:87; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0122] (aa) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:88; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0123] (ab) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:89; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs; or

[0124] (ac) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:90; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs.

[0125] In some implementations, the CDR is defined according to the Kabat, IMGT, Chothia, or AbM numbering system.

[0126] In some embodiments, the anti-CD117 antibody of this disclosure comprises HCDR1, HCDR2, and HCDR3 sequences, wherein:

[0127] (1)HCDR1 contains X1X2X3X4X5 (SEQ ID NO:28), wherein X1 is Y, T, S, R, N, I, F or D, X2 is Y, S, L or D, X3 is Y, W, V, T, S, R, P, N, I, G or A, X4 is Y, V, M, L, I or A, X5 is Y, V, T, S, N, G or A, or contains variants having no more than 3, no more than 2, or no more than 1 amino acid residue substitutions to the sequence shown in SEQ ID NO:28.

[0128] In some embodiments, the HCDR1 comprises the sequence shown in any one of SEQ ID NO:21-27, 29-38 and 91-100 or a variant comprising no more than 3, no more than 2, or no more than 1 amino acid residue substitutions of the sequence shown in any one of SEQ ID NO:21-27, 29-38 and 91-100.

[0129] (2) HCDR2 includes X6X7X8X9X 10 X 11 X 12 X 13 X 14 X 15 X 16X 17 X 18 X 19 X 20 X 21 (SEQ ID NO:59), where X6 is V, T, S, R, I, G, C or A, X7 is M or I, X8 is V, T, S, N, L, K, G or D, X9 is Y, W, T, S, R, Q, L, G or F, X 10 For W, T, S, N, L, G, D or A, X 11 For V, S, P, L, G or A, X 12 For T, S, R, P, N, G, or A, X 13 For V, T, S, R, M, I or A, X 14 For Y, V, T, N, M, L or I, X 15 For Y, W, T, S, N, M or A, X 16 For Y, S, F or A, X 17 For Y, V, T, P, G, D or A, X 18 For S, E, D, or A, X 19 For V, S, M, or D, X 20 For V, S, M, K, or I, X 21 It is V, K, G or D, or a variant containing no more than 3, 2 or 1 amino acid residue substitutions to the sequence shown in SEQ ID NO:59.

[0130] In some embodiments, HCDR2 comprises the sequence shown in any one of SEQ ID NO:40-58 and 101-110 or comprises a variant having no more than 3, no more than 2, or no more than 1 amino acid residue substitutions for the sequence shown in any one of SEQ ID NO:40-58 and 101-110.

[0131] (3) HCDR3 contains X 22 X 23 X 24 X 25 X 26 X 27 X 28 (SEQ ID NO:121), where X 22 For Y, V, T, R, N, M, K, H, G, E, D or A, X 23 For Y, W, V, T, R, Q, N, L, K, G, F, E, or D, X 24 For W, V, T, S, R, Q, P, N, H, G or F, X 25 For Y, V, T, S, R, P, L, K, I, G or F, X 26For Y, W, S, R, P, I, H, G, E, D or A, X 27 For Y, W, V, S, R, Q, N, L, K, I, F, D, C or A, X 28 It can be Y, W, V, T, S, P, N, L, K, G, E, D, or A.

[0132] In some embodiments, HCDR3 comprises the sequence shown in any of SEQ ID NO:60-78 and 111-120 or a variant comprising substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of one, two, or three amino acids) of the sequence shown in SEQ ID NO:60-78 and 111-120.

[0133] In some embodiments, the antibody or its antigen-binding fragment framework region FR includes FR1, FR2, FR3, and FR4 sequences, wherein,

[0134] (1) FR1 contains X 29 VX 30 X 31 X 32 ESGGGX 33 VX 34 X 35 GGX 36 X 37 X 38 LSCX 39 X 40 X 41 X 42 X 43 X 44 X 45 X 46 (SEQ ID NO:122), where X 29 For Q or E, X 30 For R or Q, X 31 For V or L, X 32 For V or Q, X 33 For T, S, or L, X 34 For Q or E, X 35 For A or P, X 36 For S or A, X 37 For L or V, X 38 For K, R, or T, X 39 For A, T, or V, X 40 For A, F, or V, X 41 For S or T, X 42 For I, G, or D, X 43 For S, R, I, or F, X 44 For V, T, G, or A, X 45 For Y, S, R, L, F or D, X46 It is T, S, G, F or D, or a variant containing a sequence having no more than 3, no more than 2 or no more than 1 amino acid residue substitutions with the sequence shown in SEQ ID NO:122.

[0135] In some embodiments, the FR1 comprises the sequence shown in any one of SEQ ID NO:126-154 or a variant comprising no more than 3, no more than 2, or no more than 1 amino acid residue substitutions of the sequence shown in any one of SEQ ID NO:126-154.

[0136] (2) FR2 includes WX 47 RX 48 X 49 PGX 50 X 51 X 52 X 53 X 54 VX 55 (SEQ ID NO:123), where X 47 For Y, V, or F, X 48 For R or Q, X 49 For G, F, or A, X 50 For N or K, X 51 For V, Q, K, G, or E, X 52 For R or L, X 53 For K or E, X 54 For W, L, G or F, X 55 It is T, S, G or A, or a variant containing a sequence of no more than 3, no more than 2 or no more than 1 amino acid residue substitutions with the sequence shown in SEQ ID NO:123.

[0137] In some embodiments, the FR2 comprises the sequence shown in any one of SEQ ID NO:155-183 or a variant comprising no more than 3, no more than 2, or no more than 1 amino acid residue substitutions of the sequence shown in any one of SEQ ID NO:155-183;

[0138] (3) FR3 includes RFX 56 X 57 X 58 X 59 DNX 60 X 61 X 62 X 63 X 64 X 65 LX 66 MX 67 X 68 X 69 KX 70EDX 71 X 72 X 73 YX 74 CX 75 X 76 (SEQ ID NO:124), where X 56 For A or T, X 57 For L, I, or A, X 58 For S or F, X 59 For V, R, or K, X 60 For V, S, R, or A, X 61 For Q, K, or E, X 62 For S or N, X 63 For T, M, or I, X 64 For V, M, L or I, X 65 For Y, S, N, L or F, X 66 For Q, L, or E, X 67 For N, M, or D, X 68 For S, N, K, or G, X 69 For V, M, L or A, X 70 For S or P, X 71 For T or M, X 72 For S or A, X 73 For V, L, or H, X 74 For Y or S, X 75 For Y, S, R, N, G or A, X 76 It is V, T, R, K, G or A, or a variant containing a sequence shown in SEQ ID NO:124 with a substitution of no more than 3, no more than 2 or no more than 1 amino acid residue.

[0139] In some embodiments, FR3 comprises the sequence shown in any of SEQ ID NO:184-212 or a variant comprising no more than 3, no more than 2, or no more than 1 amino acid residue substitutions of the sequence shown in any of SEQ ID NO:184-212.

[0140] (4) FR4 contains X 77 GX 78 GTX 79 VTVSS (SEQ ID NO:125), where X 77 For W, R, or G, X 78 For Q or K, X 79 It is Q or L, or contains a variant with no more than 3, 2, or 1 amino acid residue substitutions to the sequence shown in SEQ ID NO:125.

[0141] In some embodiments, FR4 comprises the sequence shown in any one of SEQ ID NO:213-241 or a variant comprising no more than 3, no more than 2, or no more than 1 amino acid residue substitutions of the sequence shown in any one of SEQ ID NO:213-241.

[0142] In some embodiments, the anti-CD117 antibody provided in this disclosure comprises a sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence of any one of SEQ ID NO:2-20 and 81-90, but the anti-CD117 antibody comprising this sequence retains the ability to bind CD117.

[0143] In some embodiments, the anti-CD117 antibody provided in this disclosure comprises at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of a reference sequence (SEQ ID NO: 2-20 and 81-90) with substitutions (e.g., conserved modifications), insertions, or deletions relative to the reference sequence, but the anti-CD117 antibody comprising this sequence retains its ability to bind CD117. In some embodiments, the substitutions, insertions, or deletions occur in regions outside the CDR (i.e., in the FR). In some embodiments, the CDRs of the CD117 antibody are shown in Tables 6 and 8.

[0144] In some implementations, the antibody also includes a human-derived frame region.

[0145] In some implementations, the antibody also includes a mouse-derived frame region.

[0146] In some implementations, the antibody constant region is human-derived.

[0147] In some embodiments, the antibody is selected from the group consisting of animal-derived antibodies, chimeric antibodies, humanized antibodies, fully human antibodies, or combinations thereof.

[0148] In some implementations, the antibody is a full-length antibody protein or an antigen-binding fragment.

[0149] In some implementations, the antibody is a bispecific antibody or a multispecific antibody.

[0150] In some implementations, the antigen-binding fragment includes a Fab fragment, an F(ab')2 fragment, an Fv fragment, a disulfide-linked Fv, scFv, a diabody, and a single-domain antibody (sdAb).

[0151] Production of anti-CD117 antibodies

[0152] The antibodies disclosed herein can be prepared using any antibody production technique known in the art. For example, see Harlow and Lane, *Antibodies: A Laboratory Manual*, 1998, Cold Spring Harbor Laboratory, New York. In some cases, high-affinity anti-CD117 antibodies can be identified and characterized using conventional screening strategies. See, for example, Example 1 herein.

[0153] Antibodies obtained using methods known in the art and described herein can be characterized using methods well-known in the art. For example, one method is to identify antigen-binding epitopes, i.e., “epitope mapping.” Many methods for locating and characterizing epitope positions on proteins are known in the art, including resolving the crystal structure of antibody-antigen complexes, competition assays, gene fragment expression assays, and synthetic peptide-based assays, as described in Chapter 11 of Harlow and Lane, Using: Antibodies, a Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1999.

[0154] In some implementations, the anti-CD117 antibody disclosed herein can be prepared by the recombinant technique shown below.

[0155] Generally, the nucleic acid sequence encoding any anti-CD117 antibody disclosed herein can be cloned into a suitable expression vector using methods known in the art and operatively ligated to a suitable promoter. For example, the nucleotide sequence and the vector can be contacted with a restriction endonuclease under suitable conditions to generate complementary ends on each molecule, which can then pair with each other and be ligated together by a ligase. Alternatively, synthetic nucleic acid adapters can be ligated to the ends of the gene. These synthetic adapters contain nucleic acid sequences corresponding to specific restriction sites in the vector. The choice of expression vector / promoter will depend on the type of host cell used to produce the antibody.

[0156] In some cases, the coding sequence of anti-CD117 antibodies can be codon-optimized based on the expression system used to generate the antibody. Such codon-optimized coding sequences are also within the scope of this disclosure. A variety of promoters can be used to express the antibodies described herein, including but not limited to cytomegalovirus (CMV) intermediate early promoters, viral long terminal repeats (LTRs) such as Rous sarcoma virus LTR, HIV-LTR, HTLV-1 LTR, simian virus 40 (SV40) early promoter, Escherichia coli lacUV5 promoter, and herpes simplex virus thymidine kinase (tk) promoter.

[0157] Vectors (e.g., expression vectors) containing nucleic acids encoding any of the anti-CD117 antibodies described herein can be introduced into suitable host cells to produce antibodies. Host cells can be cultured under suitable conditions to express antibodies. Such antibodies, protein complexes, or polypeptide chains thereof can be recovered from cultured cells (e.g., from cells or culture supernatant) using conventional methods, such as affinity purification. If necessary, the polypeptide chains of antibodies or protein complexes can be incubated under suitable conditions for an appropriate time to produce antibodies.

[0158] Standard molecular biology techniques are used to prepare recombinant expression vectors, transfect host cells, screen transformants, culture host cells, and recover antibodies from the culture medium. For example, some antibodies (Fc fusion forms) can be separated by affinity chromatography with a matrix conjugated to protein A or protein G.

[0159] Any nucleic acid encoding an anti-CD117 antibody described herein, vectors containing such nucleic acids (e.g., expression vectors), and host cells containing said vectors are all within the scope of this disclosure.

[0160] Anti-CD117 antibody structure

[0161] In some implementations, the antibodies provided in this disclosure are full-length antibodies.

[0162] In some embodiments, the antibodies provided in this disclosure are antibody fragments, for example, antibody fragments may be Fab, Fab', Fab'-SH, VHH, or F(ab')2 fragments, particularly Fab fragments. "Fab" is a monovalent fragment composed of VL, VH, CL, and CH1 domains. A "Fab fragment" may be generated by cleavage of an antibody with papain. "Fab'" contains VL, CL, VH, and CH1, and also contains a region between the CH1 and CH2 domains such that interchain disulfide bonds can be formed between the two heavy chains of two Fab' fragments to form an F(ab')2 molecule. "Fab'-SH" is a Fab' fragment in which the cysteine ​​residues in its constant region have free thiol groups. "F(ab')2" is a divalent fragment comprising two Fab fragments linked by disulfide bonds in their hinge region.

[0163] In another embodiment, the antibody fragment is a biantibody, triantibody, or tetraantibody. A biantibody is an antibody fragment having two antigen-binding sites, the fragment containing linked VH and VL within the same polypeptide chain (VH-VL). By using an excessively short linker that prevents the two domains on the same chain from pairing, these domains are forced to pair with complementary domains of another chain, thereby creating two antigen-binding sites, the two antigens of which may be the same or different.

[0164] In another embodiment, the antibody fragment is a single-chain Fab fragment, "single-chain Fab fragment" or "scFab" being a polypeptide composed of VH, CH1, VL, CL, and a linker, wherein the antibody domain and the linker have one of the following sequences in the N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1, or d) VL-CH1-linker-VH-CL. In one embodiment, the linker is a polypeptide having at least 30 amino acids. In another embodiment, the linker is a polypeptide having between 32 and 50 amino acids. The single-chain Fab fragment is stabilized via a native disulfide bond between CL and CH1. Additionally, these single-chain Fab molecules can be further stabilized by inserting cysteine ​​residues to create interchain disulfide bonds.

[0165] In some embodiments, the antibody fragment is a single-chain variable fragment (scFv). As used herein, "scFv" is a fusion protein comprising at least one antibody fragment containing a light chain variable region and at least one antibody fragment containing a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region are sequentially linked by a short, flexible peptide linker, capable of being expressed as a single-chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it is derived. Unless otherwise specified, the scFv may have VL and VH variable regions in any order herein; for example, relative to the N-terminus and C-terminus of the polypeptide, the scFv may comprise VL-linker-VH or may comprise VH-linker-VL.

[0166] In some implementations, the antibody fragment is an Fd fragment composed of VH and CH1 domains.

[0167] In some implementations, the antibody fragment is an Fv fragment composed of the VH and VL domains of a single arm of the antibody.

[0168] In some embodiments, the antibody fragment is dsFv, which is obtained by linking polypeptides in which one amino acid residue in each VH and VL is replaced by a cysteine ​​residue via disulfide bonds between cysteine ​​residues. The amino acid residues to be replaced by cysteine ​​residues can be selected based on prediction of the antibody's three-dimensional structure using known methods (Protein Engineering. 7:697 (1994)).

[0169] In some implementations, the antibody fragment is a single-domain antibody, which is an antibody fragment containing all or part of the variable domain of the heavy chain of the antibody.

[0170] In some embodiments, the antibody fragment is a domain antibody (dAb); see, for example, US Patent 6248516. A domain antibody (dAb) is the functional binding domain of an antibody, corresponding to the variable region of the heavy (VH) or light (VL) chain of a human antibody. dAbs have a molecular weight of approximately 13 kDa, or are less than one-tenth the size of a complete antibody. dAbs are well expressed in a variety of hosts, including bacterial, yeast, and mammalian cell systems. Furthermore, dAbs are highly stable and retain their activity even under harsh conditions, such as lyophilization or heat denaturation.

[0171] In some implementations, the antibodies provided herein are chimeric antibodies. In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region.

[0172] In some embodiments, the antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce its immunogenicity to humans while retaining the specificity and affinity of the parent non-human antibody. Generally, a humanized antibody contains one or more variable regions, wherein the CDR or a portion thereof is derived from the non-human antibody, and the FR or a portion thereof is derived from the human antibody. Optionally, the humanized antibody may also contain a portion of a human constant region. In some embodiments, some FR residues in the humanized antibody may be replaced with corresponding residues from the non-human antibody (e.g., an antibody providing the CDR sequence).

[0173] Humanized antibodies and their generation methods are reviewed in Almagro and Fransson, Front. Biosci. 13:1619-1633 (2008), and further described in Riechmann et al., Nature 332:323-329 (1988); Queen et al., Proc. Natl. Acad. Sci. USA 86:10029-10033 (1989); U.S. Patent Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri et al., Methods 36:25-34 (2005) (describes specificity-determining region (SDR) grafting); Padlan, Mol. Immunol. 28:489-498 (1991) (describes “resurfuacing”); Dall'Acqua et al., Methods 36:43-60 (2005) (describes “FR reorganization”); and Osbourn et al., Methods 36:61-68 (2005); and Klimka et al., Br. J. Cancer 83:252-260 (2000) (describes the “guided selection” approach to FR reorganization).

[0174] Human frame regions that can be used for humanization include, but are not limited to: frame regions selected using a "best-fit" method (see, for example, Sims et al., J. Immunol. 151:2296 (1993)); frame regions of the common sequence of human antibodies derived from specific subgroups of light chain variable regions or heavy chain variable regions (see, for example, Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al., J. Immunol., 151:2623 (1993)); mature human (somatic mutant) frame regions or human germline frame regions (see, for example, Almagro and Fransson, Front. Biosci. 13: 1619-1633 (2008)); and the frame regions obtained by screening FR libraries (see, for example, Baca et al., J. Biol. Chem. 272: 10678-10684 (1997) and Rosok et al., J. Biol. Chem. 271: 22611-22618 (1996)).

[0175] In some embodiments, the antibodies provided herein are multispecific antibodies, such as bispecific antibodies. A multispecific antibody is a monoclonal antibody that has binding specificity to at least two different sites (i.e., different epitopes on different antigens or different epitopes on the same antigen). In some embodiments, a multispecific antibody has three or more binding specificities. In some embodiments, one binding specificity is against CD117, while the others are against any other antigen. In some embodiments, a bispecific antibody may bind to two (or more) different epitopes of CD117. Multispecific (e.g., bispecific) antibodies can also be used to target cytotoxic agents or cells to cells expressing CD117. Multispecific antibodies can be prepared as full-length antibodies or antibody fragments.

[0176] (LNP nanoparticles)

[0177] As used herein, the term "lipid nanoparticle" or "LNP" refers to a particle having a nanometer scale (nm) (e.g., 1 nm to 1000 nm) that contains one or more types of lipid molecules. The LNPs provided herein may further contain at least one non-lipid payload molecule (e.g., one or more nucleic acid molecules). In some embodiments, the LNP contains a non-lipid payload molecule partially or completely encapsulated within a lipid shell. In particular, in some embodiments, the payload is a negatively charged molecule (e.g., mRNA encoding a viral protein), and the lipid component of the LNP contains at least one cationic lipid. It is contemplated that the cationic lipid can interact with the negatively charged payload molecule and promote payload incorporation and / or encapsulation into the LNP during LNP formation. Other lipids that can form part of an LNP, as provided herein, include, but are not limited to, neutral lipids and charged lipids, such as steroids, PEG lipids, and various zwitterionic lipids.

[0178] In some embodiments, the nanoparticle compositions provided herein may comprise one or more charged or ionizable lipids. It is contemplated that certain charged or zwitterionic lipid components of the nanoparticle compositions may resemble lipid components in cell membranes, thereby improving cellular uptake of the nanoparticles. In some embodiments, the ionizable lipids may be positively or negatively charged. For example, ionizable lipids may be positively charged at lower pH, in which case they may be referred to as "cationic lipids." Exemplary charged or ionizable lipids that can form part of the nanoparticle compositions disclosed herein include, but are not limited to, 3-(docoacylamino)-N1,N1,4-tridodecyl-1-piperazinethylamine (KL10), N1-[2-(docoacylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazindieneamide (KL22), 14,25-docodecyl-15,18,21,24-tetraazaoctaporane (KL25), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), and 2,2-dilinoleyl... -4-Dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), heptadecyl alcohol ester (heptatriaconta)-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butyrate (DLin-MC3-DMA), 2,2-dilinoleoyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), 1,2-dioloxy-N,N-dimethylaminopropane (DODMA), 2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy) -N,N-dimethyl-3-[(9Z,12Z)-octadec-9,12-dien-1-yloxy]prop-1-amine (octyl-CLinDMA), (2R)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[[(9Z,12Z)-octadec-9,12-dien-1-yloxy]prop-1-amine (octyl-CLinDMA(2R)), (2S)-2-({8-[(3β)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethylethyl-3-[((9Z,12Z)-[ ... Z-,12Z)-octadec-9,12-dien-1-yloxy]prop-1-amine (octyl-CLinDMA(2S)), (12Z,15Z)-N,N-dimethyl-2-nonyldocodecyl-12,15-den-1-amine, N,N-dimethyl-1-{((1S,2R)-2-octylcyclopropyl}heptadecane-8-amine, 11-({8-[(2-butyloctyl)oxy]-8-oxylideneoctyl}amino)-10-(3-ethyl-6-oxylidene-3,7-diazahexadecane-7-yl)-11-oxylidene undecanoate-2-butyloctyl ester.Other exemplary charged or ionizable lipids that may form part of the nanoparticle compositions disclosed herein include those described in Sabnis et al., “A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates,” Molecular Therapy V01.26 No 6, 2018, the entire contents of which are incorporated herein by reference.

[0179] In some embodiments, suitable ionizable lipids include N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA); N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP); 1,2-dioleoyl-sn-glycero-3-ethylcholine phosphate (DOEPC); 1,2-dilauroyl-sn-glycero-3-ethylcholine phosphate (DLEPC); 1,2-dimyristoyl-sn-glycero-3-ethylcholine phosphate. Alkaline phosphate (DMEPC); 1,2-Dimyristoleoyl-sn-glycero-3-ethylcholine phosphate (14:1); N1-[2-((1S)-1-[(3-aminopropyl)amino]-4-[di(3-aminopropyl)amino]butylcarbamoyl]ethyl]-3,4-di[oleyloxy]-benzamide (MVL5); bis(octadecylamino-glycyl)spermine (DOGS); 3b-[N-(N′,N′-dimethylaminoethyl)carbamoyl]cholesterol (DC-Cho1); bis(octadecyl) Methylammonium bromide (DDAB); SAINT-2, N-methyl-4-(diolenoyl)methylpyridine; 1,2-dimyristyloxypropyl-3-dimethylhydroxyethylammonium bromide (DMRIE); 1,2-dioleoyl-3-dimethyl-hydroxyethylammonium bromide (DORIE); 1,2-dioleoyloxypropyl-3-dimethylhydroxyethylammonium chloride (DORI); di-alkylated amino acids (DILA2) (e.g., C18:1-norArg-C16); diolenoyl dimethylammonium chloride (DODAC); 1 - Palmitoyl-2-oleoyl-sn-glycero-3-ethylcholine phosphate (POEPC); 1,2-Dimyristoleoyl-sn-glycero-3-ethylcholine phosphate (MOEPC); (R)-5-(dimethylamino)pentane-1,2-diyldioleoyl ester hydrochloride (DODAPen-C1); (R)-5-guanidinopentane-1,2-diyldioleoyl ester hydrochloride (DOPen-G); and (R)-N,N,N-trimethyl-4,5-bis(oleoyloxy)pentane-1-ammonium chloride (DOTAPen). Cationic lipids with head groups charged at physiological pH, such as primary amines (e.g., DODAGN′, N′-bis(octadecyl-N-4,8-diaza-10-aminodecanoylglycine amide) and guanidine salt head groups (e.g., bis-guanidine-spermine-cholesterol (BGSC), bis-guanidine-triaminoethylamine-cholesterol (BGTC), PONA, and (R)-5-guanidinylpentane-1,2-dimethyldioleoyl ester hydrochloride (DOPen-G)), are also suitable. Another suitable cationic lipid is (R)-5-(dimethylamino)pentane-1,2-dimethyldioleoyl ester hydrochloride (DODAPen-C1).In some embodiments, the cationic lipid is a specific enantiomer or racemic form and includes multiple salt forms of the cationic lipid as described above (e.g., chlorides or sulfates). For example, in some embodiments, the cationic lipid is N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP-Cl) or N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium sulfate (DOTAP-sulfate). In some embodiments, the cationic lipids are ionizable cationic lipids, such as (e.g.) bis(octadecyl)dimethylammonium bromide (DDAB); 1,2-dilinoleyloxy-3-dimethylaminopropane (DLinDMA); 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA); hepta-trianediane-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butyrate (DLin-MC3-DMA); 1,2-dioleoyloxy-3-dimethylaminopropane (DODAP); 1,2-dioleenyloxy-3-dimethylaminopropane (DODMA); and morpholinocholesterol (Mo-CHOL). In some embodiments, the lipid nanoparticles comprise a combination of two or more cationic lipids (e.g., the two or more cationic lipids described above).

[0180] In some embodiments, the ionizable lipid is according to 01-I, 02-I, 02-I-1, 02-I-2, 02-I-3, 02-I-4, 02-I-5, 02-I-6, 02-I-7, 02-I-8, 02-I-9, 02-I-10, 02-I-11, 02-I-12 , 02-I-13, 02-I-14, 03-I, 03-I-1, 03-I-2, 04-I, 04-I-1, 04-I-2, 04-I-1-3, 04-I-4, 04-II, 04-II-1, 04-II-2, 04-II-3 and compounds of any formula thereof.

[0181] In one embodiment, the lipid nanoparticles (LNPs) described herein, or the ionizable lipids contained in the pharmaceutical composition, are the ionizable lipids described in International Patent Publication No. WO2024152512, the full text of which is incorporated herein by reference.

[0182] In one embodiment, the cationic lipid is a compound of formula (01-I):

[0183] in:

[0184] G1 C 1-6 Alkylene;

[0185] R 1 R 2 Each independently is C 1-6 alkyl;

[0186] Optional, R 1 R 2 Together with the attached N, they form a 3-8 membered heterocyclic group, or, R 1 R 2 Any of the two G 1 Any carbon atom in the group can be directly linked to form a 3-8 membered heterocyclic group;

[0187] L 1 Selected from Heteroatoms O, N, and S may not be present;

[0188] R 3 R 4 R 5 R 6 R 7 Each independently is hydrogen, C 1-8 Alkyl or -OC 2-12 alkenyl;

[0189] a and b are each independently selected from integers from 1 to 10;

[0190] L 2 Selected from Heteroatoms O, N, and S may not be present;

[0191] R 8 R 9 R 10 R 11 R 12 Each is independently hydrogen or C 1-8 alkyl;

[0192] c and d are each independently selected from integers from 1 to 10;

[0193] L 3 Selected from Heteroatoms O, N, and S may not be present;

[0194] R 13 R 14 R 15 R 16 R 17 Each independently is hydrogen, C 1-8 Alkyl or -OC 2-12 alkenyl;

[0195] e and f are each independently selected from integers from 1 to 10.

[0196] According to some specific embodiments of this disclosure, in formula 01-I, the G 1 It can be methylene, ethylene, propylene, butylene, or pentylene.

[0197] According to some specific implementation schemes of this disclosure, in formula 01-I, R 1 R 2 Each is independently methyl, ethyl, or propyl; or, R 1 R 2 Together with the connected N, it forms a 5- or 6-membered heterocyclic group. According to other specific embodiments of this disclosure, in formula I, R... 1 R 2 One of them is directly bonded to any carbon atom in G1 to form a 5- or 6-membered heterocyclic group, R 1 R 2 The other one is methyl, ethyl, or propyl.

[0198] According to some specific implementation schemes of this disclosure, in formula 01-I, G 1 R 1 R 2 Each corresponds to a group shown in compound 01-01 or at least any of compounds 01-35 (see Table 1).

[0199] According to some specific implementation schemes, in formula 01-I,

[0200] L 1 for Or it may not exist;

[0201] R 3 R 4 R 5 At least two of them are not hydrogen, R 6 R 7 It is hydrogen;

[0202] a is an integer selected from 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10);

[0203] b can be 2, 3, 4, 5, 6, 7, 8, or 9.

[0204] According to some specific implementation schemes of this disclosure, in formula 01-I, L 1 R 3 R 4 R 5 R 6 R 7 a and b correspond to the functional groups or values ​​shown in any of the compounds from 01-01 to 01-35.

[0205] According to some specific implementation schemes of this disclosure, in formula 01-I,

[0206] L 2 for It may not exist; preferably, it does not exist.

[0207] R 8 R 9 R 10 R 11 R 12 Each is independently hydrogen;

[0208] c and d are each independently selected from integers from 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).

[0209] According to some specific implementation schemes of this disclosure, the sum of c and d is 4, 5, 6, 7, 8, 9, 10.

[0210] According to some specific implementation schemes of this disclosure, L 2 It does not exist; the sum of c and d is 5, 6, 7, 8, 9, or 10.

[0211] According to some specific implementation schemes of this disclosure, in formula 01-I, L 2 R 8 R 9 R 10 R 11 R 12 c and d correspond to the functional groups or values ​​shown in any of the compounds 01-01 to 01-35.

[0212] According to some specific implementation schemes of this disclosure, in formula 01-I,

[0213] L 3 for

[0214] R 13 R 14 Each is hydrogen; R 15 R 16 R 17 At least neither of them is hydrogen;

[0215] e is 2, 3, 4, 5, 6, 7, 8, or 9;

[0216] f is an integer selected from 1 to 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).

[0217] According to a specific embodiment of this disclosure, in formula 01-I, L 3 R 13R 14 R 15 R 16 R 17 e and f correspond to the groups or values ​​shown in any of the compounds 01-01 to 01-35.

[0218] In this disclosure, when the values ​​of a, b, c, d, e, and f are not 1, the corresponding multiple R... 3 Multiple R 4 Multiple R 6 Multiple R 7 Multiple R 8 Multiple R 9 Multiple R 10 Multiple R 11 Multiple R 13 Multiple R 14 Multiple R 15 Multiple R 17 They can be the same or different independently.

[0219] According to one specific embodiment of this disclosure, the compound is selected from one or more of compounds 01-01 to 01-35 shown in Table 1.

[0220] Table 1

[0221] In some embodiments, the lipid nanoparticles (LNPs) described herein and the ionizable lipids contained in the pharmaceutical compositions are the ionizable lipids described in International Patent Application No. PCT / CN2024 / 082316, the entire contents of which are incorporated herein by reference.

[0222] In one embodiment, the cationic lipid is a compound of formula O2-I:

[0223] in:

[0224] G 1 C 1-6 Alkylene;

[0225] R 1 R 2 Each independently is C 1-6 Alkyl or C 1-6 Alkoxy group; wherein the alkyl or alkoxy group has 0 to 3 H atoms, optionally further converted to halogen, hydroxyl, or C atoms. 1-6 Alkyl, C 1-6 alkoxy- or halogen-substituted C 1-6 alkyl or hydroxy substituted C 1-6 Alkyl groups are substituted;

[0226] Optional, R 1 R 2 Together with the attached N, they form a 3-8 membered heterocyclic group, or, R 1 R 2 Any of the two G 1 Any carbon atom in the group is directly bonded to form a 3-8 membered heterocyclic group; 0 to 3 ring Cs in the heterocyclic group are optionally further replaced by N, O or S; 0 to 3 Hs in the heterocyclic group are optionally further replaced by halogens, hydroxyl groups, C 1-6 Alkyl, C 1-6 alkoxy- or halogen-substituted C 1-6 alkyl or hydroxy substituted C 1-6 Alkyl groups are substituted;

[0227] L 1 Selected from The alkynyl group, heteroatom O, N, S, or none exist; h, i, k are selected from integers from 1 to 10; j is selected from 0 or 1;

[0228] R 3 R 4 R 5 R 6 R 7 Each independently is hydrogen, C 1-12 Alkyl, C 1-12 alkenyl, C 1-12 alkynyl or C 1-12 Alkoxy; wherein the alkyl, alkenyl, alkynyl or alkoxy group has 0 to 3 H atoms, optionally further converted to halogen, hydroxyl, or C atoms. 1-12 Alkyl, C 1-12 alkenyl, C 1-12 alkynyl group, C 1-12 alkoxy- or halogen-substituted C 1-12 alkyl or hydroxy substituted C 1-12 Alkyl groups are substituted;

[0229] a and b are each independently selected from integers between 0 and 10;

[0230] L 2 Selected from The alkynyl group, heteroatom O, N, S, or none exist; h, i, k are selected from integers from 1 to 10; j is selected from 0 or 1;

[0231] R 8 R 9 R 10 R 11 R 12 Each independently is hydrogen, C 1-12 Alkyl, C1-12 alkenyl, C 1-12 alkynyl or C 1-12 Alkoxy; wherein the alkyl, alkenyl, alkynyl or alkoxy group has 0 to 3 H atoms, optionally further converted to halogen, hydroxyl, or C atoms. 1-12 Alkyl, C 1-12 alkenyl, C 1-12 alkynyl group, C 1-12 alkoxy- or halogen-substituted C 1-12 alkyl or hydroxy substituted C 1-12 Alkyl groups are substituted;

[0232] c and d are each independently selected from integers between 0 and 10;

[0233] L 3 L 4 Each independently selected The alkynyl group, heteroatom O, N, S, or none exist; l and n are integers selected from 1 to 10; m is selected from 0 or 1;

[0234] R 13 R 14 R 15 R 16 R 17 R 18 R 19 Each independently is hydrogen, C 1-12 Alkyl, C 1-12 alkenyl, C 1-12 alkynyl or C 1-12 Alkoxy; wherein the alkyl, alkenyl, alkynyl or alkoxy group has 0 to 3 H atoms, optionally further converted to halogen, hydroxyl, or C atoms. 1-12 Alkyl, C 1-12 alkenyl, C 1-12 alkynyl group, C 1-12 alkoxy- or halogen-substituted C 1-12 alkyl or hydroxy substituted C 1-12 Alkyl groups are substituted;

[0235] e, f, and g are each independently selected from integers between 0 and 10.

[0236] In some implementations, in formula 02-I, the G 1 The compounds are methylene, ethylene, propylene, butylene, pentylene, or hexylene. The propylene, butylene, pentylene, or hexylene compounds can be straight-chain or branched.

[0237] In some implementations, in formula 02-I, the G 1 It can be methylene, ethylene, propylene, butylene, or pentylene.

[0238] In some embodiments, the compounds are shown as formulas O2-I-1, O2-I-2, O2-I-3, O2-I-4, and O2-I-5, respectively.

[0239] In some specific implementation schemes, in formula 02-I, the G 1 This refers to the group corresponding to compounds 02-7 or 02-14. (In this document, when describing a substituent as corresponding to a group shown in a compound, it means that the substituent corresponds to the position of that substituent in the corresponding formula 02-I of that compound. For example, G...) 1 The group corresponding to compound 02-7 refers to G. 1 The propylidene group between N and S on the far left of the structural formula of compound 02-7 is shown in the structural formula. The group shown in the middle frame.

[0240] In some implementations, in formula 02-I, the G 1 The corresponding group is shown in compound 02-11.

[0241] In some implementations, in formula 02-I, the G 1 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0242] In some implementations, in formula 02-I, the G 1 The corresponding group is shown in compound 02-9 or compound 02-1.

[0243] In some implementations, in formula 02-I, the G 1 The corresponding group is shown in compound 02-5.

[0244] In some implementations, in formula 02-I, the G 1 The corresponding group is shown in compound 02-2.

[0245] In some implementations, in formula 02-I, the G 1 The corresponding group is shown in compound 02-8.

[0246] In some implementations, in formula 02-I, the G 1 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0247] In some implementations, in formula 02-I, the G 1 The group is represented by any of the compounds 02-15 to 02-31.

[0248] In some implementations, in formula 02-I, R 1 R 2 Each alkyl or alkoxy group is independently methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, pentoxy, or hexoxy; wherein the alkyl or alkoxy group has 0, 1, 2, or 3 H atoms, optionally further converted to halogen, hydroxyl, or C. 1-6 Alkyl, C 1-6 alkoxy- or halogen-substituted C 1-6 alkyl or hydroxy substituted C 1-6 Alkyl groups are substituted.

[0249] In some implementations, in formula 02-I, R 1 R 2 Each is independently methyl, ethyl, propyl, or butyl, wherein the methyl, ethyl, propyl, or butyl group has 0, 1, or 2 H atoms, optionally further converted by a halogen, hydroxyl group, or C. 1-3 Alkyl-substituted; or, R 1 R 2 Together with the attached N, it forms a 5- or 6-membered heterocyclic group, wherein 0, 1, or 2 ring Cs in the heterocyclic group are optionally further substituted with N, O, or S, and 0, 1, or 2 Hs in the heterocyclic group are optionally further substituted with halogens, hydroxyl groups, or C. 1-3 Alkyl groups are substituted.

[0250] In some implementations, in formula 02-I, optionally, R 1 R 2 Together with the connected N, they form 3-, 4-, 5-, 6-, 7-, or 8-membered heterocyclic groups, or, R 1 R 2 Any of the two G 1 Any carbon atom in the group is directly bonded to form a 3-membered, 4-membered, 5-membered, 6-membered, 7-membered, or 8-membered heterocyclic group; 0, 1, 2, or 3 ring Cs in the heterocyclic group may be further replaced by N, O, or S; 0, 1, 2, or 3 Hs in the heterocyclic group may be further replaced by halogens, hydroxyl groups, or C. 1-6 Alkyl, C 1-6 alkoxy- or halogen-substituted C 1-6 alkyl or hydroxy substituted C 1-6 Alkyl groups are substituted.

[0251] According to other specific embodiments of this disclosure, in formula 02-I, R 1 R 2 One of the middle and G 1 Any carbon atom in R can be directly bonded to form a 5- or 6-membered heterocyclic group. 1 R 2The other is methyl, ethyl, propyl, or butyl, wherein the methyl, ethyl, propyl, or butyl group has 0, 1, or 2 H atoms, optionally further converted by a halogen, hydroxyl group, or C atom. 1-3 Alkyl groups are substituted. The heterocyclic group has 0, 1, or 2 ring carbons optionally further substituted with N, O, or S, and the heterocyclic group has 0, 1, or 2 hydrogens optionally further substituted with halogens, hydroxyl groups, or C. 1-3 Alkyl groups are substituted.

[0252] In some implementations, in formula 02-I, the R 1 The group corresponding to compound 02-7 or compound 02-14.

[0253] In some implementations, in formula 02-I, the R 1 The corresponding group is shown in compound 02-11.

[0254] In some implementations, in formula 02-I, the R 1 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0255] In some implementations, in formula 02-I, the R 1 The corresponding group is shown in compound 02-9 or compound 02-1.

[0256] In some implementations, in formula 02-I, the R 1 The corresponding group is shown in compound 02-5.

[0257] In some implementations, in formula 02-I, the R 1 The corresponding group is shown in compound 02-2.

[0258] In some implementations, in formula 02-I, the R 1 The corresponding group is shown in compound 02-8.

[0259] In some implementations, in formula 02-I, the R 1 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0260] In some implementations, in formula 02-I, the R 1 The group is represented by any of the compounds 02-15 to 02-31.

[0261] In some implementations, in formula 02-I, the R 2 The group corresponding to compound 02-7 or compound 02-14.

[0262] In some implementations, in formula 02-I, the R 2 The corresponding group is shown in compound 02-11.

[0263] In some implementations, in formula 02-I, the R 2 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0264] In some implementations, in formula 02-I, the R 2 The corresponding group is shown in compound 02-9 or compound 02-1.

[0265] In some implementations, in formula 02-I, the R 2 The corresponding group is shown in compound 02-5.

[0266] In some implementations, in formula 02-I, the R 2 The corresponding group is shown in compound 02-2.

[0267] In some implementations, in formula 02-I, the R 2 The corresponding group is shown in compound 02-8.

[0268] In some implementations, in formula 02-I, the R 2 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0269] In some implementations, in formula 02-I, the R 2 The group is represented by any of the compounds 02-15 to 02-31.

[0270] In some implementations, in formula 02-I, the R 1 R 2 These are the groups corresponding to compounds 02-7 or 02-14, respectively. (In this text, when describing two or more substituents as corresponding to groups shown in a compound, it means that the two or more substituents correspond to the positions of the two or more substituents in the corresponding formula 02-I of that compound. For example, R...) 1 R 2 The groups shown in compounds 02-7 respectively refer to R. 1 R 2 Each of these is independently the ethyl group on the leftmost N-position of the structural formula of compound 02-7, i.e., as shown in the structural formula. The group shown in the middle frame.

[0271] In some implementations, in formula 02-I, the R 1 R2 These are the groups shown in compounds 02-11.

[0272] In some implementations, in formula 02-I, the R 1 R 2 These are the groups shown in compounds 02-13, 02-12, or 6, respectively.

[0273] In some implementations, in formula 02-I, the R 1 R 2 These are the groups shown in compounds 02-9 or 02-1, respectively.

[0274] In some implementations, in formula 02-I, the R 1 R 2 These are the groups shown in compounds 02-5.

[0275] In some implementations, in formula 02-I, the R 1 R 2 These are the groups shown in the corresponding compound 02-2.

[0276] In some implementations, in formula 02-I, the R 1 R 2 These are the groups shown in compounds 02-8, respectively.

[0277] In some implementations, in formula 02-I, the R 1 R 2 These are the groups shown in compounds 02-3, 02-4, or 02-10, respectively.

[0278] In some implementations, in formula 02-I, the R 1 R 2 These are the groups represented by any one of compounds 02-15 to 02-31.

[0279] In some implementations, in formula 02-I, the above G 1 R 1 R 2 They can freely combine to form corresponding compounds.

[0280] In some implementations, in formula 02-I, G 1 R 1 R 2 These correspond to the groups shown in any of the compounds 02-1 to 02-31.

[0281] In some embodiments, the compounds are shown as those of formulas O2-I-6, O2-I-7, O2-I-8, and O2-I-9, respectively.

[0282] In Formulas 02-I-6, 02-I-7, 02-I-8, and 02-I-9, each substituent is as described in any of the schemes herein.

[0283] In some implementations, in formula 02-I,

[0284] L 1 for The alkynyl group, O, or none; h, i, and k are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; j is selected from 0 or 1.

[0285] In this document, unless otherwise specified, in Formula 02-I, when a certain group has a specific structure, the other groups can be defined in accordance with the definitions of each group in Formula 02-I. For example, when L in Formula 02-I... 1 for In this case, the remaining groups in formula 02-I can be consistent with the definitions of any scheme described in this paper.

[0286] In some implementations, in formula 02-I, R 3 R 4 R 5 At least two of them are not hydrogen, R 6 R 7 It is hydrogen.

[0287] In some implementations, in formula 02-I, a is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0288] In some implementations, in Formula 02-I, b is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0289] In some implementations, in formula 02-I, preferably, at least one of a and b or both are not 0.

[0290] In some implementations, in formula 02-I, the L 1 The group corresponding to compound 02-7 or compound 02-14.

[0291] In some implementations, in formula 02-I, the L 1 The corresponding group is shown in compound 02-11.

[0292] In some implementations, in formula 02-I, the L 1The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0293] In some implementations, in formula 02-I, the L 1 The corresponding group is shown in compound 02-9 or compound 02-1.

[0294] In some implementations, in formula 02-I, the L 1 The corresponding group is shown in compound 02-5.

[0295] In some implementations, in formula 02-I, the L 1 The corresponding group is shown in compound 02-2.

[0296] In some implementations, in formula 02-I, the L 1 The corresponding group is shown in compound 02-8.

[0297] In some implementations, in formula 02-I, the L 1 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0298] In some implementations, in formula 02-I, the L 1 The group is represented by any of the compounds 02-15 to 02-31.

[0299] In some implementations, in formula 02-I, the R 3 The group corresponding to compound 02-7 or compound 02-14.

[0300] In some implementations, in formula 02-I, the R 3 The corresponding group is shown in compound 02-11.

[0301] In some implementations, in formula 02-I, the R 3 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0302] In some implementations, in formula 02-I, the R 3 The corresponding group is shown in compound 02-9 or compound 02-1.

[0303] In some implementations, in formula 02-I, the R 3 The corresponding group is shown in compound 02-5.

[0304] In some implementations, in formula 02-I, the R 3 The corresponding group is shown in compound 02-2.

[0305] In some implementations, in formula 02-I, the R 3 The corresponding group is shown in compound 02-8.

[0306] In some implementations, in formula 02-I, the R 3 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0307] In some implementations, in formula 02-I, the R 3 The group is represented by any of the compounds 02-15 to 02-31.

[0308] In some implementations, in formula 02-I, the R 4 The group corresponding to compound 02-7 or compound 02-14.

[0309] In some implementations, in formula 02-I, the R 4 The corresponding group is shown in compound 02-11.

[0310] In some implementations, in formula 02-I, the R 4 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0311] In some implementations, in formula 02-I, the R 4 The corresponding group is shown in compound 02-9 or compound 02-1.

[0312] In some implementations, in formula 02-I, the R 4 The corresponding group is shown in compound 02-5.

[0313] In some implementations, in formula 02-I, the R 4 The corresponding group is shown in compound 02-2.

[0314] In some implementations, in formula 02-I, the R 4 The corresponding group is shown in compound 02-8.

[0315] In some implementations, in formula 02-I, the R 4 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0316] In some implementations, in formula 02-I, the R 4 The group is represented by any of the compounds 02-15 to 02-31.

[0317] In some implementations, in formula 02-I, the R 3 R 4 These are the groups shown in compounds 02-7 or 02-14, respectively.

[0318] In some implementations, in formula 02-I, the R 3 R 4 These are the groups shown in compounds 02-11.

[0319] In some implementations, in formula 02-I, the R 3 R 4 These are the groups shown in compounds 02-13, 02-12, or 02-6, respectively.

[0320] In some implementations, in formula 02-I, the R 3 R 4 These are the groups shown in compounds 02-9 or 02-1, respectively.

[0321] In some implementations, in formula 02-I, the R 3 R 4 These are the groups shown in compounds 02-5.

[0322] In some implementations, in formula 02-I, the R 3 R 4 These are the groups shown in the corresponding compound 02-2.

[0323] In some implementations, in formula 02-I, the R 3 R 4 These are the groups shown in compounds 02-8, respectively.

[0324] In some implementations, in formula 02-I, the R 3 R 4 These are the groups shown in compounds 02-3, 02-4, or 02-10, respectively.

[0325] In some implementations, in formula 02-I, the R 3 R 4 These are the groups represented by any one of compounds 02-15 to 02-31.

[0326] In the above specific implementation schemes, 'a' can be selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. Preferably, 'a' and 'R' are... 3 R 4These are the groups represented by any one of compounds 02-1 to 02-31.

[0327] In some implementations, in formula 02-I, the R 5 The group corresponding to compound 02-7 or compound 02-14.

[0328] In some implementations, in formula 02-I, the R 5 The corresponding group is shown in compound 02-11.

[0329] In some implementations, in formula 02-I, the R 5 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0330] In some implementations, in formula 02-I, the R 5 The corresponding group is shown in compound 02-9 or compound 02-1.

[0331] In some implementations, in formula 02-I, the R 5 The corresponding group is shown in compound 02-5.

[0332] In some implementations, in formula 02-I, the R 5 The corresponding group is shown in compound 02-2.

[0333] In some implementations, in formula 02-I, the R 5 The corresponding group is shown in compound 02-8.

[0334] In some implementations, in formula 02-I, the R 5 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0335] In some implementations, in formula 02-I, the R 5 The group is represented by any of the compounds 02-15 to 02-31.

[0336] In some implementations, in formula 02-I, the R 3 R 4 R 5 These are the groups shown in compounds 02-7 or 02-14, respectively.

[0337] In some implementations, in formula 02-I, the R 3 R 4 R 5 These are the groups shown in compounds 02-11.

[0338] In some implementations, in formula 02-I, the R 3 R 4 R 5 These are the groups shown in compounds 02-13, 02-12, or 02-6, respectively.

[0339] In some implementations, in formula 02-I, the R 3 R 4 R 5 These are the groups shown in compounds 02-9 or 02-1, respectively.

[0340] In some implementations, in formula 02-I, the R 3 R 4 R 5 These are the groups shown in compounds 02-5.

[0341] In some implementations, in formula 02-I, the R 3 R 4 R 5 These are the groups shown in the corresponding compound 02-2.

[0342] In some implementations, in formula 02-I, the R 3 R 4 R 5 These are the groups shown in compounds 02-8, respectively.

[0343] In some implementations, in formula 02-I, the R 3 R 4 R 5 These are the groups shown in compounds 02-3, 02-4, or 02-10, respectively.

[0344] In some implementations, in formula 02-I, the R 3 R 4 R 5 These are the groups represented by any one of compounds 02-15 to 02-31.

[0345] In the above specific implementation schemes, 'a' can be selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. Preferably, 'a' and 'R' are... 3 R 4 R 5 These are the groups represented by any one of compounds 02-1 to 02-31.

[0346] In some implementations, in formula 02-I, the R 6The group corresponding to compound 02-7 or compound 02-14.

[0347] In some implementations, in formula 02-I, the R 6 The corresponding group is shown in compound 02-11.

[0348] In some implementations, in formula 02-I, the R 6 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0349] In some implementations, in formula 02-I, the R 6 The corresponding group is shown in compound 02-9 or compound 02-1.

[0350] In some implementations, in formula 02-I, the R 6 The corresponding group is shown in compound 02-5.

[0351] In some implementations, in formula 02-I, the R 6 The corresponding group is shown in compound 02-2.

[0352] In some implementations, in formula 02-I, the R 6 The corresponding group is shown in compound 02-8.

[0353] In some implementations, in formula 02-I, the R 6 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0354] In some implementations, in formula 02-I, the R 6 The group is represented by any of the compounds 02-15 to 02-31.

[0355] In some implementations, in formula 02-I, the R 7 The group corresponding to compound 02-7 or compound 02-14.

[0356] In some implementations, in formula 02-I, the R 7 The corresponding group is shown in compound 02-11.

[0357] In some implementations, in formula 02-I, the R 7 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0358] In some implementations, in formula 02-I, the R 7The corresponding group is shown in compound 02-9 or compound 02-1.

[0359] In some implementations, in formula 02-I, the R 7 The corresponding group is shown in compound 02-5.

[0360] In some implementations, in formula 02-I, the R 7 The corresponding group is shown in compound 02-2.

[0361] In some implementations, in formula 02-I, the R 7 The corresponding group is shown in compound 02-8.

[0362] In some implementations, in formula 02-I, the R 7 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0363] In some implementations, in formula 02-I, the R 7 The group is represented by any of the compounds 02-15 to 02-31.

[0364] In some implementations, in formula 02-I, the R 6 R 7 These are the groups shown in compounds 02-7 or 02-14, respectively.

[0365] In some implementations, in formula 02-I, the R 6 R 7 These are the groups shown in compounds 02-11.

[0366] In some implementations, in formula 02-I, the R 6 R 7 These are the groups shown in compounds 02-13, 02-12, or 02-6, respectively.

[0367] In some implementations, in formula 02-I, the R 6 R 7 These are the groups shown in compounds 02-9 or 02-1, respectively.

[0368] In some implementations, in formula 02-I, the R 6 R 7 These are the groups shown in compounds 02-5.

[0369] In some implementations, in formula 02-I, the R 6 R 7These are the groups shown in the corresponding compound 02-2.

[0370] In some implementations, in formula 02-I, the R 6 R 7 These are the groups shown in compounds 02-8, respectively.

[0371] In some implementations, in formula 02-I, the R 6 R 7 These are the groups shown in compounds 02-3, 02-4, or 02-10, respectively.

[0372] In some implementations, in formula 02-I, the R 6 R 7 These are the groups represented by any one of compounds 02-15 to 02-31.

[0373] In the above specific implementation schemes, b can be selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. Preferably, b and R 6 R 7 These are the groups or values ​​represented by any one of compounds 02-1 to 02-31.

[0374] In some implementations, in formula 02-I, the R 6 R 7 R 5 These are the groups shown in compounds 02-7 or 02-14, respectively.

[0375] In some implementations, in formula 02-I, the R 6 R 7 R 5 These are the groups shown in compounds 02-11.

[0376] In some implementations, in formula 02-I, the R 6 R 7 R 5 These are the groups shown in compounds 02-13, 02-12, or 02-6, respectively.

[0377] In some implementations, in formula 02-I, the R 6 R 7 R 5 These are the groups shown in compounds 02-9 or 02-1, respectively.

[0378] In some implementations, in formula 02-I, the R 6 R 7 R5 These are the groups shown in compounds 02-5.

[0379] In some implementations, in formula 02-I, the R 6 R 7 R 5 These are the groups shown in the corresponding compound 02-2.

[0380] In some implementations, in formula 02-I, the R 6 R 7 R 5 These are the groups shown in compounds 02-8, respectively.

[0381] In some implementations, in formula 02-I, the R 6 R 7 R 5 These are the groups shown in compounds 02-3, 02-4, or 02-10, respectively.

[0382] In some implementations, in formula 02-I, the R 6 R 7 R 5 These are the groups represented by any one of compounds 02-15 to 02-31.

[0383] In the above specific implementation schemes, b can be selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. Preferably, b and R 6 R 7 R 5 These are the groups or values ​​represented by any one of compounds 02-1 to 02-31.

[0384] In some implementations, in formula 02-I, the above L 1 R 3 R 4 R 5 R 6 R 7 a and b can be freely combined to form corresponding compounds.

[0385] In some implementations, in formula 02-I, L 1 R 3 R 4 R 5 R 6 R 7 a and b correspond to the groups or values ​​shown in any of the compounds 02-1 to 02-31.

[0386] In some implementations, in formula 02-I,

[0387] L 2 for The group is alkynyl, O, or absent; h is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;

[0388] R 8 R 9 Each is independently hydrogen, R 10 R 11 R 12 At least two of them are not hydrogen;

[0389] c and d are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; preferably, at least one or both of c and d are not 0.

[0390] In some implementations, in formula 02-I, the L 2 The group corresponding to compound 02-7 or compound 02-14.

[0391] In some implementations, in formula 02-I, the L 2 The corresponding group is shown in compound 02-11.

[0392] In some implementations, in formula 02-I, the L 2 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0393] In some implementations, in formula 02-I, the L 2 The corresponding group is shown in compound 02-9 or compound 02-1.

[0394] In some implementations, in formula 02-I, the L 2 The corresponding group is shown in compound 02-5.

[0395] In some implementations, in formula 02-I, the L 2 The corresponding group is shown in compound 02-2.

[0396] In some implementations, in formula 02-I, the L 2 The corresponding group is shown in compound 02-8.

[0397] In some implementations, in formula 02-I, the L 2 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0398] In some implementations, in formula 02-I, the L 2The group is represented by any of the compounds 02-15 to 02-31.

[0399] In some implementations, in formula 02-I, the R 10 The group corresponding to compound 02-7 or compound 02-14.

[0400] In some implementations, in formula 02-I, the R 10 The corresponding group is shown in compound 02-11.

[0401] In some implementations, in formula 02-I, the R 10 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0402] In some implementations, in formula 02-I, the R 10 The corresponding group is shown in compound 02-9 or compound 02-1.

[0403] In some implementations, in formula 02-I, the R 10 The corresponding group is shown in compound 02-5.

[0404] In some implementations, in formula 02-I, the R 10 The corresponding group is shown in compound 02-2.

[0405] In some implementations, in formula 02-I, the R 10 The corresponding group is shown in compound 02-8.

[0406] In some implementations, in formula 02-I, the R 10 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0407] In some implementations, in formula 02-I, the R 10 The group is represented by any of the compounds 02-15 to 02-31.

[0408] In some implementations, in formula 02-I, the R 11 The group corresponding to compound 02-7 or compound 02-14.

[0409] In some implementations, in formula 02-I, the R 11 The corresponding group is shown in compound 02-11.

[0410] In some implementations, in formula 02-I, the R 11The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0411] In some implementations, in formula 02-I, the R 11 The corresponding group is shown in compound 02-9 or compound 02-1.

[0412] In some implementations, in formula 02-I, the R 11 The corresponding group is shown in compound 02-5.

[0413] In some implementations, in formula 02-I, the R 11 The corresponding group is shown in compound 02-2.

[0414] In some implementations, in formula 02-I, the R 11 The corresponding group is shown in compound 02-8.

[0415] In some implementations, in formula 02-I, the R 11 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0416] In some implementations, in formula 02-I, the R 11 The group is represented by any of the compounds 02-15 to 02-31.

[0417] In some implementations, in formula 02-I, the R 10 R 11 These are the groups shown in compounds 02-7 or 02-14, respectively.

[0418] In some implementations, in formula 02-I, the R 10 R 11 These are the groups shown in compounds 02-11.

[0419] In some implementations, in formula 02-I, the R 10 R 11 These are the groups shown in compounds 02-13, 02-12, or 02-6, respectively.

[0420] In some implementations, in formula 02-I, the R 10 R 11 These are the groups shown in compounds 02-9 or 02-1, respectively.

[0421] In some implementations, in formula 02-I, the R 10 R 11These are the groups shown in compounds 02-5.

[0422] In some implementations, in formula 02-I, the R 10 R 11 These are the groups shown in the corresponding compound 02-2.

[0423] In some implementations, in formula 02-I, the R 10 R 11 These are the groups shown in compounds 02-8, respectively.

[0424] In some implementations, in formula 02-I, the R 10 R 11 These are the groups shown in compounds 02-3, 02-4, or 02-10, respectively.

[0425] In some implementations, in formula 02-I, the R 10 R 11 These are the groups represented by any one of compounds 02-15 to 02-31.

[0426] In the above specific implementation schemes, d can be selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. Preferably, d and R 10 R 11 These are the groups or values ​​represented by any one of compounds 02-1 to 02-31.

[0427] In some implementations, in formula 02-I, the R 12 The group corresponding to compound 02-7 or compound 02-14.

[0428] In some implementations, in formula 02-I, the R 12 The corresponding group is shown in compound 02-11.

[0429] In some implementations, in formula 02-I, the R 12 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0430] In some implementations, in formula 02-I, the R 12 The corresponding group is shown in compound 02-9 or compound 02-1.

[0431] In some implementations, in formula 02-I, the R 12 The corresponding group is shown in compound 02-5.

[0432] In some implementations, in formula 02-I, the R 12 The corresponding group is shown in compound 02-2.

[0433] In some implementations, in formula 02-I, the R 12 The corresponding group is shown in compound 02-8.

[0434] In some implementations, in formula 02-I, the R 12 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0435] In some implementations, in formula 02-I, the R 12 The group is represented by any of the compounds 02-15 to 02-31.

[0436] In some implementations, in formula 02-I, the R 10 R 11 R 12 These are the groups shown in compounds 02-7 or 02-14, respectively.

[0437] In some implementations, in formula 02-I, the R 10 R 11 R 12 These are the groups shown in compounds 02-11.

[0438] In some implementations, in formula 02-I, the R 10 R 11 R 12 These are the groups shown in compounds 02-13, 02-12, or 02-6, respectively.

[0439] In some implementations, in formula 02-I, the R 10 R 11 R 12 These are the groups shown in compounds 02-9 or 02-1, respectively.

[0440] In some implementations, in formula 02-I, the R 10 R 11 R 12 These are the groups shown in compounds 02-5.

[0441] In some implementations, in formula 02-I, the R 10 R 11 R 12 These are the groups shown in the corresponding compound 02-2.

[0442] In some implementations, in formula 02-I, the R 10 R 11 R 12 These are the groups shown in compounds 02-8, respectively.

[0443] In some implementations, in formula 02-I, the R 10 R 11 R 12 These are the groups shown in compounds 02-3, 02-4, or 02-10, respectively.

[0444] In some implementations, in formula 02-I, the R 10 R 11 R 12 These are the groups represented by any one of compounds 02-15 to 02-31.

[0445] In the above specific implementation schemes, d can be selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. Preferably, d and R 10 R 11 R 12 These are the groups or values ​​represented by any one of compounds 02-1 to 02-31.

[0446] In some implementations, in formula 02-I, the R 8 The group corresponding to compound 02-7 or compound 02-14.

[0447] In some implementations, in formula 02-I, the R 8 The corresponding group is shown in compound 02-11.

[0448] In some implementations, in formula 02-I, the R 8 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0449] In some implementations, in formula 02-I, the R 8 The corresponding group is shown in compound 02-9 or compound 02-1.

[0450] In some implementations, in formula 02-I, the R 8 The corresponding group is shown in compound 02-5.

[0451] In some implementations, in formula 02-I, the R 8 The corresponding group is shown in compound 02-2.

[0452] In some implementations, in formula 02-I, the R 8 The corresponding group is shown in compound 02-8.

[0453] In some implementations, in formula 02-I, the R 8 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0454] In some implementations, in formula 02-I, the R 8 The group is represented by any of the compounds 02-15 to 02-31.

[0455] In some implementations, in formula 02-I, the R 9 The group corresponding to compound 02-7 or compound 02-14.

[0456] In some implementations, in formula 02-I, the R 9 The corresponding group is shown in compound 02-11.

[0457] In some implementations, in formula 02-I, the R 9 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0458] In some implementations, in formula 02-I, the R 9 The corresponding group is shown in compound 02-9 or compound 02-1.

[0459] In some implementations, in formula 02-I, the R 9 The corresponding group is shown in compound 02-5.

[0460] In some implementations, in formula 02-I, the R 9 The corresponding group is shown in compound 02-2.

[0461] In some implementations, in formula 02-I, the R 9 The corresponding group is shown in compound 02-8.

[0462] In some implementations, in formula 02-I, the R 9 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0463] In some implementations, in formula 02-I, the R 9 The group is represented by any of the compounds 02-15 to 02-31.

[0464] In some implementations, in formula 02-I, the R 8 R 9 These are the groups shown in compounds 02-7 or 02-14, respectively.

[0465] In some implementations, in formula 02-I, the R 8 R 9 These are the groups shown in compounds 02-11.

[0466] In some implementations, in formula 02-I, the R 8 R 9 These are the groups shown in compounds 02-13, 02-12, or 02-6, respectively.

[0467] In some implementations, in formula 02-I, the R 8 R 9 These are the groups shown in compounds 02-9 or 02-1, respectively.

[0468] In some implementations, in formula 02-I, the R 8 R 9 These are the groups shown in compounds 02-5.

[0469] In some implementations, in formula 02-I, the R 8 R 9 These are the groups shown in the corresponding compound 02-2.

[0470] In some implementations, in formula 02-I, the R 8 R 9 These are the groups shown in compounds 02-8, respectively.

[0471] In some implementations, in formula 02-I, the R 8 R 9 These are the groups shown in compounds 02-3, 02-4, or 02-10, respectively.

[0472] In some implementations, in formula 02-I, the R 8 R 9 These are the groups represented by any one of compounds 02-15 to 02-31.

[0473] In the above specific implementation schemes, c can be selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. Preferably, c and R 8 R 9 These are the groups or values ​​represented by any one of compounds 02-1 to 02-31.

[0474] In some implementations, in formula 02-I, the R 8 R 9 R 12 These are the groups shown in compounds 02-7 or 02-14, respectively.

[0475] In some implementations, in formula 02-I, the R 8 R 9 R 12 These are the groups shown in compounds 02-11.

[0476] In some implementations, in formula 02-I, the R 8 R 9 R 12 These are the groups shown in compounds 02-13, 02-12, or 02-6, respectively.

[0477] In some implementations, in formula 02-I, the R 8 R 9 R 12 These are the groups shown in compounds 02-9 or 02-1, respectively.

[0478] In some implementations, in formula 02-I, the R 8 R 9 R 12 These are the groups shown in compounds 02-5.

[0479] In some implementations, in formula 02-I, the R 8 R 9 R 12 These are the groups shown in the corresponding compound 02-2.

[0480] In some implementations, in formula 02-I, the R 8 R 9 R 12 These are the groups shown in compounds 02-8, respectively.

[0481] In some implementations, in formula 02-I, the R 8 R 9 R 12 These are the groups shown in compounds 02-3, 02-4, or 02-10, respectively.

[0482] In some implementations, in formula 02-I, the R 8 R 9 R 12These are the groups represented by any one of compounds 02-15 to 02-31.

[0483] In the above specific implementation schemes, c can be selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. Preferably, c and R 6 R 7 R 5 These are the groups or values ​​represented by any one of compounds 02-1 to 02-31.

[0484] In some implementations, in formula 02-I, the above L 2 R 8 R 9 R 10 R 11 R 12 c and d can freely combine to form corresponding compounds.

[0485] In some implementations, in formula 02-I, L 2 R 8 R 9 R 10 R 11 R 12 c and d correspond to the functional groups or values ​​shown in any of the compounds 02-1 to 02-31.

[0486] In some implementations, in formula 02-I,

[0487] L 3 L 4 Each independently selected alkyne group, O, or none;

[0488] R 13 R 14 Each is hydrogen; R 15 R 16 R 17 R 18 R 19 At least neither of them is hydrogen; preferably, R 16 R 18 R 19 At least neither of them is hydrogen;

[0489] e, f, and g are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0490] In some embodiments, the compounds are shown as those of formulas 02-I-10, 02-I-11, 02-I-12, 02-I-13, and 02-I-14, respectively.

[0491] In Formulas 02-I-10, 02-I-11, 02-I-12, 02-I-13, and 02-I-14, each substituent is as described in any of the schemes herein.

[0492] In some implementations, in formula 02-I,

[0493] L 3 for alkyne group, O, or none;

[0494] R 13 R 14 Each is hydrogen; R 15 R 16 R 17 At least neither of them is hydrogen;

[0495] e and f are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.

[0496] In some implementations, in formula 02-I,

[0497] L 4 for alkyne group, O, or none;

[0498] R 13 R 14 Each is hydrogen; R 15 R 16 R 17 R 18 R 19 At least neither of them is hydrogen;

[0499] e, f, and g are each independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0500] In some implementations, in formula 02-I, the L 3 The group corresponding to compound 02-7 or compound 02-14.

[0501] In some implementations, in formula 02-I, the L 3 The corresponding group is shown in compound 02-11.

[0502] In some implementations, in formula 02-I, the L 3 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0503] In some implementations, in formula 02-I, the L 3The corresponding group is shown in compound 02-9 or compound 02-1.

[0504] In some implementations, in formula 02-I, the L 3 The corresponding group is shown in compound 02-5.

[0505] In some implementations, in formula 02-I, the L 3 The corresponding group is shown in compound 02-2.

[0506] In some implementations, in formula 02-I, the L 3 The corresponding group is shown in compound 02-8.

[0507] In some implementations, in formula 02-I, the L 3 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0508] In some implementations, in formula 02-I, the L 3 The group is represented by any of the compounds 02-15 to 02-31.

[0509] In some implementations, in formula 02-I, the L 4 The group corresponding to compound 02-7 or compound 02-14.

[0510] In some implementations, in formula 02-I, the L 4 The corresponding group is shown in compound 02-11.

[0511] In some implementations, in formula 02-I, the L 4 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0512] In some implementations, in formula 02-I, the L 4 The corresponding group is shown in compound 02-9 or compound 02-1.

[0513] In some implementations, in formula 02-I, the L 4 The corresponding group is shown in compound 02-5.

[0514] In some implementations, in formula 02-I, the L 4 The corresponding group is shown in compound 02-2.

[0515] In some implementations, in formula 02-I, the L 4 The corresponding group is shown in compound 02-8.

[0516] In some implementations, in formula 02-I, the L 4 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0517] In some implementations, in formula 02-I, the L 4 The group is represented by any of the compounds 02-15 to 02-31.

[0518] In some implementations, in formula 02-I, the L 3 L 4 These are the groups shown in compounds 02-7 or 02-14, respectively.

[0519] In some implementations, in formula 02-I, the L 3 L 4 These are the groups shown in compounds 02-11.

[0520] In some implementations, in formula 02-I, the L 3 L 4 These are the groups shown in compounds 02-13, 02-12, or 02-6, respectively.

[0521] In some implementations, in formula 02-I, the L 3 L 4 These are the groups shown in compounds 02-9 or 02-1, respectively.

[0522] In some implementations, in formula 02-I, the L 3 L 4 These are the groups shown in compounds 02-5.

[0523] In some implementations, in formula 02-I, the L 3 L 4 These are the groups shown in the corresponding compound 02-2.

[0524] In some implementations, in formula 02-I, the L 3 L 4 These are the groups shown in compounds 02-8, respectively.

[0525] In some implementations, in formula 02-I, the L 3 L 4 These are the groups shown in compounds 02-3, 02-4, or 02-10, respectively.

[0526] In some implementations, in formula 02-I, the L3 L 4 These are the groups represented by any one of compounds 02-15 to 02-31.

[0527] In some implementations, in formula 02-I, the R 13 The group corresponding to compound 02-7 or compound 02-14.

[0528] In some implementations, in formula 02-I, the R 13 The corresponding group is shown in compound 02-11.

[0529] In some implementations, in formula 02-I, the R 13 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0530] In some implementations, in formula 02-I, the R 13 The corresponding group is shown in compound 02-9 or compound 02-1.

[0531] In some implementations, in formula 02-I, the R 13 The corresponding group is shown in compound 02-5.

[0532] In some implementations, in formula 02-I, the R 13 The corresponding group is shown in compound 02-2.

[0533] In some implementations, in formula 02-I, the R 13 The corresponding group is shown in compound 02-8.

[0534] In some implementations, in formula 02-I, the R 13 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0535] In some implementations, in formula 02-I, the R 13 The group is represented by any of the compounds 02-15 to 02-31.

[0536] In some implementations, in formula 02-I, the R 14 The group corresponding to compound 02-7 or compound 02-14.

[0537] In some implementations, in formula 02-I, the R 14 The corresponding group is shown in compound 02-11.

[0538] In some implementations, in formula 02-I, the R14 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0539] In some implementations, in formula 02-I, the R 14 The corresponding group is shown in compound 02-9 or compound 02-1.

[0540] In some implementations, in formula 02-I, the R 14 The corresponding group is shown in compound 02-5.

[0541] In some implementations, in formula 02-I, the R 14 The corresponding group is shown in compound 02-2.

[0542] In some implementations, in formula 02-I, the R 14 The corresponding group is shown in compound 02-8.

[0543] In some implementations, in formula 02-I, the R 14 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0544] In some implementations, in formula 02-I, the R 14 The group is represented by any of the compounds 02-15 to 02-31.

[0545] In some implementations, in formula 02-I, the above R 13 R 14 They can be combined in any way to form compounds.

[0546] In some implementations, in formula 02-I, the above R 13 R 14 These correspond to the groups shown in any of the compounds 02-1 to 02-31.

[0547] In some implementations, in formula 02-I, the R 15 The group corresponding to compound 02-7 or compound 02-14.

[0548] In some implementations, in formula 02-I, the R 15 The corresponding group is shown in compound 02-11.

[0549] In some implementations, in formula 02-I, the R 15 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0550] In some implementations, in formula 02-I, the R 15 The corresponding group is shown in compound 02-9 or compound 02-1.

[0551] In some implementations, in formula 02-I, the R 15 The corresponding group is shown in compound 02-5.

[0552] In some implementations, in formula 02-I, the R 15 The corresponding group is shown in compound 02-2.

[0553] In some implementations, in formula 02-I, the R 15 The corresponding group is shown in compound 02-8.

[0554] In some implementations, in formula 02-I, the R 15 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0555] In some implementations, in formula 02-I, the R 15 The group is represented by any of the compounds 02-15 to 02-31.

[0556] In some implementations, in formula 02-I, the R 17 The group corresponding to compound 02-7 or compound 02-14.

[0557] In some implementations, in formula 02-I, the R 17 The corresponding group is shown in compound 02-11.

[0558] In some implementations, in formula 02-I, the R 17 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0559] In some implementations, in formula 02-I, the R 17 The corresponding group is shown in compound 02-9 or compound 02-1.

[0560] In some implementations, in formula 02-I, the R 17 The corresponding group is shown in compound 02-5.

[0561] In some implementations, in formula 02-I, the R 17 The corresponding group is shown in compound 02-2.

[0562] In some implementations, in formula 02-I, the R 17The corresponding group is shown in compound 02-8.

[0563] In some implementations, in formula 02-I, the R 17 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0564] In some implementations, in formula 02-I, the R 17 The group is represented by any of the compounds 02-15 to 02-31.

[0565] In some implementations, in formula 02-I, the above R 15 R 17 They can be combined in any way to form compounds.

[0566] In some implementations, in formula 02-I, the above R 15 R 17 These correspond to the groups shown in any of the compounds 02-1 to 02-31.

[0567] In some implementations, in formula 02-I, the R 19 The group corresponding to compound 02-7 or compound 02-14.

[0568] In some implementations, in formula 02-I, the R 19 The corresponding group is shown in compound 02-11.

[0569] In some implementations, in formula 02-I, the R 19 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0570] In some implementations, in formula 02-I, the R 19 The corresponding group is shown in compound 02-9 or compound 02-1.

[0571] In some implementations, in formula 02-I, the R 19 The corresponding group is shown in compound 02-5.

[0572] In some implementations, in formula 02-I, the R 19 The corresponding group is shown in compound 02-2.

[0573] In some implementations, in formula 02-I, the R 19 The corresponding group is shown in compound 02-8.

[0574] In some implementations, in formula 02-I, the R 19The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0575] In some implementations, in formula 02-I, the R 19 The group is represented by any of the compounds 02-15 to 02-31.

[0576] In some implementations, in formula 02-I, the R 18 The group corresponding to compound 02-7 or compound 02-14.

[0577] In some implementations, in formula 02-I, the R 18 The corresponding group is shown in compound 02-11.

[0578] In some implementations, in formula 02-I, the R 18 The group is the one shown in compound 02-13, compound 02-12 or compound 02-6.

[0579] In some implementations, in formula 02-I, the R 18 The corresponding group is shown in compound 02-9 or compound 02-1.

[0580] In some implementations, in formula 02-I, the R 18 The corresponding group is shown in compound 02-5.

[0581] In some implementations, in formula 02-I, the R 18 The corresponding group is shown in compound 02-2.

[0582] In some implementations, in formula 02-I, the R 18 The corresponding group is shown in compound 02-8.

[0583] In some implementations, in formula 02-I, the R 18 The group corresponding to compound 02-3, compound 02-4 or compound 02-10.

[0584] In some implementations, in formula 02-I, the R 18 The group is represented by any of the compounds 02-15 to 02-31.

[0585] In some implementations, in formula 02-I, the above R 19 R 18 They can be combined in any way to form compounds.

[0586] In some implementations, in formula 02-I, the above R 19R 18 These correspond to the groups shown in any of the compounds 02-1 to 02-31.

[0587] In some implementations, in formula 02-I, the above L 3 L 4 R 13 R 14 R 15 R 16 R 17 R 18 R 19 They can be combined arbitrarily, where e, f, and g can each be independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0588] In some implementations, in formula 02-I, the above L 3 L 4 R 13 R 14 R 15 R 16 R 17 R 18 R 19 e, f, and g can be combined in any way to form compounds.

[0589] In some implementations, in formula 02-I, L 3 L 4 R 13 R 14 R 15 R 16 R 17 R 18 R 19 e, f, and g correspond to the groups or values ​​shown in any of the compounds 02-1 to 02-31.

[0590] In this disclosure, when the values ​​of a, b, c, d, e, and f are greater than 1, the corresponding multiple R... 3 Multiple R 4 Multiple R 6 Multiple R 7 Multiple R 8 Multiple R 9 Multiple R 10 Multiple R 11 Multiple R 13 Multiple R 14 Multiple R 15 Multiple R 17 They can be the same or different independently.

[0591] In some embodiments, the compound is selected from one or more of compounds 02-1 to 02-31 shown in Table 2.

[0592] Table 2

[0593] In some embodiments, the ionizable lipid in the lipid nanoparticles of this disclosure is 11-({8-[(2-butyloctyl)oxy]-8-oxoylideneoctyl}amino)-10-(3-ethyl-6-oxoylidene-3,7-diazahexadecane-7-yl)-11-oxoylideneundecanoate-2-butyloctyl ester.

[0594] In some embodiments, the lipid nanoparticles (LNPs) described herein and the ionizable lipids contained in the pharmaceutical compositions are the ionizable lipids described in International Patent Application No. PCT / CN2023 / 116607, the entire contents of which are incorporated herein by reference.

[0595] In one embodiment, the ionizable lipid is an O3-I compound:

[0596] in,

[0597] R1 and R2 are each independently selected from H, C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group or C1-C 10 Halogenated alkyl; or

[0598] R1 and R2 together with the N that connects them form a 4-10 membered heterocyclic group containing 1-3 heteroatoms selected from N, S and O;

[0599] G1 is -(CH2)n-, where n is a positive integer from 1 to 15, preferably a positive integer from 1 to 10, and more preferably a positive integer from 1 to 6;

[0600] R3 is selected from H, substituted or unsubstituted C1-C. 20 Alkyl, C2-C 20 alkenyl, C2-C 20 alkynyl group, C3-C 20 cycloalkyl or or R a -L a -R b "Substitution" refers to substitution having one or more substituents selected from the group consisting of: halogens, C1-C... 15 Alkyl, C2-C 15 alkenyl, C2-C15 alkynyl group, O-(C2-C 15 Hydrocarbon groups (including alkyl, alkenyl, or ynyl groups), C1-C 15 Haloalkyl, C1-C 15 The haloalkoxy group, -OH, -CN, -NH2, and Ra are -(CH2)s, where s is a positive integer from 1 to 15, preferably a positive integer from 1 to 10, and L... a Selected from -(C=O)O-, -O(C=O)-, -(SS)-, -O(S=O)-, -(C=O)S-, -S(C=O)-, -(C=S)O-, -NH(C=O)-, -(C=S)NH-, -NH(C=S)-, -(C=O)NH-, preferably -(C=O)O; R b Selected from C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 alkynyl group;

[0601] R4 is -(CH2)m-, where m is a positive integer from 1 to 20, preferably a positive integer from 1 to 15; more preferably a positive integer from 1 to 10;

[0602] L1 is selected from -(C=O)O-, -O(C=O)-, -(SS)-, -O(S=O)-, -(C=O)S-, -S(C=O)-, -(C=S)O-, -NH(C=O)-, -(C=S)NH-, -NH(C=S)-, -(C=O)NH-, preferably -(C=O)O, -O(C=O)-;

[0603] R5 is selected from C1-C 30 Alkyl, C2-C 30 alkenyl, C2-C 30 alkynyl group;

[0604] R6 is -(CH2)q-, where q is a positive integer from 1 to 20, preferably a positive integer from 1 to 15; more preferably a positive integer from 1 to 10;

[0605] L2 is selected from -(C=O)O-, -O(C=O)-, -(SS)-, -O(S=O)-, -(C=O)S-, -S(C=O)-, -(C=S)O-, -NH(C=O)-, -(C=S)NH-, -NH(C=S-, -(C=O)NH-, with -(C=O)O and -O(C=O)- being preferred;

[0606] R7 is selected from substituted or unsubstituted C1-C. 20 Alkyl, C2-C 20 alkenyl, C2-C 20Alkyne group, wherein "substitution" refers to a substitution having one or more (preferably one or two) substituents selected from the group consisting of halogens, C1-C... 15 Alkyl, C2-C 15 alkenyl, C2-C 15 alkynyl group, O-(C2-C 15 Hydrocarbon groups (including alkyl, alkenyl, or ynyl groups), C1-C 15 Haloalkyl, C1-C 15 Halogenated alkoxy groups, -OH, -CN, -NH2.

[0607] In one implementation, R7 is Where R c It is -(CH2)p-, where p is a positive integer from 1 to 15, preferably a positive integer from 1 to 10; more preferably a positive integer from 1 to 6; R d and R e Each is independently selected from C1-C 15 Alkyl, C2-C 15 alkenyl, C2-C 15 alkynyl group, or R d and R e Together with their intermediate atoms, they form an optionally substituted ring: Where x is selected from 1 or 2.

[0608] In one embodiment, R1 and R2 are each independently selected from H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C1-C6 haloalkyl.

[0609] In one embodiment, R1 and R2 together with the N that connects them form a 5-10 membered heterocyclic group containing 1-2 heteroatoms selected from N and O.

[0610] In one embodiment, R1 and R2 together with the N that connects them form a 5-7 membered heterocyclic group containing 1-2 heteroatoms selected from N and O.

[0611] In one embodiment, R3 is selected from substituted or unsubstituted C1-C. 15 Alkyl, C2-C 15 alkenyl, C2-C 15 alkynyl group, C3-C 15 Cycloalkyl, wherein "substituted" is a substitution having one or more substituents selected from the group consisting of: halogens, C1-C... 10 Alkyl, C2-C 10 alkenyl, C2-C 10 alkynyl group, O-(C2-C 10 Hydrocarbon groups (including alkyl, alkenyl, or ynyl groups), C1-C 10 Haloalkyl, C1-C10 Halogenated alkoxy groups, -OH, -CN, -NH2.

[0612] In one embodiment, R3 is selected from substituted or unsubstituted C1-C. 15 Alkyl, C2-C 15 alkenyl, C2-C 15 alkynyl group, C3-C 10 Cycloalkyl, wherein “substitution” means substitution having one or more substituents selected from the group consisting of: halogens, C1-C... 10 Alkyl, C2-C 10 alkenyl, C2-C 10 alkynyl group, O-(C2-C 10 Hydrocarbon groups (including alkyl, alkenyl, or ynyl groups), C1-C 10 Haloalkyl, C1-C 10 Halogenated alkoxy groups, -OH, -CN, -NH2.

[0613] In one implementation, R b Selected from C1-C 15 Alkyl, C2-C 15 alkenyl, C2-C 15 Alkyne group.

[0614] In one implementation, R5 is selected from C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 Alkyne group.

[0615] In one implementation, R5 is selected from C2-C 12 alkenyl, C2-C 12 Alkyne group.

[0616] In one implementation, R7 is selected from C1-C 12 Alkyl, C2-C 12 alkenyl, C2-C 12 Alkyne group.

[0617] In one implementation, R7 is selected from substituted C1-C. 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group, wherein "substitution" is a substitution having one or more substituents selected from the group consisting of: halogen, C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 alkynyl group, O-(C2-C 10 Hydrocarbon groups (including alkyl, alkenyl, or ynyl groups), C1-C 10 Haloalkyl, C1-C 10Halogenated alkoxy groups, -OH, -CN, -NH2.

[0618] In one embodiment, R7 is selected from substituted C1-C6 alkyl, C2-C6 alkenyl, and C2-C6 alkynyl groups, wherein "substituted" is a substitution having one or more substituents selected from the group consisting of: halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, and C2-C6 alkenyl groups. 10 Alkyl, C2-C 10 alkenyl, C2-C 10 alkynyl group, O-(C2-C 10 Hydrocarbon groups (including alkyl, alkenyl, or ynyl groups), C1-C 10 Haloalkyl, C1-C 10 Halogenated alkoxy groups, -OH, -CN, -NH2.

[0619] In one embodiment, the ionizable lipid is a compound of formula 03-I-1 or formula 03-I-2:

[0620] In equation 03-I-1,

[0621] The definitions of R1-R6, G1, and L1 are as described above;

[0622] R7 is selected from substituted or unsubstituted C1-C. 20 Alkyl, C2-C 20 alkenyl, C2-C 20 Alkyne group, wherein "substitution" is substitution having one or more (preferably one or two) substituents selected from the group consisting of: halogens, C1-C... 15 Alkyl, C2-C 15 alkenyl, C2-C 15 alkynyl group, O-(C2-C 15 Hydrocarbon groups (including alkyl, alkenyl, or ynyl groups), C1-C 15 Haloalkyl, C1-C 15 Halogenated alkoxy groups, -OH, -CN, -NH2.

[0623] In one implementation, R7 is selected from substituted C1-C. 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group, wherein "substitution" is substitution having one or more (preferably one or two) substituents selected from the group consisting of: halogens, C1-C... 10 Alkyl, C2-C 10 alkenyl, C2-C 10 alkynyl group, O-(C2-C 10 Hydrocarbon groups (including alkyl, alkenyl, or ynyl groups), C1-C 10 Haloalkyl, C1-C 10Halogenated alkoxy groups, -OH, -CN, -NH2.

[0624] In equation 03-I-2,

[0625] The definitions of R1-R6, G1, and L1 are as described above;

[0626] R7 is selected from C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 Alkyne group.

[0627] In one implementation, R7 is selected from C1-C 12 Alkyl, C2-C 12 alkenyl, C2-C 12 Alkyne group.

[0628] In some implementations, the ionizable lipid is a compound in Table 3, or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.

[0629] Table 3

[0630] In some embodiments, the lipid nanoparticles (LNPs) described herein and the ionizable lipids contained in the pharmaceutical compositions are the ionizable lipids described in International Patent Application No. PCT / CN2024 / 104304, the entire contents of which are incorporated herein by reference.

[0631] In one embodiment, the ionizable lipid is an O4-I compound:

[0632] in

[0633] R1 is absent or selected from -OH and R a (R b )N-, where R a and R b Each independently constitutes H, C1-C 10 Alkyl or C1-C 10 Halogenated alkyl groups;

[0634] R2 is C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 alkynyl group;

[0635] R3 is C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 alkynyl or R c-(CH2)n-, where n is a positive integer from 1 to 20, preferably a positive integer from 1 to 14, and more preferably a positive integer from 1 to 10;

[0636] Rc is selected from the following structure: in, Represents a connection key;

[0637] L1, L2, L3, L4, and L5 are either absent or independently selected from the following groups:

[0638] X is either none, -CH-, or N;

[0639] R4 is either none or C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 alkynyl group;

[0640] R5 is either none or C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 alkynyl group;

[0641] R6 is C1-C 30 Alkyl, C2-C 30 alkenyl, C2-C 30 alkynyl group;

[0642] R7 is C1-C 14 Alkyl, C2-C 14 alkenyl, C2-C 14 alkynyl group;

[0643] R8 and R9 are either absent or independently C1-C. 14 Alkyl, C2-C 14 alkenyl, C2-C 14 alkynyl or -R h -C1-C 14 Alkyl, -R h -C2-C 14 alkenyl, -R h -C2-C 14 Alkynyl group, wherein Rh is O or S;

[0644] R 10 R 11 Each independently is C1-C 14 Alkyl, C2-C 14 alkenyl, C2-C 14 alkynyl or -R h -C1-C 14 Alkyl, -R h -C2-C 14alkenyl, -R h -C2-C 14 alkynyl group, wherein R h It can be O or S.

[0645] In one implementation, R a and R b Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl.

[0646] In one embodiment, R2 is selected from -(CH2)m-, where m is a positive integer from 1 to 20, preferably a positive integer from 1 to 14, more preferably a positive integer from 1 to 10, and even more preferably a positive integer from 1 to 6.

[0647] In one implementation, R3 is C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group.

[0648] In one embodiment, R3 is a C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0649] In one implementation, R6 is C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 Alkyne group.

[0650] In one implementation, R2 is C1-C 14 Alkyl, C2-C 14 alkenyl, C2-C 14 Alkyne group.

[0651] In one implementation scheme, R2 and R7 are each independently C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group.

[0652] In one implementation, R4 and R5 are each independently -(CH2)q-CH3, where q is selected from positive integers from 1 to 20, preferably positive integers from 1 to 12, and more preferably positive integers from 1 to 8.

[0653] In one implementation scheme, R4 and R5 each independently have -R d -R e -structure;

[0654] Where R d It is either absent or selected from the following functional groups: -(CH2)-(CH=CH)-;

[0655] R eIt is -(CH2)p-CH3, where p is selected from positive integers from 0 to 20, preferably from positive integers from 0 to 12, and more preferably from positive integers from 0 to 8.

[0656] In one implementation, R8 and R9 are each independently -(CH2)q-CH3, where q is selected from positive integers from 1 to 14, preferably positive integers from 1 to 12, and more preferably positive integers from 1 to 8.

[0657] In one embodiment, R7 is -(CH2)q-CH3, where q is a positive integer selected from 1 to 14, preferably a positive integer from 1 to 12, and more preferably a positive integer from 1 to 8.

[0658] In one implementation, R6 has -R f -R g - structure;

[0659] Where R f Selected from the following functional groups: -(CH2)s1-(CH=CH)-CH2-(CH=CH)-(CH2)s2-CH3, where s1 is a positive integer from 1 to 14, preferably a positive integer from 1 to 10, and s2 is a positive integer from 1 to 8, preferably a positive integer from 1 to 6;

[0660] R g It is -(CH2)m-, where m is a positive integer from 1 to 14, preferably a positive integer from 1 to 10, and more preferably a positive integer from 1 to 6.

[0661] In one implementation, R 10 R 11 Each independently is C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 alkynyl or -R h -C1-C 10 Alkyl, -R h -C2-C 10 alkenyl, -R h -C2-C 10 alkynyl group, wherein R h It can be O or S.

[0662] In one implementation, R 11 It is C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0663] In one implementation scheme, R8 and R9 are each independently C1-C. 10 Alkyl, C2-C 10 alkenyl, C2-C 10 alkynyl or -R h -C1-C 10Alkyl, -R h -C2-C 10 alkenyl, -R h -C2-C 10 alkynyl group, wherein R h It can be O or S.

[0664] In one embodiment, R9 is a C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0665] In one implementation, X is either none or -CH-.

[0666] In one embodiment, the ionizable lipid is a compound of formula 04-I-1, 04-I-2, 04-I-3, or 04-I-4:

[0667] Or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.

[0668] In Equation 04-I-1,

[0669] R1-R2, R6-R 11 The definitions of L2-L5 are as described above;

[0670] R3 is C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 Alkyne group.

[0671] In one implementation, R3 is C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group.

[0672] In one embodiment, R3 is a C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0673] In Equation 04-I-2,

[0674] R1-R2, R6-R7, R 10 -R 11 The definitions of L1-L5 are as described above;

[0675] R3 is C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 alkynyl group, or R c -(CH2)n-, where n is a positive integer from 1 to 20, preferably a positive integer from 1 to 14, more preferably a positive integer from 1 to 10, R c The definition is as described above;

[0676] R5 is C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 alkynyl group;

[0677] R8 and R9 are each independently C1-C 14 Alkyl, C2-C 14 alkenyl, C2-C 14 Alkyne group.

[0678] In one implementation, R5 is C1-C 14 Alkyl, C2-C 14 alkenyl, C2-C 14 Alkyne group.

[0679] In one implementation, R5 is C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group.

[0680] In one implementation, R3 is C1-C 14 Alkyl, C2-C 14 alkenyl, C2-C 14 Alkyne group.

[0681] In one implementation, R3 is C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group.

[0682] In Equation 04-I-3,

[0683] R1-R3, R6, R7, R 10 R 11 The definitions of L1-L5 are as described above;

[0684] R4 is C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 alkynyl group;

[0685] R5 is C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 alkynyl group;

[0686] R8 and R9 are each independently C1-C 14 Alkyl, C2-C 14 alkenyl, C2-C 14 Alkyne group.

[0687] In one implementation, R4 is C1-C14 Alkyl, C2-C 14 alkenyl, C2-C 14 Alkyne group.

[0688] In one implementation, R4 is C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group.

[0689] In one embodiment, R5 is a C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0690] In one implementation scheme, R8 and R9 are each independently C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group.

[0691] In one embodiment, R9 is a C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl.

[0692] In Equation 04-I-4,

[0693] R1-R7, R 10 -R 11 The definitions of L1-L3 and L5 are as described above.

[0694] In some embodiments, the ionizable lipid is a compound of formula O4-II:

[0695] Or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.

[0696] In the formula,

[0697] R1 is selected from -OH and R a (R b )N-, where R a and R b Each is independently H, C1-C6 alkyl, or C1-C6 haloalkyl;

[0698] R3 is C1-C 15 Alkyl, C2-C 15 alkenyl, C2-C 15 alkynyl or R c -(CH2)n-, where n is a positive integer from 1 to 20, preferably a positive integer from 1 to 14, more preferably a positive integer from 1 to 10, and even more preferably a positive integer from 1 to 6;

[0699] R c Selected from the structure shown below:

[0700] in Represents a connection key;

[0701] L1, L2, L3, L4, and L5 are either absent or independently selected from the following groups:

[0702] R4 is either none or C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 alkynyl group;

[0703] R5 is either none or C1-C 20 Alkyl, C2-C 20 alkenyl, C2-C 20 alkynyl group;

[0704] R8 and R9 are each independently C1-C 14 Alkyl, C2-C 14 alkenyl, C2-C 14 alkynyl or -R h -C1-C 14 Alkyl, -R h -C2-C 14 alkenyl, -R h -C2-C 14 alkynyl group, wherein R h For O or S;

[0705] R 10 R 11 Each independently is C1-C 14 Alkyl, C2-C 14 alkenyl, C2-C 14 alkynyl group, or -R h -C1-C 14 Alkyl, -R h -C2-C 14 alkenyl, -R h -C2-C 14 alkynyl group, wherein R h For O or S;

[0706] r is 2 or 3;

[0707] u is a positive integer from 1 to 10;

[0708] t is a positive integer from 1 to 10;

[0709] Furthermore, when R1 is selected from R a (R b When N-, r is 2.

[0710] In one implementation, R3 is C1-C 10 Alkyl, C2-C10 alkenyl, C2-C 10 Alkyne group.

[0711] In one implementation, R4 is either none or C1-C. 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group.

[0712] In one implementation, R5 is either none or C1-C. 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group.

[0713] In one implementation, R8 is C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group.

[0714] In one implementation, R9 is C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group.

[0715] In one implementation, R 10 It is C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group.

[0716] In one implementation, R 11 It is C1-C 10 Alkyl, C2-C 10 alkenyl, C2-C 10 Alkyne group.

[0717] In one implementation, u is a positive integer from 3 to 6, preferably a positive integer from 3 to 5, and more preferably 4.

[0718] In one implementation, t is a positive integer from 3 to 6, preferably a positive integer from 3 to 5, and more preferably 4.

[0719] In one implementation, L1, R4, and R5 are absent.

[0720] In one implementation scheme, L1, L2, L3, L4, and L5 are each independently selected from the following groups:

[0721] In one embodiment, the ionizable lipid is a compound of formula 04-II-1, 04-II-2, or 04-II-3:

[0722] in

[0723] In Equation 04-II-1, R3, r, R8-R 11 The definitions of L2-L5 are as described above;

[0724] In Equation 04-II-2, r, R3-R5, R8-R 11 The definitions of L1-L5 are as described above;

[0725] In Equation 04-II-3, R a R b R3-R5, R8-R 11 The definitions of r, L1-L5 are as described above.

[0726] In one embodiment, the ionizable lipid is a compound in Table 4, or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.

[0727] Table 4

[0728] In some embodiments, the ionizable lipids are selected from the compounds listed in any of Tables 1 to 4.

[0729] In some embodiments, the lipid component of the nanoparticle composition may include one or more structural lipids. It is contemplated that structural lipids can stabilize the amphiphilic structure of the nanoparticles, such as, but not limited to, the lipid bilayer structure of the nanoparticles. Exemplary structural lipids that may be incorporated into this disclosure include, but are not limited to, cholesterol, nonsteroidal anti-steroids, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, ursolic acid, α-tocopherol, and mixtures thereof. In some embodiments, the structural lipid is cholesterol. In some embodiments, the structural lipid includes cholesterol and corticosteroids (e.g., prednisolone, dexamethasone, prednisolone, and hydrocortisone) or combinations thereof. In some embodiments, the lipid nanoparticles provided herein comprise steroids or steroid analogues. In some embodiments, the steroid or steroid analogue is cholesterol.

[0730] In some embodiments, the lipid component of the nanoparticle composition may include one or more phospholipids, such as one or more (poly)unsaturated lipids. It is contemplated that the phospholipids can assemble into one or more lipid bilayer structures. Exemplary phospholipids that can form part of this nanoparticle composition include, but are not limited to, 1,2-distearyl-sn-glycerol-3-phosphate choline (DSPC), 1,2-dioleoyl-sn-glycerol-3-phosphate ethanolamine (DOPE), 1,2-dioleoyl-sn-glycerol-3-phosphate choline (DLPC), 1,2-dimyristoyl-sn-glycerol-3-phosphate choline (DMPC), and 1,2-dioleoyl-sn-glycerol-3-phosphate ethanolamine (DOPE). Choline (DOPC), 1,2-dipalmitoyl-sn-glycerol-3-phosphate choline (DPPC), 1,2-eicosanoyl-sn-glycerol-3-phosphate choline (DUPC), 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphate choline (POPC), 1,2-di-O-octadecenyl-sn-glycerol-3-phosphate choline (18:0DietherPC), 1-oleoyl-2-cholestanoyl-sn-glycerol-3-phosphate choline (18:0DietherPC), 1-oleoyl-2-cholestanoyl-sn-glycerol-3-phosphate choline (18:0DietherPC), - Phosphocholine (OChemsPC), 1-hexadecyl-sn-glycerol-3-phosphocholine (C16LysoPC), 1,2-dilinoleoyl-sn-glycerol-3-phosphocholine, 1,2-disarachidonicoyl-sn-glycerol-3-phosphocholine, 1,2-docosahexaenooyl-sn-glycerol-3-phosphocholine, 1,2-diphydanoyl-sn-glycerol-3-phosphoethanolamine (ME16.0PE), 1,2-distearate Acyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinoleoyl-1-sn-glycerol-3-phosphate ethanolamine, 1,2-dilinoleoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-disarachidanoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-docosahexaenoyl-sn-glycerol-3-phosphate ethanolamine, 1,2-dioleoyl-sn-glycerol-3-phosphate-rac-(1-glycerol) sodium salt (DOPG), and sphingomyelin. In some embodiments, the nanoparticle composition includes DSPC. In some embodiments, the nanoparticle composition comprises DOPE. In some embodiments, the nanoparticle composition includes both DSPC and DOPE.

[0731] Exemplarily, neutral lipids also include dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoylphosphatidylethanolamine 4-(N-maleiminomethyl)-cyclohexane-1-carboxylic acid ester (DOPE-mal), dipalmitoylphosphatidylphosphatidylethanolamine (DPPE), distearate-phosphatidylethanolamine (DSPE), 16-O-monomethylPE, 16-O-dimethylPE, 18-1-transPE, 1-stearoyl-2-oleoylphosphatidylethanolamine (SOPE), and 1,2-divalloyl-sn-glycerol-3-phosphate ethanolamine (transDOPE). In one embodiment, the neutral lipid is 1,2-distearate-sn-glycerol-3-phosphate choline (DSPC). In one embodiment, the neutral lipid is selected from DSPC, DPPC, DMPC, DOPC, POPC, DOPE, and SM. In one embodiment, the neutral lipid is phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidic acid (PA), or phosphatidylglycerol (PG).

[0732] In some embodiments, the lipid component of the nanoparticle composition may include one or more PEG lipids (polyethylene glycol lipids). It is contemplated that the PEG lipid component in the nanoparticle composition can improve colloidal stability and / or reduce protein uptake by the nanoparticles. Exemplary cationic lipids that may be incorporated into this disclosure include, but are not limited to, PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol, and mixtures thereof. For example, the PEG lipid may be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, PEG-DSPE, ceramide-PEG2000, or Chol-PEG2000.

[0733] In some embodiments, the lipid component of the nanoparticle composition comprises a functionalized PEG lipid containing one or more fatty acid tails, wherein for straight-chain fatty acids, each fatty acid tail is not shorter than C0. 16 And not longer than C 20 For branched-chain fatty acids, the length must be at least C. 14 And not longer than C 20 The fatty acid tail is acceptable. In some implementations, the fatty acid tail is C... 16 In some implementations, the fatty acid tail is C. 18In some embodiments, the functionalized PEG lipids comprise dipalmitoyl lipids. In some embodiments, the functionalized PEG lipids comprise distearate lipids. The fatty acid tail serves as a means of anchoring the PEG lipids to the LNP, thereby reducing or eliminating detachment of the PEG lipids from the LNP. This is a useful property for both PEG lipids and / or functionalized PEG lipids, but it is more significant for functionalized PEG lipids because it will bind the targeting moiety (e.g., an antibody), and if the PEG lipid (along with the conjugated binding moiety) detaches from the LNP, the targeting function of the LNP may be impaired.

[0734] Any suitable chemical method can be used to couple the target moiety to the PEG moiety of a PEG lipid, including Michael addition reactions (see Parhiz et al., Journal of Controlled Release, 291:106-115, 2018) and click chemistry (see Kolb et al., Angewandte Chemie International Edition, 40(11):2004-2021, 2001; and Evans, Australian Journal of Chemistry, 60(6):384-395, 2007). Reagents for such reactions include PEG lipid-maleimide, PEG lipid-cysteine, PEG lipid-alkyne, PEG lipid-DBCO, and PEG lipid-azide. Conjugation / coupling reactions utilize PEG lipid-bromomaleimide, PEG lipid-alkylamide, PEG lipid-alkynylamide, and PEG lipid-alkynylene reactions. On the binding side of the reaction, an existing cysteine ​​thiol group can be used, or the protein can be derived, for example, by adding a sulfur-containing carboxylic acid to the ε-amino group of lysine, to react with maleimide, bromomaleimide, alkylamide, or acetylide. Alternatively, an alkyne can be added to the thiol group or the ε-amino group of lysine to participate in the click chemistry reaction.

[0735] In some embodiments, the molar ratio of ionizable lipids, neutral lipids, steroids, PEG lipids, and functionalized PEG lipids in the lipid nanoparticles is (20-60):(5-30):(25-45):(0.1-5):(0.1-15).

[0736] In some embodiments, functionalized PEG lipids are conjugated to a targeting portion (e.g., an antibody). In some embodiments, the targeting portion is an antibody or antigen-binding portion targeting CD117 as disclosed herein.

[0737] Lipid nanoparticle conjugates

[0738] In one aspect, this disclosure provides a lipid nanoparticle conjugate comprising a targeting portion and a lipid nanoparticle (LNP) encapsulating a bioactive substance, wherein the targeting portion is conjugated to the lipid nanoparticle (LNP) via a linker portion.

[0739] In some embodiments, the targeting moiety is an antibody or antigen-binding fragment. In some embodiments, the targeting moiety is an antibody, a Fab fragment, Fab', (Fab')2, Fv, a disulfide-linked Fv, ScFv, a biantibody, or a single-domain antibody. In some embodiments, the targeting moiety is a folic acid moiety, an antibiotic mimic, a polynucleotide (e.g., a DNA or RNA aptamer), a carbohydrate, a vitamin, or N-acetylgalactosamine (GalNac). Conjugation of the targeting moiety to an LNP results in a targeted LNP. In some embodiments, the targeting moiety is a ligand that binds to a receptor on the cell surface. In some embodiments, the ligand may be a natural ligand of the receptor. In some embodiments, the ligand may be a synthetic ligand of the receptor. In some embodiments, the targeting moiety is a small molecule, such as a small molecule ligand for a cell surface receptor. In some embodiments, the targeting moiety is a peptide or polypeptide, such as a peptide or polypeptide ligand for a cell surface receptor. In some embodiments, the peptide or polypeptide is linear or cyclic. In some embodiments, the targeting moiety is a cytokine, such as causing a targeting cell group to bind to a cytokine receptor on the cell surface. The coupling of the target portion with the LNP will generate a targeted LNP.

[0740] In some embodiments, the targeting portion is selected from the anti-CD117 antibody disclosed herein or its antigen-binding fragment.

[0741] In some embodiments, the conjugate is used to treat genetic diseases or conditions, including sickle cell disease, hemoglobinopathies, hemophilia, thalassemia, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute myeloid leukemia, chronic myeloid leukemia or chronic lymphocytic leukemia, Duchenne muscular dystrophy, factor V Leiden thrombophilia, familial hypercholesterolemia, Fragile X syndrome, Gaucher disease, hemochromatosis, hemophilia, holoencephaly, Huntington's disease, inherited metabolic disorders, Klinefelter syndrome, Marfan syndrome, methylmalonic academia, myotonic dystrophy, neurofibromatosis, Noonan syndrome, osteogenesis imperfecta, Parkinson's disease, phenylketonuria, and Poland syndrome. Anomaly, porphyria, progeria, prostate cancer, retinitis pigmentosa, severe combined immunodeficiency, sickle cell disease, skin cancer, spinal muscular atrophy, trimethylaminuria, Turner syndrome, velocardiofacial syndrome, and Wilson disease.

[0742] Generation of lipid nanoparticle conjugates

[0743] Any method capable of conjugating an antibody to an LNP can be used, and exemplary conjugation methods may include, but are not limited to, covalent bonds, electrostatic interactions, and hydrophobic (“van der Waals”) interactions. In one embodiment, the conjugation is reversible. In another embodiment, the conjugation is irreversible.

[0744] In some embodiments, a covalent bond is conjugated between at least one of the functionalized PEG lipid and a targeting moiety (e.g., an antibody). The term "functionalized PEG lipid" refers to a molecule comprising a lipid moiety and a PEG moiety, which is activated by functionalizing the PEG lipid with a first coupling group. In one embodiment, the functionalized PEG lipid comprises a first coupling group capable of reacting with a second coupling group. In one embodiment, the functionalized PEG lipid is a functionalized PEG lipid (polyethylene glycol-modified lipid). In one embodiment, the first coupling group is bound to the lipid moiety of the PEG lipid. In another embodiment, the first coupling group is bound to the PEG moiety of the polyethylene glycol-modified lipid. In one embodiment, the second functional group is covalently linked to the targeting domain.

[0745] The first and second coupling groups can be any functional groups known to those skilled in the art, for example, that form a covalent bond together under mild reaction conditions or physiological conditions. In some embodiments, the first or second coupling group is selected from the group consisting of: maleimide, N-hydroxysuccinimide (NHS) ester, carbodiimide, acylhydrazine, pentafluorophenyl (PFP) ester, phosphine, hydroxymethylphosphine, psoralen, imidoester, pyridyl disulfide, isocyanate, vinyl sulfone, α-haloacetyl, aryl azide, acyl azide, alkyl azide, diaziridine, benzophenone, epoxide, carbonate, acid anhydride, sulfonyl chloride, cyclooctyne, aldehyde, and mercapto. In some embodiments, the first or second coupling group is selected from the group consisting of: free amine (-NH2), free mercapto (-SH), free hydroxyl (-OH), carboxylic acid ester, acylhydrazine, and alkoxyamine. In some embodiments, the first coupling group is a functional group reactive to a thiol group, such as maleimide, pyridyl disulfide, or haloacetyl. In one embodiment, the first coupling group is maleimide.

[0746] In one embodiment, the second coupling group is a thiol group. The thiol group can be attached to the targeting moiety (e.g., an antibody) using any method known to those skilled in the art. In one embodiment, the thiol group is present on a free cysteine ​​residue. In one embodiment, the thiol group is exposed by reducing the disulfide bond used for the targeting moiety, for example, by reacting with 2-mercaptoethylamine. In one embodiment, the thiol group is attached by a chemical reaction, such as the reaction between a free amine and 2-iminotetrahydrothiophene or N-succinimide-S-acetylthioacetate (SATA).

[0747] In some embodiments, the PEG lipid and the targeting portion are functionalized with groups used in "click" chemistry. Bioorthogonal click chemistry involves a reaction between a functional group having a 1,3-dipolar polaritron (e.g., azides, nitriles, nitrile ketones, isocyanates) and a linker (having an olefin or alkyne dipolarophile). Exemplary dipolarophiles include any strained cyclic olefins and cyclic alkynes known to those skilled in the art, including but not limited to cyclooctyne, dibenzocyclooctyne, monofluorinated cyclooctyne, difluorinated cyclooctyne, and diarylazirazine octyneones.

[0748] In some implementations, a sorting enzyme-mediated method can be used to conjugate anti-CD117 antibodies with lipid nanoparticles (LNPs) to functionalize the antibodies, that is, to couple functional groups to the antibody, which can form covalent bonds with a portion of the LNP through a chemical reaction.

[0749] In some implementations, antibody conjugation with LNP is performed as described in the examples.

[0750] Load for delivery

[0751] The lipid nanoparticles of this disclosure may carry cargo to be delivered to target cells. In some embodiments, the cargo may be a therapeutic agent, such as a peptide, polypeptide, protein, nucleic acid, small molecule, etc., or may generate a therapeutic agent, such as an expression cassette for expressing a therapeutic agent. Alternatively, the cargo may be a diagnostic agent.

[0752] In some embodiments, the payload may contain one or more components of a gene editing system. As used herein, a gene editing system refers to a composition comprising protein components and optional nucleic acid components required by design to perform genetic editing at a target genetic site. Any of the goods disclosed herein can be loaded into lipid nanoparticles by conventional methods (e.g., by encapsulation or attachment).

[0753] In some implementation schemes, the prophylactic or therapeutic agent is selected from RNA, DNA, antisense nucleic acid, aptamer, nuclease, immunostimulatory nucleic acid, or PNA component;

[0754] In some implementations, the antisense nucleic acid is an antisense oligonucleotide;

[0755] In some embodiments, the RNA includes one or more of mRNA, rRNA, circRNA, siRNA, saRNA, tRNA, snRNA, antagomir, microRNA inhibitors, microRNA activators, or shRNA;

[0756] In some implementations, the DNA includes plasmids;

[0757] In some embodiments, the nucleic acid component encodes a gene editing composition / system comprising a nuclease or a nucleic acid encoding a nuclease, and an RNA guide or a nucleic acid encoding an RNA guide;

[0758] In some embodiments, the nucleic acid component is mRNA;

[0759] In some embodiments, the nuclease comprises nuclease mRNA;

[0760] In some embodiments, the nuclease is selected from Cas9, Cas12, Cas13, IscB, TnpB, IsrB and their homologs;

[0761] In some embodiments, the bioactive substance comprises at least one mRNA encoding an antigen or a fragment thereof or an epitope.

[0762] In some embodiments, the nucleic acid molecule contains non-classical nucleobases. In some embodiments, classical nucleobases in the nucleotide (e.g., adenine, guanine, uracil, thymine, and cytosine) may be modified or substituted to provide one or more functional analogs of the nucleotide. Exemplary modifications of nucleobases include, but are not limited to, one or more substitutions or modifications, including, but not limited to, alkyl, aryl, halogen, oxo, hydroxyl, alkoxy, and / or thio substitutions; one or more fused or ring-opening, oxidation, and / or reduction.

[0763] In some embodiments, the non-classical nucleobase is a modified uracil. Exemplary nucleobases and nucleosides having modified uracil include pseudouridine (ψ), pyridine-4-ketoribonucleotide, 5-azauracil, 6-azauracil, 2-thio-5-azauracil, 2-thiouracil (s2U), 4-thiouracil (s4U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxyuracil (ho5U), 5-aminoallyluracil, 5-halouracil (e.g., 5-iodouracil or 5-bromouracil), 3-methyluracil (m3U), 5-methoxyuracil (mo5U), and uracil 5- Oxyacetic acid (cmo5U), methyl 5-oxyacetic acid ester (mcmo5U), 5-carboxymethyl-uracil (cm5U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uracil (chm5U), methyl 5-carboxyhydroxymethyl-uracil ester (mchm5U), 5-methoxycarbonylmethyl-uracil (mcm5U), 5-methoxycarbonylmethyl-2-thiouracil (mcm5s2U), 5-aminomethyl-2-thiouracil (nm5s2U), 5-methylaminomethyluracil (mnm5U), 5-methylaminomethyl-2- Thiouracil (mnm5s2U), 5-methylaminomethyl-2-selenouracil (mnm5se2U), 5-carbamoylmethyluracil (ncm5U), 5-carboxymethylaminomethyl-uracil (cmnm5U), 5-carboxymethylaminomethyl-2-thiouracil (cmnm5s2U), 5-propynyl-uracil, 1-propynyl-pseudouracil, 5-tauronic acid methyl-uracil (τm5U), 1-tauronic acid methyl-pseudouridine, 5-tauronic acid methyl-2-thio-uracil (τm55s2U), 1-tauronic acid methyl-4- Thio-pseudouridine, 5-methyl-uracil (m5U, i.e., deoxythymidine with nucleobase), 1-methyl-pseudouridine (m1ψ), 1-ethyl-pseudouridine (Et1ψ), 5-methyl-2-thio-uracil (m5s2U), 1-methyl-4-thio-pseudouridine (m1s4ψ), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m3ψ), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deazo-pseudouridine, 2-thio-1-methyl-1-deazo-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-Dihydrouracil, 5-Methyl-Dihydrouracil (m5D), 2-Thio-Dihydrouracil, 2-Thio-Dihydropseudouridine, 2-Methoxy-uracil, 2-Methoxy-4-Thio-uracil, 4-Methoxy-pseudouridine, 4-Methoxy-2-Thio-pseudouridine, N1-Methyl-pseudouridine, 3-(3-amino-3-carboxypropyl)uracil (acp3U), 1-Methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp3ψ), 5-(isopentenylaminomethyl)uracil (m5U), 5-(isopentenylaminomethyl)-2-Thio-uracil (m5s2U), 5,2'-O-Dimethyluridine (m5Um), 2-Thio-2'-O-Methyluridine (s2Um), 5-Methoxycarbonyl 5-Carbamoylmethyl-2'-O-methyluridine (mcm5Um), 5-carbamoylmethyl-2'-O-methyluridine (ncm5Um), 5-carboxymethylaminomethyl-2'-O-methyluridine (cmnm5Um), 3,2'-O-dimethyluridine (m3Um), and 5-(isopentenylaminomethyl)-2'-O-methyluridine (inm5Um), 1-thiouracil, deoxythymidine, 5-(2-methoxycarbonylvinyl)uracil, 5-(carbamoylhydroxymethyl)uracil, 5-carbamoylmethyl-2-thiouracil, 5-carboxymethyl-2-thiouracil, 5-cyanomethyluracil, 5-methoxy-2-thiouracil, and 5-[3-(1-E-propenylamino)]uracil.

[0764] In some implementations, the non-classical nucleobase is a modified cytosine. Exemplary nucleobases and nucleosides having modified cytosine include 5-azacytosine, 6-azacytosine, pseudocytosine, 3-methylcytosine (m3C), N4-acetylcytosine (ac4C), 5-formylcytosine (f5C), N4-methylcytosine (m4C), 5-methylcytosine (m5C), 5-halocytosine (e.g., 5-iodocytosine), 5-hydroxymethylcytosine (hm5C), 1-methyl-pseudocytosine, pyrrolocytosine, pyrrolopseudocytosine, 2-thiocytosine (s2C), 2-thio-5-methylcytosine, 4-thiopseudocytosine, 4-thio-1-methylpseudocytosine, 4-thio-1-methyl-1-deazo-pseudocytosine, 1-methyl-1-deazo-pseudocytosine, zebularine, 5 -aza-za-zabraline, 5-methyl-zabraline, 5-aza-2-thio-zabraline, 2-thio-zabraline, 2-methoxy-cytosine, 2-methoxy-5-methyl-cytosine, 4-methoxy-pseudo-cytosine, 4-methoxy-1-methyl-pseudo-cytosine, lysidine (k2C), 5,2'-O-dimethyl-cytosine (m5Cm), N4-ethyl Acyl-2'-O-methyl-cytidine (ac4Cm), N4,2'-O-dimethyl-cytidine (m4Cm), 5-formyl-2'-O-methyl-cytidine (fSCm), N4,N4,2'-O-trimethyl-cytidine (m42Cm), 1-thio-cytosine, 5-hydroxy-cytosine, 5-(3-azidopropyl)-cytosine, and 5-(2-azidoethyl)-cytosine.

[0765] In some embodiments, the non-classical nucleobase is a modified adenine, and exemplary nucleobases and nucleosides having alternative adenine include 2-amino-purine, 2,6-diamino-purine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6-halo-purine (e.g., 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenine, 7-deadenine, 7-deadenine-8-aza-adenine, 7-deadenine-2-amino-purine, 7-deadenine-8-aza-2-amino-purine, 7-deadenine ... 6-Diaminopurine, 7-deazo-8-aza-2,6-diaminopurine, 1-methyl-adenine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenine (m6A), 2-methylthio-N6-methyl-adenine (ms2m6A), N6-isopentenyl-adenine (i6A), 2-methylthio-N6-isopentenyl-adenine (ms2i6A), N6-(cis-hydroxyisopentenyl)adenine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenine (ms2io6A) N6-glycylcarbamoyl-adenine (g6A), N6-threonylcarbamoyl-adenine (t6A), N6-methyl-N6-threonylcarbamoyl-adenine (m6t6A), 2-methylthio-N6-threonylcarbamoyl-adenine (ms2g6A), N6,N6-dimethyl-adenine (m62A), N6-hydroxyn-valinecarbamoyl-adenine (hn6A), 2-methylthio-N6-hydroxyn-valinecarbamoyl-adenine (ms2hn6A), N6-acetyl-adenine (ac6A), 7-methyl-adenine, 2-methylthio-adenine, 2-methoxy-adenine, N6,2'-O-dimethyl-adenine (m6Am), N6,N6,2'-O-trimethyl-adenine (m62Am), 1,2'-O-dimethyl-adenine (m1Am), 2-amino-N6-methyl-purine, 1-thio-adenine, 8-azido-adenine, N6-(19-amino-pentaenodecyl)-adenine, 2,8-dimethyl-adenine, N6-formyl-adenine, and N6-hydroxymethyl-adenine.

[0766] In some embodiments, the non-classical nucleobase is a modified guanine, and exemplary nucleobases and nucleosides of modified guanine include inosine (I), 1-methyl-inosine (m1I), wyosine (imG), methyl-wyosine (mimG), 4-demethyl-wyosine (imG-14), isowyosine (imG2), wybutosine (yW), peroxy-wyosine (o2yW), hydroxy-wyosine (OHyW), and undermodified nucleosine. Hydroxyguanine (OHyW*), 7-denitroguanine, queuosine (Q), epoxyqueuosine (oQ), galactosylqueuosine (galQ), mannosylqueuosine (manQ), 7-cyano-7-denitroguanine (preQO), 7-aminomethyl-7-denitroguanine (preQ1), archaeosine (G+), 7-denitro-8-aza-guanine, 6-thio-guanine, 6-thio-7-denitroguanine, 6-thio-7-denitro- 8-aza-guanine, 7-methyl-guanine (m7G), 6-thio-7-methyl-guanine, 7-methyl-inosine, 6-methoxy-guanine, 1-methyl-guanine (m1G), N2-methyl-guanine (m2G), N2,N2-dimethyl-guanine (m22G), N2,7-dimethyl-guanine (m2,7G), N2,N2,7-dimethyl-guanine (m2,2,7G), 8-oxo-guanine, 7-methyl-8-oxo-guanine, 1-methyl-6-thio-guanine, N2 -Methyl-6-thio-guanine, N2,N2-dimethyl-6-thio-guanine, N2-methyl-2'-O-methyl-guanosine (m2Gm), N2,N2-dimethyl-2'-O-methyl-guanosine (m22Gm), 1-methyl-2'-O-methyl-guanosine (m1Gm), N2,7-dimethyl-2'-O-methyl-guanosine (m2,7Gm), 2'-O-methyl-inosine (Im), 1,2'-O-dimethyl-inosine (m1Im), 1-thio-guanine and O-6-methyl-guanine.

[0767] In some embodiments, the noncanonical nucleobase of the functional nucleotide analog may independently be a purine, pyrimidine, a purine analog, or a pyrimidine analog. Exemplarily, the noncanonical nucleobase may be a modified adenine, cytosine, guanine, uracil, or hypoxanthine. In other embodiments, non-classical nucleobases may also include, for example, naturally occurring and synthetic derivatives of the base, including pyrazolo[3,4-d]pyrimidine; 5-methylcytosine (5-me-C); 5-hydroxymethylcytosine; xanthine; hypoxanthine; 2-aminoadenine; 6-methyl and other alkyl derivatives of adenine and guanine; 2-propyl and other alkyl derivatives of adenine and guanine; 2-thiouracil, 2-thiothymine, and 2-thiocytosine; 5-propynyluracil and cytosine; 6-azouracil, cytosine, and thymine; 5-uracil (pseudouracil); 4-thiouracil; 8-halogenated (e.g., 8-bromo), 8-amino, 8-thiol 8-Thioalkyl, 8-hydroxy and other 8-substituted adenine and guanine; 5-halogenated, especially 5-bromo, 5-trifluoromethyl and other 5-substituted uracil and cytosine; 7-methylguanine and 7-methyladenine; 8-azaguanine and 8-azaaadenine; deadenine, 7-deadenine, 3-deadenine; deadenine, 7-deadenine, 3-deadenine; pyrazolo[3,4-d]pyrimidine; imidazo[1,5-a]1,3,5-triazinone; 9-deadenine; imidazo[4,5-d]pyrazine; thiazo[4,5-d]pyrimidine; pyrazin-2-one; 1,2,4-triazine; pyridazine; or 1,3,5-triazine.

[0768] Treatment of diseases or symptoms

[0769] In one aspect, this disclosure provides a method for treating a disease or condition in a subject, comprising delivering a therapeutic agent for treating the disease or condition. In some embodiments, this disclosure provides a method for targeted delivery of a therapeutic agent for treating a disease or condition in a subject, comprising delivering the therapeutic agent for treating the disease or condition, wherein the delivery carrier comprises a portion targeting CD117+ cells. Exemplarily, CD117+ cells include hematopoietic cells, mast cells, germ cells, stromal cells, and tumor cells. In some embodiments, the subject is a human patient suffering from a genetic disease associated with a target gene. In some implementations, the genetic diseases include sickle cell disease, hemoglobinopathies, hemophilia, thalassemia, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute myeloid leukemia, chronic myeloid leukemia or chronic lymphocytic leukemia, Duchenne muscular dystrophy, factor V Leiden thrombophilia, familial hypercholesterolemia, Fragile X syndrome, Gaucher disease, hemochromatosis, hemophilia, holoencephaly, Huntington's disease, inherited metabolic disorders, Klinefelter syndrome, Marfan syndrome, methylmalonic academia, myotonic dystrophy, neurofibromatosis, Noonan syndrome, osteogenesis imperfecta, Parkinson's disease, phenylketonuria, and Poland syndrome. Anomaly, porphyria, progeria, prostate cancer, retinitis pigmentosa, severe combined immunodeficiency, sickle cell disease, skin cancer, spinal muscular atrophy, trimethylaminuria, Turner syndrome, velocardiofacial syndrome, and Wilson disease.

[0770] Pharmaceutical Composition

[0771] Any anti-CD117 antibody-conjugated LNP disclosed herein can be mixed with one or more pharmaceutically acceptable carriers or excipients to form a pharmaceutical composition. The number of carriers can be the amount of cargo that can be effectively delivered to achieve the intended therapeutic or diagnostic purpose, such as editing genetic target sites and / or treating related diseases, disorders, or conditions in patients in need. As used herein and unless otherwise stated, the term “pharmaceuticalally acceptable carrier, diluent, or excipient” includes, but is not limited to, any adjuvant, carrier, excipient, gliding agent, sweetener, diluent, preservative, dye / coloring agent, flavor enhancer, surfactant, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier approved by the U.S. Food and Drug Administration for acceptable use in humans or livestock.

[0772] In some embodiments, the LNP can be administered in solution. In some embodiments, the LNP can be formulated into a suitable pharmaceutical composition for administration via any desired route of administration. Exemplary routes of administration include, for example, but not limited to, topical, oral, or parenteral routes. Depending on the intended mode of administration, the composition used can be in solid, semi-solid, or liquid dosage forms such as tablets, suppositories, pills, capsules, powders, liquids, suspensions, etc. In some embodiments, a unit dosage form suitable for a precise single-dose administration is employed. The pharmaceutical composition may comprise the particles, pharmaceutically acceptable excipients, and optionally may comprise other pharmaceutical preparations, drug formulations, carriers, adjuvants, etc. In some embodiments, administration is topical. In some embodiments, administration is systemic.

[0773] In some embodiments, injectable formulations for parenteral administration can be prepared as liquid solutions or suspensions, solid forms suitable for dissolving or suspending in a liquid prior to injection, or emulsions. Suitable excipients are, for example, water, saline, dextran, glycerol, ethanol, etc. Furthermore, if desired, the pharmaceutical composition to be administered may also contain small amounts of non-toxic excipients such as wetting agents or emulsifiers, pH buffers, etc., such as sodium acetate, sorbitol monolaurate, triethanolamine oleate, etc. Aqueous injection suspensions may also contain substances that increase the viscosity of the suspension, including, for example, sodium carboxymethyl cellulose, sorbitol, and / or dextran. Optionally, the suspension may also contain stabilizers. Parenteral formulations may be present in single-dose or multi-dose sealed containers such as ampoules and vials and can be stored under lyophilized (freeze-dried) conditions, requiring only the addition of a sterile liquid carrier, such as water for injection, immediately before use. In some embodiments, parenteral administration includes intravenous administration.

[0774] In some embodiments, for oral administration, pharmaceutically acceptable non-toxic compositions can be formed by incorporating any commonly used excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, croscarmellose sodium, glucose, gelatin, sucrose, magnesium carbonate, etc. Such compositions include solutions, suspensions, tablets, dispersible tablets, pills, capsules, powders, sustained-release formulations, etc. Formulations suitable for oral administration can consist of: liquid solutions, such as an effective amount of the compound dissolved in a diluent such as water, saline, or orange juice; sachets, lozenges, and tablets, each containing a predetermined amount of the active ingredient as a solid or granule; powders; suspensions in suitable liquids; and suitable emulsions. Liquid formulations may contain diluents such as water and alcohols (e.g., ethanol, benzyl alcohol, and polyvinyl alcohol), with or without the addition of pharmaceutically acceptable surfactants, suspending agents, or emulsifiers.

[0775] The embodiments described herein are further described below with reference to specific examples. It should be understood that these embodiments are for illustrative purposes only and are not intended to be limiting. Therefore, this disclosure should in no way be construed as limited to the following embodiments, but should be construed as covering any and all variations that become apparent as a result of the teachings provided herein.

[0776] Experimental methods in the following examples, unless otherwise specified, were performed under standard conditions as described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or as recommended by the manufacturer. Percentages and parts are by weight unless otherwise stated.

[0777] Unless otherwise specified, all materials and reagents used in the examples are commercially available products.

[0778] Example 1: Preparation of c-kit nanobodies

[0779] 1. Antigen preparation

[0780] Using the human c-kit extracellular domain (c-kit ECD, SEQ ID NO:1) as an immunogenic antigen, the nucleotide coding sequences of the Human c-kit ECD fused with a His tag at the C-terminus and the c-kit ECD fused with a human IgG1Fc tag at the C-terminus were cloned into the pcDNA3.4 vector (Invitrogen) to obtain two antigen expression vectors expressing c-kit ECD-His and c-kit ECD-Fc, respectively. After transfecting 293F cells and culturing them for 8 days, the protein supernatant was collected by centrifugation and purified by chromatography, anti-His column, or Protein A column to obtain c-kit ECD-His and c-kit ECD-Fc.

[0781] Among them, c-kit The amino acid sequence of ECD is as follows: MRGARGAWDFLCVLLLLLRVQTGSSQPSVSPGEPSPPSIHPGKSDLIVRVGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFVRDPAKLFLV DRSLYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYHRLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEFTVTCTIKDVSSSVYSTWKRENSQTK LQEKYNSWHHGDFNYERQATLTISSARVNDSGVFMCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQWIYMNRTFTDKWEDYPKSENESNIRYVSELHLTRLKGTEGG TYTFLVSNSDVNAAIAFNVYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRCSASVLPVDVQTLNSSGPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPH(SEQ ID NO:1).

[0782] 2. Immunize alpacas

[0783] The c-kit ECD-His and c-kit ECD-Fc obtained in step 1 were used to immunize an alpaca once a week, as shown in Table 5.

[0784] Table 5

[0785] Peripheral blood was collected in week 6 for serum titer testing, and the results showed that the alpaca immunization was effective. In week 8, blood samples were collected to isolate PBMCs, total RNA was extracted from PBMCs, and then reverse transcribed into cDNA. VHH was amplified by nested PCR, and the VHH fragment was inserted into phage particles. Phage amplification yielded an antibody library (antibody sequences are shown in SEQ ID NO:2-20). After humanization, the antibodies were linked to the human IgG1 Fc backbone (SEQ ID NO:39) to obtain 19 humanized antibodies capable of binding c-kit (exemplarily, the P249645 antibody sequence linked to the human IgG1 Fc backbone is shown in SEQ ID NO:80). Their amino acid sequences and CDR region sequences are shown in Table 6.

[0786] Table 6. Amino acid sequences of each single-domain antibody (defined according to the Kabat numbering system).

[0787] As can be seen from the amino acid sequences of the CDR and FR regions of each antibody shown in Table 6 (the bold, italicized and underlined parts are the CDR regions, and the amino acid sequences with wavy lines are the FR regions), the amino acid sequences of the CDR and FR regions of each antibody are highly similar.

[0788] The amino acid sequences of the CDR and FR regions of each antibody are shown in Table 7.

[0789] Table 7. Amino acid sequences of the CDR and FR regions of each antibody.

[0790] 3. Antibody affinity detection

[0791] The Fc-antibody-encoded nucleotide sequence obtained in step 2 (exemplarily, the P249645 nucleotide-encoded sequence is shown in SEQ ID NO:79) was cloned into the pCHO1.0 plasmid.

[0792] The constructed pCHO1.0 plasmid was then transfected into the CHO cell line (Life Technology) using PEI. After culturing, the cell supernatant was collected and purified with Protein A. The purity of the purified antibody was ≥95%.

[0793] Example 2: c-kit nanobody binding activity detection

[0794] The c-kit ECD-His obtained in Example 1 was diluted to 2ug / mL with PBS, and 30uL was added to each well of the ELISA coated plate and incubated overnight at 4°C.

[0795] The coated plate was washed three times with PBST and then blocked at room temperature for 2 hours with PBST solution containing 5% skim milk.

[0796] The blocking plate was washed three times with PBST, and the antibody was diluted with PBST solution containing 1% skim milk, 30 μL per well, and incubated at room temperature for 1 h.

[0797] The plate was washed three times with PBST. The anti-human IgG-Fc-HRP secondary antibody (abcam, ab97225) was diluted 1:8000 with PBST solution containing 1% skim milk and incubated at room temperature for 1 hour.

[0798] The ELISA plate was washed 6 times with PBST after incubation. The substrate TMB and stop solution were added, and the absorbance of each well at 450 nm was detected using a microplate reader.

[0799] The test data are shown in Figures 1A and 1B. As can be seen from Figures 1A and 1B, the nanobodies involved in this example all exhibited high binding activity to human SCFR / c-Kit / CD117.

[0800] Example 3: Preparation of YolLipid (11-({8-[(2-butyloctyl)oxy]-8-oxoylideneoctyl}amino)-10-(3-ethyl-6-oxoylidene-3,7-diazahexadecane-7-yl)-11-oxoylideneundecanoate-2-butyloctyl ester)

[0801] The synthesis method is as follows:

[0802] The synthesis steps are as follows:

[0803] Step 1: Synthesis of Compound 1-1:

[0804] Compounds 1-2 (2.69 g, 13.44 mmol, 1.5 eq), EDCI (2.58 g, 13.44 mmol, 1.5 eq), DMAP (0.55 g, 4.48 mmol, 0.5 eq), and diisopropylethylamine (3.47 g, 26.88 mmol, 3.0 eq) were sequentially added to 25 mL of dichloromethane. After stirring at room temperature for 0.5 hours, alcohol 1-1 (2.00 g, 8.96 mmol, 1.0 eq) was added. The reaction solution was stirred at room temperature for 15.5 hours and then extracted with dichloromethane. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and subjected to column chromatography to give compound 1-3 (2.10 g, yield 57.8%).

[0805] Step 2: Synthesis of Compound 1:

[0806] Compounds 1-4 (200.0 mg, 2.66 mmol, 1.0 eq), 1-3 (2.70 g, 6.65 mmol, 2.5 eq), potassium carbonate (1.10 g, 7.98 mmol, 3.0 eq), and potassium iodide (0.22 g, 1.33 mmol, 0.5 eq) were added sequentially to 20 mL of acetonitrile. After stirring at 80 °C for 16 hours, the solvent was removed by distillation under reduced pressure. The solution was diluted with 50 mL of water and extracted three times with 20 mL of ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by column chromatography to give compound 1 (1.25 g, 64.8% yield).

[0807] Example 4: Conjugating c-kit antibodies to lipid nanoparticles to develop c-kit targeted delivery vectors

[0808] 1. LNP preparation

[0809] (1) YolLipid (11-({8-[(2-butyloctyl)oxy]-8-oxomylideneoctyl}amino)-10-(3-ethyl-6-oxomylidene-3,7-diazahexadecane-7-yl)-11-oxomylidene undecanoate-2-butyloctyl ester) was dissolved in anhydrous ethanol with DSPC, cholesterol, PEG-DMG, and DSPE-PEG-Mal in a molar ratio of 50:10:38:1.5:0.5. The lipid carrier solution was mixed with Luc mRNA (Genscript Biotechnology, SC2325) buffer at a ratio of 1:3 (volume / volume) (where the mass ratio of total lipids to Luc mRNA was 40:1), and nucleic acid lipid nanoparticles were obtained by passing the mixture through a microfluidic nanomedicine manufacturing system (NanoAssemblr Ignite, Canada) at a flow rate of 12 ml / min. The obtained nucleic acid lipid nanoparticles were immediately diluted 40-fold in 1×DPBS buffer. The diluted nucleic acid lipid nanoparticle solution was concentrated to the target volume using an ultracentrifuge tube and stored at 4°C.

[0810] (2) A control group, LNP, was also set up: liposomes 11-({8-[(2-butyloctyl)oxy]-8-oxomylidene octyl}amino)-10-(3-ethyl-6-oxomylidene-3,7-diazahexadecane-7-yl)-11-oxomylidene undecanoate-2-butyloctyl ester / DSPC / cholesterol / PEG-bound lipids PEG-DMG were prepared at a molar ratio of 50:10:38.5:1.5. An ethanol solution of the liposomes was mixed with a buffer of Luc mRNA at a ratio of 1:3 (volume / volume) (where the mass ratio of total lipids to mRNA was 40:1), and nucleic acid lipid nanoparticles were obtained as a control using a microfluidic nanomedicine manufacturing system (NanoAssemblr Ignite, Canada) at a flow rate of 12 mL / min.

[0811] 2. Conjugate the antibody obtained in Example 1 with the LNP obtained in step 1(1):

[0812] Five equivalents of PBS solution containing TCEP (5 mM) were added to the antibody solution. After gentle shaking at 37°C for 1 hour, the resulting antibody solution was added dropwise to the LNP solution (10 equivalents, relative to DSPE-PEG-Mal). The reaction solution was gently shaken at 25°C for 1 hour, then loaded onto an SEC column (Sepharose CL-4B). The column was eluted with PBS solution (1x), and the fraction containing LNPs was collected. The fraction was then concentrated to the desired concentration by ultrafiltration to obtain c-kit / LNP. The size change of the LNPs after conjugation was determined by dynamic light scattering (DLS) to confirm that the c-kit antibody was conjugated with the LNP.

[0813] Example 5: c-kit / LNP in vivo cell-targeted delivery

[0814] Remove CD34+ cells (Beijing Novobio, 903410) from the liquid nitrogen container and place them in a 37°C water bath until thawed. Transfer them to a biosafety cabinet. Prepare a 15ml centrifuge tube, add 5ml of X vivo 15 medium (Gibco), and then transfer all the thawed cells to this 15ml centrifuge tube. Centrifuge at 400g for 8 minutes at room temperature. After centrifugation, discard the supernatant, then resuspend the cells in complete culture medium and evenly seed them into 96-well plates at 100,000 cells per well. Incubate overnight at 37°C.

[0815] Each antibody-LNP prepared in Example 4 and the LNP control group were added to the plated CD34+ cells at a dose of 1 μg Luc mRNA per well. The cells were then transferred to a 37°C cell culture incubator and cultured for 16 h.

[0816] Sixteen hours after transfection, 100 μL of X vivo 15 medium was added to each well transfected with LNPs, and the mixture was pipetted and transferred to an 8-tube strip. 10 μL of cell suspension was then drawn from the tube and counted using a cell counter. Other cells were centrifuged at 400g for 8 minutes, the supernatant was discarded, and the cells were resuspended in 100 μL of DPBS, then centrifuged again at 400g for 8 minutes. After discarding the supernatant, 100 μL of lysis buffer (Beyotime, RG009M) was added and the mixture was pipetted and mixed. 40 μL of cell lysis buffer was then transferred to a microplate, and 40 μL of luciferase assay reagent (Beyotime, RG009M) was added to each well. Luciferase activity (RLU / cells) = (Luc value of sample wells - Luc value of control wells) / (Number of cells × 40 / 100).

[0817] The test results are shown in Figures 2A-2C. Analysis shows that CD34+ cells treated with Pro44-LNP, Pro49-LNP, Pro50-LNP, Pro51-LNP, Pro55-LNP, and Pro56-LNP all exhibited enhanced luciferase activity levels, with Pro44-LNP, Pro55-LNP, and Pro56-LNP showing the most significant effects.

[0818] Example 6: Single-domain antibodies obtained through reimmunization were tested, and their binding activity and antibody-LNP delivery activity were evaluated.

[0819] This example uses the same Human c-kit ECD (SEQ ID NO:1) as the immunogen as in Example 1. High-purity c-kit ECD-His and c-kit ECD-Fc fusion proteins were prepared using the protein expression and purification system described in Example 1 for subsequent immunization enhancement and specific screening. Following immunization, a new single-domain antibody was obtained, and its amino acid sequence and CDR region sequence are shown in Table 8.

[0820] Table 8. Amino acid sequences of each single-domain antibody (defined according to the Kabat numbering system).

[0821] As shown in Table 8, the amino acid sequences of the CDR and FR regions of each antibody (the bold, italicized and underlined parts are the CDR regions, and the amino acid sequences with wavy lines are the FR regions) are highly similar.

[0822] The amino acid sequences of the CDR and FR regions of each antibody are shown in Table 9.

[0823] Table 9. Amino acid sequences of the CDR and FR regions of each antibody.

[0824] Using the methods described in Examples 1-2, the binding activity of the aforementioned antibodies was tested, and the data obtained are shown in Figure 3. Figure 3 shows that the nanobodies involved in this example all exhibited high binding activity with human SCFR / c-Kit / CD117. Using the methods described in Examples 4 and 5, the aforementioned antibodies were conjugated with lipid nanoparticles to develop targeted delivery vectors. In vivo cell-targeted delivery was tested. CD34+ cells treated with A051-LNP, A061-LNP, A165-LNP, A278-LNP, A284-LNP, and Pro56-LNP all showed enhanced luciferase activity levels, with A165-LNP showing the best performance (Figure 4).

[0825] The sequence information involved in this disclosure is described below.

[0826] SEQ ID NO:1,c-kit ECD amino acid sequence: MRGARGAWDFLCVLLLLLRVQTGSSQPSVSPGEPSPPSIHPGKSDLIVRVGDEIRLLCTDPGFVKWTFEILDETNENKQNEWITEKAEATNTGKYTCTNKHGLSNSIYVFVRDPAKLFLVDRS LYGKEDNDTLVRCPLTDPEVTNYSLKGCQGKPLPKDLRFIPDPKAGIMIKSVKRAYHRLCLHCSVDQEGKSVLSEKFILKVRPAFKAVPVVSVSKASYLLREGEEFTVTCTIKDVSSSVYSTWKRENSQTKL QEKYNSWHHGDFNYERQATLTISSARVNDSGVFMCYANNTFGSANVTTTLEVVDKGFINIFPMINTTVFVNDGENVDLIVEYEAFPKPEHQQWIYMNRTFTDKWEDYPKSENESNIRYVSELHLTRLKGTEG GTYTFLVSNSDVNAAIAFNVYVNTKPEILTYDRLVNGMLQCVAAGFPEPTIDWYFCPGTEQRCSASVLPVDVQTLNSSGPPFGKLVVQSSIDSSAFKHNGTVECKAYNDVGKTSAYFNFAFKGNNKEQIHPH

[0827] SEQ ID NO:2, P249645 amino acid sequence: EVRLVESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSGINSGGGSTWYADSVKGRFTISRDNAENTLYLQMNKLKPEDTALYYCAKHFGTSYSSAYLRGQGTQVTVSS

[0828] SEQ ID NO:3, P249647 amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAVSGFTSGYDAIGWFRQAPGKEREWVSCISRTVGVTNSADSVKGRFTISRDNAKSTVYLQMNGLKPEDTAHYYCGAKRWVDSTCRTSGTYDYWGQGTQVTVSS

[0829] SEQ ID NO:4, P249648 amino acid sequence: QVQLVESGGGLVEAGGSLRLSCAASGRTFSNLVMGWFRQAPGKEREFVAAIGWWSGSMTSYADSVKGRFTISRDNAKNIMSLQMNNLKPEDTAVYSCAADVSFRDLTIGRPDYWGQGTQVTVSS

[0830] SEQ ID NO:5, P249649 amino acid sequence: EVQVVESGGGLVQAGGSLTLSCVASGITFSRYPVTWYRQAPGKQRELVATISSGGTTNYADSMKGRFTISRDNAKNTVYLQMNSAKPEDTAVYYCNTMFFRGSTSLDYWGQGTQVTVSS

[0831] SEQ ID NO:6, P249650 amino acid sequence: QVQLQESGGGLVQPGGSLRLSCAASDSGRTFSSYVMAWFRQAPGKERKFVAGIKWTGSATSYTASVVGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAANEVLEIPIRESEYDYWGQGTQVTVSS

[0832] SEQ ID NO:7, P249651 amino acid sequence: EVQLVESGGGLVQAGGSLRLSCAASGSTSSISGIGWYRQAPGKQRELVAVMDGGGNTNYADSVKDRFTISRDNAKNTVNLLMNSLKPEDTSVYYCSVRKRFWNKDYDFWGQGTQVTVSS

[0833] SEQ ID NO:8, P249652 amino acid sequence: EVQLVESGGGLVQAGGSLRLSCAVSGSTDSIYTMAWYRQAPGKQRELVARISSALPTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCRAVVRGSLDYWGQGTQVTVSS

[0834] SEQ ID NO:9, P249653 amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSGITSGGGSTMYAESVKGRFTISRDNAENTLYLQMNKLKPEDTALYYCAKHFGIHYSSAYVRGQGTQVTVSS

[0835] SEQ ID NO:10, P249654 amino acid sequence: QVQLVESGGGLVQAGGSLKLSCAASGITFSNYNMGWYRQAPGKQRELVATISYDGSTVYADSVIGRFTIFKDNAKNTVYLQMNSLKPEDTALYYCNARQPSYWLTSTQYWGQGTQVTVSS

[0836] SEQ ID NO:11, P249655 amino acid sequence: EVQVQESGGGLVQAGGSLRLSCAASGRTFSTYAMGWFRQAPGKEREFVAAISWSGGSTYYADSVKGRFTISRDNAKNTVYLQMMSLKPEDTAVYYCAAAYGSRWYADGPPLQYDYWGQGTQVTVSS

[0837] SEQ ID NO:12, P249656 amino acid sequence: QVQLQESGGGLVQAGGSLRLSCAASGRTFSSYAMGWFRQAPGKEREFVTAISWSGSSTYYADSVKGRFTISRDNAKNTVYLQMDSLKPEDTAVYYCAAKRPGSSWYGGYEYDYWGQGTQVTVSS

[0838] SEQ ID NO:13, P249657 amino acid sequence: EVQLVESGGGLVQAGGSLRLSCAASISAFSYYRMGWYRQAPGKQRELVAAISLDGTTLYADSVKGRFTISRDNSKNTIYLQMNSLKPEDTAVYYCNTVFHVDFTTMRARPVSDDYWGQGTQVTVSS

[0839] SEQ ID NO:14, P249658 amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSAITWNGGSTYYGESMKGRFTISRDNAKNTLYLQMNSLKSEDTAVYYCAKYGVSWVGRGPPDYWGQGTQVTVSS

[0840] SEQ ID NO:15, P249659 amino acid sequence: EVQLVESGGGLVQAGGSLRLSCAVSGSTYSIYAMAWYRQAPGKQRELVARIVSGLSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCRAVVSGAREFWGQGTQVTVSS

[0841] SEQ ID NO:16, P249660 amino acid sequence: EVQVQESGGGLVQAGGSLRLSCAASGRTFSRYAMAWFRQAPGKEREFVAAISWSGGSTAYADSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAEGQSYYLTPTASHEYDYWGQGTQVTVSS

[0842] SEQ ID NO: 17, P249661 amino acid sequence: QVQLVESGGGLVQAGGSLRLSCVASGITFSRYPVSWYRQAPGNVRELVAIISSGGTTNYADSMKGRFTISRDNAKNTVYLQMNSAKPEDTAVYYCNTKFFRGSSSLDYWGQGTQVTVSS

[0843] SEQ ID NO: 18, P249662 amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMYWVRQAPGKGLEWVSAINTGGGSTYYADSVKGRFTISRDNAKNTLYLQMNSLKPEDTAVYYCARGFSKDAYREPGGQGTQVTVSS

[0844] SEQ ID NO: 19, P249663 amino acid sequence: EVQLVESGGGLVQPGGALRLSCAVSGFTLGYYAIGWFRQAPGKEREGVSCISSPGSTYYADSVKGRFTISRDNAKNTVYLQMNSLKPEDMAVYYCATARPGGCDYELGFVNYGMDYWGKGTLVTVSS

[0845] SEQ ID NO: 20, P249664 amino acid sequence: EVQLQESGGGLVQAGGSLRLSCAASISAFSYYRMGWYRQAPGKQRELVASISFDGSTLYADSVKGRFTISRDNSKNTVFLQMNSLKPEDTAVYYCNTVFSVDLTTMWARPVSDDYWGQGTQVTVSS

[0846] SEQ ID NO:21, P249645 / P249653HCDR1 amino acid sequence: NYAMS

[0847] SEQ ID NO:22, P249647HCDR1 amino acid sequence: YDAIG

[0848] SEQ ID NO:23, P249648HCDR1 amino acid sequence: NLVMG

[0849] SEQ ID NO:24, P249649HCDR1 amino acid sequence: RYPVT

[0850] SEQ ID NO:25, P249650HCDR1 amino acid sequence: FSSYVMA

[0851] SEQ ID NO:26, P249651HCDR1 amino acid sequence: ISGIG

[0852] SEQ ID NO:27, P249652HCDR1 amino acid sequence: IYTMA

[0853] SEQ ID NO:28, amino acid sequence of single-domain antibody HCDR1: X1X2X3X4X5

[0854] SEQ ID NO:29, P249654HCDR1 amino acid sequence: NYNMG

[0855] SEQ ID NO:30, P249655HCDR1 amino acid sequence: TYAMG

[0856] SEQ ID NO:31, P249656HCDR1 amino acid sequence: SYAMG

[0857] SEQ ID NO:32, P249657 / P249664HCDR1 amino acid sequence: YYRMG

[0858] SEQ ID NO:33, P249658HCDR1 amino acid sequence: DYAMS

[0859] SEQ ID NO:34, P249659HCDR1 amino acid sequence: IYAMA

[0860] SEQ ID NO:35, P249660HCDR1 amino acid sequence: RYAMA

[0861] SEQ ID NO:36, P249661HCDR1 amino acid sequence: RYPVS

[0862] SEQ ID NO:37, P249662HCDR1 amino acid sequence: SYWMY

[0863] SEQ ID NO:38, P249663HCDR1 amino acid sequence: YYAIG

[0864] SEQ ID NO:39, human IgG1 Fc skeleton: EPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL PAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0865] SEQ ID NO:40, P249645HCDR2 amino acid sequence: GINSGGGSTWYADSVKG

[0866] SEQ ID NO:41, P249647HCDR2 amino acid sequence: CISRTVGVTNSADSVKG

[0867] SEQ ID NO:42, P249648HCDR2 amino acid sequence: AIGWWSGSMTSYADSVKG

[0868] SEQ ID NO:43, P249649HCDR2 amino acid sequence: TISSGGTTNYADSMKG

[0869] SEQ ID NO:44, P249650HCDR2 amino acid sequence: GIKWTGSATSYTASVVG

[0870] SEQ ID NO:45, P249651HCDR2 amino acid sequence: VMDGGGNTNYADSVKD

[0871] SEQ ID NO:46, P249652HCDR2 amino acid sequence: RISSALPTYYADSVKG

[0872] SEQ ID NO:47, P249653HCDR2 amino acid sequence: GITSGGGSTMYAESVKG

[0873] SEQ ID NO:48, P249654HCDR2 amino acid sequence: TISYDGSTVYADSVIG

[0874] SEQ ID NO:49, P249655HCDR2 amino acid sequence: AISWSGGSTYYADSVKG

[0875] SEQ ID NO:50, P249656HCDR2 amino acid sequence: AISWSGSSTYYADSVKG

[0876] SEQ ID NO:51, P249657HCDR2 amino acid sequence: AISLDGTTLYADSVKG

[0877] SEQ ID NO:52, P249658HCDR2 amino acid sequence: AITWNGGSTYYGESMKG

[0878] SEQ ID NO:53, P249659HCDR2 amino acid sequence: RIVSGLSTYYADSVKG

[0879] SEQ ID NO:54, P249660HCDR2 amino acid sequence: AISWSGGSTAYADSVKG

[0880] SEQ ID NO:55, P249661HCDR2 amino acid sequence: IISSGTTNYADSMKG

[0881] SEQ ID NO:56, P249662HCDR2 amino acid sequence: AINTGGGSTYYADSVKG

[0882] SEQ ID NO:57, P249663HCDR2 amino acid sequence: CISSSPGSTYYADSVKG

[0883] SEQ ID NO:58, P249664HCDR2 amino acid sequence: SISFDGSTLYADSVKG

[0884] SEQ ID NO:59, single-domain antibody HCDR2 amino acid sequence: X6X7X8X9X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21

[0885] SEQ ID NO:60, P249645HCDR3 amino acid sequence: HFGTSYSSAYL

[0886] SEQ ID NO:61, P249647HCDR3 amino acid sequence: KRWVDSTCRTSGTYDY

[0887] SEQ ID NO:62, P249648HCDR3 amino acid sequence: DVSFRDLTIGRPDY

[0888] SEQ ID NO:63, P249649HCDR3 amino acid sequence: MFFRGSTSLDY

[0889] SEQ ID NO:64, P249650HCDR3 amino acid sequence: NEVLEIPIRESEYDY

[0890] SEQ ID NO:65, P249651HCDR3 amino acid sequence: RKRFWNKDYDF

[0891] SEQ ID NO:66, P249652HCDR3 amino acid sequence: VVRGSLDY

[0892] SEQ ID NO:67, P249653HCDR3 amino acid sequence: HFGIHYSSAYV

[0893] SEQ ID NO:68, P249654HCDR3 amino acid sequence: RQPSYWLTSTQY

[0894] SEQ ID NO:69, P249655HCDR3 amino acid sequence: AYGSRWYADGPPLQYDY

[0895] SEQ ID NO:70, P249656HCDR3 amino acid sequence: KRPGSSWYGGYEYDY

[0896] SEQ ID NO:71, P249657HCDR3 amino acid sequence: VFHVDFTTMRARPVSDDY

[0897] SEQ ID NO:72, P249658HCDR3 amino acid sequence: YGVSWVGRGPPDY

[0898] SEQ ID NO:73, P249659HCDR3 amino acid sequence: VVSGAREF

[0899] SEQ ID NO:74, P249660HCDR3 amino acid sequence: EGQSYYLTPTASHEYDY

[0900] SEQ ID NO:75, P249661HCDR3 amino acid sequence: KFFRGSSSLDY

[0901] SEQ ID NO:76, P249662HCDR3 amino acid sequence: GFSKDAYREP

[0902] SEQ ID NO:77, P249663HCDR3 amino acid sequence: ARPGGCDYELGFVNYGMDY

[0903] SEQ ID NO:78, P249664HCDR3 amino acid sequence: VFSVDLTTMWARPVSDDY

[0904]

[0905] SEQ ID NO:80, P249645 antibody sequence linked to human IgG1 Fc backbone: EVRLVESGGGLVQPGGSLRLSCAASGFTFSNYAMSWVRQAPGKGLEWVSGINSGGGSTWYADSVKGRFTISRDNAENTLYLQMNKLKPEDTALYYCAKHFGTSYSSAYLRGQGTQVTVSSEPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0906] SEQ ID NO:81, A046 amino acid sequence: QVQLQESGGGSVQAGGSVRLSCTASGRTFTNYVMGWFRQAPGKEREFVSAISQSGARTAYVDSVKGRFTLSRDNAKNMVFLQMNSLKPEDTAVYYCAAGNGYGSSAAYGTSARSENPYNYWGQGTQVTVSS

[0907] SEQ ID NO:82, A051 amino acid sequence: EVQLVESGGGLVQAGGSLRLSCVASGIAFSRYPMNWYRQAPGKQRELVATISSGGTTNYADSMKGRFTISRDNAKNTVSLQMNSVKPEDTAVYYCYTKFFRGSVTVDYWGQGTQVTVSS

[0908] SEQ ID NO:83, A061 amino acid sequence: EVRLVESGGGLVQAGGSLRLSCVASGIAFSRYPMNWYRQAPGKQRELVATISSGGTINYADSMKGRFTISRDNAKNTVSLQMNSVKPEDTAVYYCNTMFFRGRNSVDYWGQGTQVTVSS

[0909] SEQ ID NO:84, A165 amino acid sequence: EVQVVESGGGTVQAGGSLRLSCAASGITLFSYTAGWYRQAPGKQRELVASIDSGGRTNYADSVKGRFTISRDNRQNTVLLQMNSLKPEDTAVYYCNTKGPYYWTTATQKDDWGQGTQVTVSS

[0910] SEQ ID NO:85, A181 amino acid sequence: EVQLVESGGGLVQAGGSLRLSCAFTGRVLTNYYMGWYRQGPGKQRELVATISSGGSTIYAGSVKGRFAISVDNAKNTVYLQMNSLKPEDTAVYYCRGAWRGRDYWGQGTQVTVSS

[0911] SEQ ID NO:86, A278 amino acid sequence: QVQLQESGGGLVQAGGSLRLSCAASGRAFSSYGMGWFRRFPGKEREFVAAILSLGTTYYADSVKGRFAISRDNAKNTVYLEMNKMKPEDTALYYCAATRTFILPPRPTDFDSWGQGTQVTVSS

[0912] SEQ ID NO:87, A284 amino acid sequence: EVQVQESGGGLVQAGGSLRLSCAASGRTFSSYVMGWFRQAPGKEREFVAAITWSAGMTYFPDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAADGVPVYYSDYERWDYWGQGTQVTVSS

[0913] SEQ ID NO:88, A334 amino acid sequence: QVQLVESGGGLVQAGGSLRLSCVASGRTFSNYILAWFRQAPGNKREFVGAISWSGTSTYYPDSVKGRFTASRDNAKNTMYLQMNSLKPEDTAVYYCAAATNPSQLRRNEYDSWGQGTQVTVSS

[0914] SEQ ID NO:89, A081 amino acid sequence: EVQLVESGGGLVQAGGSLRLSCAASGRAFSSYAMGWFRQGPGKEREFVAAIKWSGGSTYYPDSVKGRFTISRDNVKNTVYLQMNSLKPEDTAVYYCAADLVSRKATMFQSGYWGQGTQVTVSS

[0915] SEQ ID NO:90, A105 amino acid sequence: QVQLVESGGGLVQAGGSLRLSCAASGSTFSSYYMGWYRQAPGKQRELVATISSGGSTIYAASVKGRFAISVDNAKNTVYLQMNSLKPEDTAVYYCRGGLRGRDYWGQGTLVTVSS

[0916] SEQ ID NO:91, A046 HCDR1 amino acid sequence: NYVMG

[0917] SEQ ID NO:92, A051 HCDR1 amino acid sequence: RYPMN

[0918] SEQ ID NO:93, A061 HCDR1 amino acid sequence: RYPMN

[0919] SEQ ID NO:94, A165 HCDR1 amino acid sequence: SYTAG

[0920] SEQ ID NO:95, A181 HCDR1 amino acid sequence: NYYMG

[0921] SEQ ID NO:96, A278 HCDR1 amino acid sequence: SYGMG

[0922] SEQ ID NO:97, A284 HCDR1 amino acid sequence: SYVMG

[0923] SEQ ID NO:98, A334 HCDR1 amino acid sequence: NYILA

[0924] SEQ ID NO:99, A081 HCDR1 amino acid sequence: SYAMG

[0925] SEQ ID NO:100, A105 HCDR1 amino acid sequence: SYYMG

[0926] SEQ ID NO:101, A046 HCDR2 amino acid sequence: AISQSGARTAYVDSVKG

[0927] SEQ ID NO:102, A051 HCDR2 amino acid sequence: TISSGGTTNYADSMKG

[0928] SEQ ID NO:103, A061 HCDR2 amino acid sequence: TISSGGTINYADSMKG

[0929] SEQ ID NO:104, A165 HCDR2 amino acid sequence: SIDSGGRTNYADSVKG

[0930] SEQ ID NO:105, A181 HCDR2 amino acid sequence: TISSGGSTIYAGSVKG

[0931] SEQ ID NO:106, A278 HCDR2 amino acid sequence: AILSLGTTYYADSVKG

[0932] SEQ ID NO:107, A284 HCDR2 amino acid sequence: AITWSAGMTYFPDSVKG

[0933] SEQ ID NO:108, A334 HCDR2 amino acid sequence: AISWSGTSTYYPDSVKG

[0934] SEQ ID NO:109, A081 HCDR2 amino acid sequence: AIKWSGGSTYYPDSVKG

[0935] SEQ ID NO:110, A105 HCDR2 amino acid sequence: TISSGGSTIYAASVKG

[0936] SEQ ID NO:111, A046 HCDR3 amino acid sequence: GNGYGSSAAYGTSARSENPYNY

[0937] SEQ ID NO:112, A051 HCDR3 amino acid sequence: KFFRGSVTVDY

[0938] SEQ ID NO:113, A061 HCDR3 amino acid sequence: MFFRGRNSVDY

[0939] SEQ ID NO:114, A165 HCDR3 amino acid sequence: KGPYYWTTATQKDD

[0940] SEQ ID NO:115, A181 HCDR3 amino acid sequence: AWRGRDY

[0941] SEQ ID NO:116, A278 HCDR3 amino acid sequence: TRTFILPPRPTDFDS

[0942] SEQ ID NO:117, A284 HCDR3 amino acid sequence: ADGVPVYYSDYERWDY

[0943] SEQ ID NO:118, A334 HCDR3 amino acid sequence: ATNPSQLRRNEYDS

[0944] SEQ ID NO:119, A081 HCDR3 amino acid sequence: DLVSRKATMFQSGY

[0945] SEQ ID NO:120, A105 HCDR3 amino acid sequence: GLRGRDY

[0946] SEQ ID NO:121, Single-domain antibody HCDR3 amino acid sequence: X 22 X 23 X 24 X 25 X 26 X 27 X 28

[0947] SEQ ID NO:122, Single-domain antibody FR1 amino acid sequence: X 29 VX 30 X 31 X 32 ESGGGX 33 VX 34 X 35 GGX 36 X 37 X 38 LSCX 39 X 40 X 41 X 42 X 43 X 44 X 45 X 46

[0948] SEQ ID NO:123, Single-domain antibody FR2 amino acid sequence: WX 47 RX 48 X 49 PGX 50 X 51 X 52 X 53 X 54 VX 55

[0949] SEQ ID NO:124, single-domain antibody FR3 amino acid sequence: RFX 56 X 57 X 58 X 59 DNX 60 X 61 X 62 X63 X 64 X 65 LX 66 MX 67 X 68 X 69 KX 70 EDX 71 X 72 X 73 YX 74 CX 75 X 76

[0950] SEQ ID NO:125, Single-domain antibody FR4 amino acid sequence: X 77 GX 78 GTX 79 VTVSS

[0951] SEQ ID NO:126, P249645FR1 amino acid sequence: EVRLVESGGGLVQPGGSLRLSCAASGFTFS

[0952] SEQ ID NO:127, P249647FR1 amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAVSGFTSG

[0953] SEQ ID NO:128, P249648FR1 amino acid sequence: QVQLVESGGGLVEAGGSLRLSCAASGRTFS

[0954] SEQ ID NO:129, P249649FR1 amino acid sequence: EVQVVESGGGLVQAGGSLTLSCVASGITFS

[0955] SEQ ID NO:130, P249650FR1 amino acid sequence: QVQLQESGGGLVQPGGSLRLSCAASDSGRT

[0956] SEQ ID NO:131, P249651FR1 amino acid sequence: EVQLVESGGGLVQAGGSLRLSCAASGSTSS

[0957] SEQ ID NO:132, P249652FR1 amino acid sequence: EVQLVESGGGLVQAGGSLRLSCAVSGSTDS

[0958] SEQ ID NO:133, P249653FR1 amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAASGFTFS

[0959] SEQ ID NO:134, P249654FR1 amino acid sequence: QVQLVESGGGLVQAGGSLKLSCAASGITFS

[0960] SEQ ID NO:135, P249655FR1 amino acid sequence: EVQVQESGGGLVQAGGSLRLSCAASGRTFS

[0961] SEQ ID NO:136, P249656FR1 amino acid sequence: QVQLQESGGGLVQAGGSLRLSCAASGRTFS

[0962] SEQ ID NO:137, P249657FR1 amino acid sequence: EVQLVESGGGLVQAGGSLRLSCAASISAFS

[0963] SEQ ID NO:138, P249658FR1 amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAASGFTFD

[0964] SEQ ID NO:139, P249659FR1 amino acid sequence: EVQLVESGGGLVQAGGSLRLSCAVSGSTYS

[0965] SEQ ID NO:140, P249660FR1 amino acid sequence: EVQVQESGGGLVQAGGSLRLSCAASGRTFS

[0966] SEQ ID NO:141, P249661FR1 amino acid sequence: QVQLVESGGGLVQAGGSLRLSCVASGITFS

[0967] SEQ ID NO:142, P249662FR1 amino acid sequence: EVQLVESGGGLVQPGGSLRLSCAASGFTFS

[0968] SEQ ID NO:143, P249663FR1 amino acid sequence: EVQLVESGGGLVQPGGALRLSCAVSGFTLG

[0969] SEQ ID NO:144, P249664FR1 amino acid sequence: EVQLQESGGGLVQAGGSLRLSCAASISAFS

[0970] SEQ ID NO:145, A046 FR1 amino acid sequence: QVQLQESGGGSVQAGGSVRLSCTASGRTFT

[0971] SEQ ID NO:146, A051 FR1 amino acid sequence: EVQLVESGGGLVQAGGSLRLSCVASGIAFS

[0972] SEQ ID NO:147, A061 FR1 amino acid sequence: EVRLVESGGGLVQAGGSLRLSCVASGIAFS

[0973] SEQ ID NO:148, A165 FR1 amino acid sequence: EVQVVESGGGTVQAGGSLRLSCAASGITLF

[0974] SEQ ID NO:149, A181 FR1 amino acid sequence: EVQLVESGGGLVQAGGSLRLSCAFTGRVLT

[0975] SEQ ID NO:150, A278 FR1 amino acid sequence: QVQLQESGGGLVQAGGSLRLSCAASGRAFS

[0976] SEQ ID NO:151, A284 FR1 amino acid sequence: EVQVQESGGGLVQAGGSLRLSCAASGRTFS

[0977] SEQ ID NO:152, A334 FR1 amino acid sequence: QVQLVESGGGLVQAGGSLRLSCVASGRTFS

[0978] SEQ ID NO:153, A081 FR1 amino acid sequence: EVQLVESGGGLVQAGGSLRLSCAASGRAFS

[0979] SEQ ID NO:154, A105 FR1 amino acid sequence: QVQLVESGGGLVQAGGSLRLSCAASGSTFS

[0980] SEQ ID NO:155, P249645FR2 amino acid sequence: WVRQAPGKGLEWVS

[0981] SEQ ID NO:156, P249647FR2 amino acid sequence: WFRQAPGKEREWVS

[0982] SEQ ID NO:157, P249648FR2 amino acid sequence: WFRQAPGKEREFVA

[0983] SEQ ID NO:158, P249649FR2 amino acid sequence: WYRQAPGKQRELVA

[0984] SEQ ID NO:159, P249650FR2 amino acid sequence: WFRQAPGKERKFVA

[0985] SEQ ID NO:160, P249651FR2 amino acid sequence: WYRQAPGKQRELVA

[0986] SEQ ID NO:161, P249652FR2 amino acid sequence: WYRQAPGKQRELVA

[0987] SEQ ID NO:162, P249653FR2 amino acid sequence: WVRQAPGKGLEWVS

[0988] SEQ ID NO:163, P249654FR2 amino acid sequence: WYRQAPGKQRELVA

[0989] SEQ ID NO:164, P249655FR2 amino acid sequence: WFRQAPGKEREFVA

[0990] SEQ ID NO:165, P249656FR2 amino acid sequence: WFRQAPGKEREFVT

[0991] SEQ ID NO:166, P249657FR2 amino acid sequence: WYRQAPGKQRELVA

[0992] SEQ ID NO:167, P249658FR2 amino acid sequence: WVRQAPGKGLEWVS

[0993] SEQ ID NO:168, P249659FR2 amino acid sequence: WYRQAPGKQRELVA

[0994] SEQ ID NO:169, P249660FR2 amino acid sequence: WFRQAPGKEREFVA

[0995] SEQ ID NO:170, P249661FR2 amino acid sequence: WYRQAPGNVRELVA

[0996] SEQ ID NO:171, P249662FR2 amino acid sequence: WVRQAPGKGLEWVS

[0997] SEQ ID NO:172, P249663FR2 amino acid sequence: WFRQAPGKEREGVS

[0998] SEQ ID NO:173, P249664FR2 amino acid sequence: WYRQAPGKQRELVA

[0999] SEQ ID NO:174, A046 FR2 amino acid sequence: WFRQAPGKEREFVS

[1000] SEQ ID NO:175, A051 FR2 amino acid sequence: WYRQAPGKQRELVA

[1001] SEQ ID NO:176, A061 FR2 amino acid sequence: WYRQAPGKQRELVA

[1002] SEQ ID NO:177, A165 FR2 amino acid sequence: WYRQAPGKQRELVA

[1003] SEQ ID NO:178, A181 FR2 amino acid sequence: WYRQGPGKQRELVA

[1004] SEQ ID NO:179, A278 FR2 amino acid sequence: WFRRFPGKEREFVA

[1005] SEQ ID NO:180, A284 FR2 amino acid sequence: WFRQAPGKEREFVA

[1006] SEQ ID NO:181, A334 FR2 amino acid sequence: WFRQAPGNKREFVG

[1007] SEQ ID NO:182, A081 FR2 amino acid sequence: WFRQGPGKEREFVA

[1008] SEQ ID NO:183, A105 FR2 amino acid sequence: WYRQAPGKQRELVA

[1009] SEQ ID NO:184, P249645FR3 amino acid sequence: RFTISRDNAENTLYLQMNKLKPEDTALYYCAK

[1010] SEQ ID NO:185, P249647FR3 amino acid sequence: RFTISRDNAKSTVYLQMNGLKPEDTAHYYCGA

[1011] SEQ ID NO:186, P249648FR3 amino acid sequence: RFTISRDNAKNIMSLQMNNLKPEDTAVYSCAA

[1012] SEQ ID NO:187, P249649FR3 amino acid sequence: RFTISRDNAKNTVYLQMNSAKPEDTAVYYCNT

[1013] SEQ ID NO:188, P249650FR3 amino acid sequence: RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA

[1014] SEQ ID NO:189, P249651FR3 amino acid sequence: RFTISRDNAKNTVNLLMNSLKPEDTSVYYCSV

[1015] SEQ ID NO:190, P249652FR3 amino acid sequence: RFTISRDNAKNTVYLQMNSLKPEDTAVYYCRA

[1016] SEQ ID NO:191, P249653FR3 amino acid sequence: RFTISRDNAENTLYLQMNKLKPEDTALYYCAK

[1017] SEQ ID NO:192, P249654FR3 amino acid sequence: RFTIFKDNAKNTVYLQMNSLKPEDTALYYCNA

[1018] SEQ ID NO:193, P249655FR3 amino acid sequence: RFTISRDNAKNTVYLQMMSLKPEDTAVYYCAA

[1019] SEQ ID NO:194, P249656FR3 amino acid sequence: RFTISRDNAKNTVYLQMDSLKPEDTAVYYCAA

[1020] SEQ ID NO:195, P249657FR3 amino acid sequence: RFTISRDNSKNTIYLQMNSLKPEDTAVYYCNT

[1021] SEQ ID NO:196, P249658FR3 amino acid sequence: RFTISRDNAKNTLYLQMNSLKSEDTAVYYCAK

[1022] SEQ ID NO:197, P249659FR3 amino acid sequence: RFTISRDNAKNTVYLQMNSLKPEDTAVYYCRA

[1023] SEQ ID NO:198, P249660FR3 amino acid sequence: RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA

[1024] SEQ ID NO:199, P249661FR3 amino acid sequence: RFTISRDNAKNTVYLQMNSAKPEDTAVYYCNT

[1025] SEQ ID NO:200, P249662FR3 amino acid sequence: RFTISRDNAKNTLYLQMNSLKPEDTAVYYCAR

[1026] SEQ ID NO:201, P249663FR3 amino acid sequence: RFTISRDNAKNTVYLQMNSLKPEDMAVYYCAT

[1027] SEQ ID NO:202, P249664FR3 amino acid sequence: RFTISRDNSKNTVFLQMNSLKPEDTAVYYCNT

[1028] SEQ ID NO:203, A046 FR3 amino acid sequence: RFTLSRDNAKNMVFLQMNSLKPEDTAVYYCAA

[1029] SEQ ID NO:204, A051 FR3 amino acid sequence: RFTISRDNAKNTVSLQMNSVKPEDTAVYYCYT

[1030] SEQ ID NO:205, A061 FR3 amino acid sequence: RFTISRDNAKNTVSLQMNSVKPEDTAVYYCNT

[1031] SEQ ID NO:206, A165 FR3 amino acid sequence: RFTISRDNRQNTVLLQMNSLKPEDTAVYYCNT

[1032] SEQ ID NO:207, A181 FR3 amino acid sequence: RFAISVDNAKNTVYLQMNSLKPEDTAVYYCRG

[1033] SEQ ID NO:208, A278 FR3 amino acid sequence: RFAISRIZERDNAKNTVYLEMNKMKPEDTALYYCAA

[1034] SEQ ID NO:209, A284 FR3 amino acid sequence: RFTISRDNAKNTVYLQMNSLKPEDTAVYYCAA

[1035] SEQ ID NO:210, A334 FR3 amino acid sequence: RFTAS RDNAKNTMYLQMNSLKPEDTAVYYCAA

[1036] SEQ ID NO:211, A081 FR3 amino acid sequence: RFTISRDNVKNTVYLQMNSLKPEDTAVYYCAA

[1037] SEQ ID NO:212, A105 FR3 amino acid sequence: RFAISVDNAKNTVYLQMNSLKPEDTAVYYCRG

[1038] SEQ ID NO:213, P249645FR4 amino acid sequence: RGQGTQVTVSS

[1039] SEQ ID NO:214, P249647FR4 amino acid sequence: WGQGTQVTVSS

[1040] SEQ ID NO:215, P249648FR4 amino acid sequence: WGQGTQVTVSS

[1041] SEQ ID NO:216, P249649FR4 amino acid sequence: WGQGTQVTVSS

[1042] SEQ ID NO:217, P249650FR4 amino acid sequence: WGQGTQVTVSS

[1043] SEQ ID NO:218, P249651FR4 amino acid sequence: WGQGTQVTVSS

[1044] SEQ ID NO:219, P249652FR4 amino acid sequence: WGQGTQVTVSS

[1045] SEQ ID NO:220, P249653FR4 amino acid sequence: RGQGTQVTVSS

[1046] SEQ ID NO:221, P249654FR4 amino acid sequence: WGQGTQVTVSS

[1047] SEQ ID NO:222, P249655FR4 amino acid sequence: WGQGTQVTVSS

[1048] SEQ ID NO:223, P249656FR4 amino acid sequence: WGQGTQVTVSS

[1049] SEQ ID NO:224, P249657FR4 amino acid sequence: WGQGTQVTVSS

[1050] SEQ ID NO:225, P249658FR4 amino acid sequence: WGQGTQVTVSS

[1051] SEQ ID NO:226, P249659FR4 amino acid sequence: WGQGTQVTVSS

[1052] SEQ ID NO:227, P249660FR4 amino acid sequence: WGQGTQVTVSS

[1053] SEQ ID NO:228, P249661FR4 amino acid sequence: WGQGTQVTVSS

[1054] SEQ ID NO:229, P249662FR4 amino acid sequence: GGQGTQVTVSS

[1055] SEQ ID NO:230, P249663FR4 amino acid sequence: WGKGTLVTVSS

[1056] SEQ ID NO:231, P249664FR4 amino acid sequence: WGQGTQVTVSS

[1057] SEQ ID NO:232, A046 FR4 amino acid sequence: WGQGTQVTVSS

[1058] SEQ ID NO:233, A051 FR4 amino acid sequence: WGQGTQVTVSS

[1059] SEQ ID NO:234, A061 FR4 amino acid sequence: WGQGTQVTVSS

[1060] SEQ ID NO:235, A165 FR4 amino acid sequence: WGQGTQVTVSS

[1061] SEQ ID NO:236, A181 FR4 amino acid sequence: WGQGTQVTVSS

[1062] SEQ ID NO:237, A278 FR4 amino acid sequence: WGQGTQVTVSS

[1063] SEQ ID NO:238, A284 FR4 amino acid sequence: WGQGTQVTVSS

[1064] SEQ ID NO:239, A334 FR4 amino acid sequence: WGQGTQVTVSS

[1065] SEQ ID NO:240, A081 FR4 amino acid sequence: WGQGTQVTVSS

[1066] SEQ ID NO:241, A105 FR4 amino acid sequence: WGQGTLVTVSS

[1067] Although specific embodiments of this disclosure have been described in detail, those skilled in the art will understand that various modifications and variations can be made to the details based on all the teachings published, and all such modifications and variations are within the scope of this disclosure. The entire scope of this disclosure is given by the appended claims and any equivalents thereof.

Claims

1. An antibody or antigen-binding fragment thereof that binds to CD117, comprising: (a) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:2; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (b) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:3; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (c) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:4; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (d) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:5; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (e) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:6; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (f) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:7; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (g) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:8; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (h) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:9; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (i) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:10; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (j) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:11; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (k) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:12; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (l) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:13; or CDR variants having one or more amino acid substitutions, deletions or additions (e.g., substitutions, deletions or additions of 1, 2 or 3 amino acids) with any of the three CDRs. (m) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:14; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (n) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:15; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (o) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:16; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (p) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:17; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (q) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:18; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (r) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:19; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (s) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:20; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (t) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:81; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (u) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:82; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (v) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:83; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (w) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:84; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (x) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:85; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (y) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:86; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (z) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:87; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (aa) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:88; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. (ab) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:89; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs; or (ac) Three CDRs in the heavy chain variable region amino acid sequence shown in SEQ ID NO:90; or CDR variants having one or more amino acid substitutions, deletions, or additions (e.g., substitutions, deletions, or additions of 1, 2, or 3 amino acids) with any of the three CDRs. Optionally, the CDR is defined according to the Kabat, IMGT, Chothia, or AbM numbering system.

2. The antibody or antigen-binding fragment thereof of claim 1, wherein, The antibody or its antigen-binding fragment comprises: (1) HCDR1 comprises X1X2X3X4X5 (SEQ ID NO:28), wherein X1 is Y, T, S, R, N, I, F or D, X2 is Y, S, L or D, X3 is Y, W, V, T, S, R, P, N, I, G or A, X4 is Y, V, M, L, I or A, X5 is Y, V, T, S, N, G or A, or a variant comprising no more than 3, no more than 2, or no more than 1 amino acid residue substitutions of the sequence shown in SEQ ID NO:28; optionally, HCDR1 comprises the sequence shown in any one of SEQ ID NO:21-27, 29-38 and 91-100 or a variant comprising no more than 3, no more than 2, or no more than 1 amino acid residue substitutions of the sequence shown in any one of SEQ ID NO:21-27, 29-38 and 91-100; (2) HCDR2 includes X6X7X8X9X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 (SEQ ID NO:59), where X6 is V, T, S, R, I, G, C or A, X7 is M or I, X8 is V, T, S, N, L, K, G or D, X9 is Y, W, T, S, R, Q, L, G or F, X 10 For W, T, S, N, L, G, D or A, X 11 For V, S, P, L, G or A, X 12 For T, S, R, P, N, G, or A, X 13 For V, T, S, R, M, I or A, X 14 For Y, V, T, N, M, L or I, X 15 For Y, W, T, S, N, M or A, X 16 For Y, S, F or A, X 17 For Y, V, T, P, G, D or A, X 18 For S, E, D, or A, X 19 For V, S, M, or D, X 20 For V, S, M, K, or I, X 21 V, K, G or D, or a variant containing no more than 3, 2 or 1 amino acid residue substitutions of the sequence shown in SEQ ID NO:59; Optionally, HCDR2 comprises the sequence shown in any one of SEQ ID NO:40-58 and 101-110 or comprises a variant having no more than 3, no more than 2, or no more than 1 amino acid residue substitutions with the sequence shown in any one of SEQ ID NO:40-58 and 101-110; (3) HCDR3 contains X 22 X 23 X 24 X 25 X 26 X 27 X 28 (SEQ ID NO:121), where X 22 For Y, V, T, R, N, M, K, H, G, E, D or A, X 23 For Y, W, V, T, R, Q, N, L, K, G, F, E, or D, X 24 For W, V, T, S, R, Q, P, N, H, G or F, X 25 For Y, V, T, S, R, P, L, K, I, G or F, X 26 For Y, W, S, R, P, I, H, G, E, D or A, X 27 For Y, W, V, S, R, Q, N, L, K, I, F, D, C or A, X 28 For Y, W, V, T, S, P, N, L, K, G, E, D, or A, Optionally, HCDR3 comprises the sequence shown in any one of SEQ ID NO:60-78 and 111-120 or a variant comprising a substitution, deletion, or addition (e.g., a substitution, deletion, or addition of 1, 2, or 3 amino acids) of the sequence shown in SEQ ID NO:60-78 and 111-120.

3. The antibody or its antigen-binding fragment as described in claim 1, wherein the frame region FR of the antibody or its antigen-binding fragment includes FR1, FR2, FR3, and FR4 sequences, wherein, (1) FR1 contains X 29 VX 30 X 31 X 32 ESGGGX 33 VX 34 X 35 GGX 36 X 37 X 38 LSCX 39 X 40 X 41 X 42 X 43 X 44 X 45 X 46 (SEQ ID NO:122), where X 29 For Q or E, X 30 For R or Q, X 31 For V or L, X 32 For V or Q, X 33 For T, S, or L, X 34 For Q or E, X 35 For A or P, X 36 For S or A, X 37 For L or V, X 38 For K, R, or T, X 39 For A, T, or V, X 40 For A, F, or V, X 41 For S or T, X 42 For I, G, or D, X 43 For S, R, I, or F, X 44 For V, T, G, or A, X 45 For Y, S, R, L, F or D, X 46 The sequence is T, S, G, F or D, or a variant containing no more than 3, 2 or 1 amino acid residue substitutions of the sequence shown in SEQ ID NO:122; Optionally, the FR1 comprises the sequence shown in any one of SEQ ID NO:126-154 or a variant comprising no more than 3, no more than 2, or no more than 1 amino acid residue substitutions of the sequence shown in any one of SEQ ID NO:126-154; (2) FR2 includes WX 47 RX 48 X 49 PGX 50 X 51 X 52 X 53 X 54 VX 55 (SEQ ID NO:123), where X 47 For Y, V, or F, X 48 For R or Q, X 49 For G, F, or A, X 50 For N or K, X 51 For V, Q, K, G, or E, X 52 For R or L, X 53 For K or E, X 54 For W, L, G or F, X 55 The sequence is T, S, G or A, or a variant containing no more than 3, 2 or 1 amino acid residue substitutions of the sequence shown in SEQ ID NO:123; Optionally, the FR2 comprises the sequence shown in any one of SEQ ID NO:155-183 or a variant comprising no more than 3, no more than 2, or no more than 1 amino acid residue substitutions of the sequence shown in any one of SEQ ID NO:155-183; (3) FR3 includes RFX 56 X 57 X 58 X 59 DNX 60 X 61 X 62 X 63 X 64 X 65 LX 66 MX 67 X 68 X 69 KX 70 EDX 71 X 72 X 73 YX 74 CX 75 X 76 (SEQ ID NO:124), where X 56 For A or T, X 57 For L, I, or A, X 58 For S or F, X 59 For V, R, or K, X 60 For V, S, R, or A, X 61 For Q, K, or E, X 62 For S or N, X 63 For T, M, or I, X 64 For V, M, L or I, X 65 For Y, S, N, L or F, X 66 For Q, L, or E, X 67 For N, M, or D, X 68 For S, N, K, or G, X 69 For V, M, L or A, X 70 For S or P, X 71 For T or M, X 72 For S or A, X 73 For V, L, or H, X 74 For Y or S, X 75 For Y, S, R, N, G or A, X 76 V, T, R, K, G or A, or a variant containing no more than 3, 2 or 1 amino acid residue substitutions of the sequence shown in SEQ ID NO:124; Optionally, the FR3 comprises the sequence shown in any one of SEQ ID NO:184-212 or a variant comprising no more than 3, no more than 2, or no more than 1 amino acid residue substitutions of the sequence shown in any one of SEQ ID NO:184-212; (4) FR4 contains X 77 GX 78 GTX 79 VTVSS (SEQ ID NO:125), where X 77 For W, R, or G, X 78 For Q or K, X 79 It is Q or L, or a variant containing no more than 3, no more than 2, or no more than 1 amino acid residue substitutions of the sequence shown in SEQ ID NO:125; Optionally, the FR4 comprises the sequence shown in any one of SEQ ID NO:213-241 or a variant comprising no more than 3, no more than 2, or no more than 1 amino acid residue substitutions of the sequence shown in any one of SEQ ID NO:213-241.

4. The antibody or antigen-binding fragment thereof as claimed in any one of claims 1-3, wherein the antibody or antigen-binding fragment thereof comprises a sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with any amino acid sequence in SEQ ID NO:2-20 and 81-90, and the anti-CD117 antibody comprising this sequence retains the ability to bind CD117.

5. The antibody or antigen-binding fragment thereof as described in any one of claims 1-4, wherein the variable region of the antibody heavy chain further comprises: The FR region of the heavy chain of human IgG1, IgG2, IgG3, or IgG4 or their variants. Optionally, the FR region of the human IgG1, IgG2 or IgG4 heavy chain, more preferably, the FR region of the human IgG1 or IgG2 heavy chain.

6. The antibody or antigen-binding fragment thereof as described in any one of claims 1-5, wherein the antibody or antigen-binding fragment thereof is a murine antibody, a chimeric antibody, a humanized antibody, a human antibody or antigen-binding fragment thereof; Optionally, the antigen-binding fragment is selected from Fab, Fab', (Fab')2, Fv, disulfide-linked Fv, scFv, diabody, and sdAb; Optionally, the antibody or its antigen-binding fragment includes a coupling functional group linked to a single-domain antibody fragment; Optionally, the functional group is an azide group, a dibenzocyclooctyne group (DBCO), a biotin group, a streptavidin group, or a thiol group.

7. A nucleic acid molecule, said nucleic acid molecule encoding an antibody or antigen-binding fragment thereof that binds to CD117 as described in any one of claims 1-6.

8. An expression vector comprising the nucleic acid molecule as described in claim 7.

9. A host cell containing the expression vector as described in claim 8.

10. A lipid nanoparticle conjugate comprising: (1) Lipid nanoparticles (LNPs), and (2) An antibody or antigen-binding fragment thereof that binds to CD117, wherein the antibody or antigen-binding fragment thereof is conjugated to the surface of the LNP, and the antibody or antigen-binding fragment thereof that binds to CD117 is as described in any one of claims 1-6.

11. The lipid nanoparticle conjugate of claim 10, wherein, The antibody or its antigen-binding fragment is conjugated with polyethylene glycol (PEG) lipids contained in the LNP; Optionally, in the lipid nanoparticle conjugate, the antibody or its antigen-binding fragment is covalently conjugated to the LNP; Optionally, the lipid nanoparticle conjugate further comprises a bioactive substance encapsulated by or attached to an LNP; Optionally, the bioactive substance includes a therapeutic agent, a preventive agent, or a diagnostic agent; Optionally, the bioactive substance includes a preventive agent or a therapeutic agent, and optionally, the preventive agent or therapeutic agent is selected from RNA, DNA, antisense nucleic acid, aptamer, nuclease, immunostimulatory nucleic acid or PNA component; Optionally, the antisense nucleic acid is an antisense oligonucleotide; Optionally, the RNA includes one or more of mRNA, rRNA, circRNA, siRNA, saRNA, tRNA, snRNA, antagomir, microRNA inhibitor, microRNA activator, or shRNA; Optionally, the DNA includes a plasmid; Optionally, the nucleic acid component encodes a gene editing composition / system comprising a nuclease or a nucleic acid encoding a nuclease, and an RNA guide or a nucleic acid encoding an RNA guide; Optionally, the nucleic acid component is mRNA; Optionally, the nuclease comprises nuclease mRNA; Optionally, the nuclease is selected from Cas9, Cas12, Cas13, IscB, TnpB, IsrB and their homologs; Optionally, the bioactive substance comprises at least one mRNA encoding an antigen or a fragment thereof or an epitope.

12. The lipid nanoparticle conjugate of any one of claims 10-11, wherein, The lipid nanoparticles (LNPs) comprise: ionizable lipids, neutral lipids, steroids, PEG lipids, and functionalized PEG lipids; Optionally, the ionizable lipid is a compound according to any one of the formulas 01-I, 02-I, 02-I-1, 02-I-2, 02-I-3, 02-I-4, 02-I-5, 02-I-6, 02-I-7, 02-I-8, 02-I-9, 02-I-10, 02-I-11, 02-I-12, 02-I-13, 02-I-14, 03-I, 03-I-1, 03-I-2, 04-I, 04-I-1, 04-I-2, 04-I-1-3, 04-I-4, 04-II, 04-II-1, 04-II-2, 04-II-3 and its sub-formulas, or the ionizable lipid is a compound selected from the compounds listed in any one of Tables 1 to 4; Optionally, the molar ratio of ionizable lipids, neutral lipids, steroids, PEG lipids, and functionalized PEG lipids is (20-65):(5-25):(25-55):(0.01-5):(0.1-15); Optionally, the molar ratio between ionizable lipids, neutral lipids, structured lipids, functionalized PEG lipids and unfunctionalized PEG lipids is (35-50):(10-16):(38.5-46.5):(0.15-2.2):(0.3-2.2).

13. A method for delivering a bioactive substance into cells, comprising: The lipid nanoparticle conjugate of any one of claims 10-12 is contacted with cells expressing CD117 to deliver the bioactive substance contained in the lipid nanoparticle conjugate to the cells, preferably, the contact occurs in vivo, in vitro or outside the body; Optionally, the cells include hematopoietic stem cells, mast cells, germ cells, mesenchymal cells, and tumor cells; Optionally, the contact step involves administering a lipid nanoparticle conjugate to a subject in need to deliver the bioactive substance to the subject's cells.

14. A method of editing a gene within a CD117-expressing cell, comprising: The lipid nanoparticle conjugate of any one of claims 10-12 is brought into contact with the cells to allow delivery of bioactive factors contained in the lipid nanoparticle conjugate to the cells, the bioactive factors being gene editing compositions / systems that edit target genes in the cells; Optionally, the method is an in vivo, ex vivo, or in vitro editing method; Optionally, the cells include hematopoietic cells, mast cells, germ cells, stromal cells, and tumor cells; Optionally, the contact step involves delivering the bioactive substance to the subject's CD117+ cells by administering the lipid nanoparticle conjugate to the subject in need. Optionally, the subjects are human patients suffering from a genetic disease associated with the target gene; Optionally, the genetic diseases include sickle cell disease, hemoglobinopathies, hemophilia, thalassemia, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute myeloid leukemia, chronic myeloid leukemia or chronic lymphocytic leukemia, Duchenne muscular dystrophy, factor V Leiden thrombophilia, familial hypercholesterolemia, Fragile X syndrome, Gaucher disease, hemochromatosis, hemophilia, holoencephaly, Huntington's disease, inherited metabolic disorders, Klinefelter syndrome, Marfan syndrome, methylmalonic academia, myotonic dystrophy, neurofibromatosis, Noonan syndrome, osteogenesis imperfecta, Parkinson's disease, phenylketonuria, and Poland syndrome. Anomaly, porphyria, progeria, prostate cancer, retinitis pigmentosa, severe combined immunodeficiency, sickle cell disease, skin cancer, spinal muscular atrophy, trimethylaminuria, Turner syndrome, velocardiofacial syndrome, and Wilson disease.

15. A method of making a lipid nanoparticle conjugate, the method comprising: The antibody or its antigen-binding fragment according to any one of claims 1-6 is contacted with the LNP to allow the antibody or its antigen-binding fragment to conjugate to the surface of the LNP, thereby generating the lipid nanoparticle conjugate; Optionally, the antibody is conjugated to the PEG portion of the PEG-lipid; Optionally, the conjugate is prepared by a method comprising: (1) Modify the heavy chain coding sequence of the adversary chain to introduce covalently conjugable amino acid residues at or near the C-terminus of the heavy chain constant region; (2) Prepare nanoparticles containing one or more PEG groups; and conjugate the nanoparticles to the antibody via a site-specific linker, wherein the amino acid residue located at or near the C-terminus of the heavy chain constant region is covalently bonded to one of the one or more PEG groups of the nanoparticles; Optionally, the conjugated amino acid residues include cysteine ​​residues, lysine residues, or glutamine residues.

16. The use of the antibody or antigen-binding fragment thereof as described in any one of claims 1-6, or the conjugate as described in any one of claims 10-12, in the preparation of a medicament for treating a disease; Optionally, the diseases include genetic diseases or conditions, preferably including sickle cell disease, hemoglobinopathies, hemophilia, thalassemia, multiple myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute myeloid leukemia, chronic myeloid leukemia or chronic lymphocytic leukemia, Duchenne muscular dystrophy, factor V Leiden thrombophilia, familial hypercholesterolemia, Fragile X syndrome, Gaucher disease, hemochromatosis, hemophilia, holoencephaly, Huntington's disease, inherited metabolic disorders, Klinefelter syndrome, Marfan syndrome, methylmalonic academia, myotonic dystrophy, neurofibromatosis, Noonan syndrome, osteogenesis imperfecta, Parkinson's disease, phenylketonuria, and Poland syndrome. Anomaly, porphyria, progeria, prostate cancer, retinitis pigmentosa, severe combined immunodeficiency, sickle cell disease, skin cancer, spinal muscular atrophy, trimethylaminuria, Turner syndrome, velocardiofacial syndrome, and Wilson disease.

17. A pharmaceutical composition comprising an antibody binding to CD117 as described in any one of claims 1-6 or an antigen-binding fragment thereof and / or a conjugate as described in any one of claims 10-12.